0001104659-19-057569.txt : 20191030 0001104659-19-057569.hdr.sgml : 20191030 20191030105645 ACCESSION NUMBER: 0001104659-19-057569 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 55 CONFORMED PERIOD OF REPORT: 20190930 FILED AS OF DATE: 20191030 DATE AS OF CHANGE: 20191030 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ARQULE INC CENTRAL INDEX KEY: 0001019695 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043221586 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-21429 FILM NUMBER: 191178343 BUSINESS ADDRESS: STREET 1: ONE WALL STREET STREET 2: FLOOR 6 CITY: BURLINGTON STATE: MA ZIP: 01803 BUSINESS PHONE: 781-994-0300 MAIL ADDRESS: STREET 1: ONE WALL STREET STREET 2: FLOOR 6 CITY: BURLINGTON STATE: MA ZIP: 01803 10-Q 1 tm1919474-1_10q.htm FORM 10-Q

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

FORM 10-Q

Quarterly report pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

For the Quarter Ended September 30, 2019

Commission File No. 000-21429

ArQule, Inc.

(Exact Name of Registrant as Specified in its Charter)

Delaware			04-3221586
(State of Incorporation)			(I.R.S. Employer Identification Number)

One Wall Street, Burlington, Massachusetts 01803
(Address of Principal Executive Offices)

(781) 994-0300

(Registrant’s Telephone Number, including Area Code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.01 par value		ARQL		The NASDAQ Stock Market LLC (NASDAQ Global Market)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405) of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ¨		Accelerated filer x
Non-accelerated filer ¨		Smaller reporting company x
		Emerging growth company ¨

If an emerging growth company, indicate by check by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

Number of shares outstanding of the registrant’s Common Stock as of October 16, 2019:

Common Stock, par value $.01 120,733,695 shares outstanding

ARQULE, INC.

QUARTER ENDED SEPTEMBER 30, 2019

TABLE OF CONTENTS

PART I - FINANCIAL INFORMATION

Item 1. — Unaudited Condensed Financial Statements

Condensed Balance Sheets (Unaudited) September 30, 2019 and December 31, 2018	3

Condensed Statements of Operations and Comprehensive Income (Loss) (Unaudited) Three and Nine months ended September 30, 2019 and 2018	4

Condensed Statements of Stockholders’ Equity (Unaudited) Nine months ended September 30, 2019 and 2018	5

Condensed Statements of Cash Flows (Unaudited) Nine months ended September 30, 2019 and 2018	7

Notes to Unaudited Condensed Financial Statements	8

Item 2. — Management’s Discussion and Analysis of Financial Condition and Results of Operations	19

Item 3. — Quantitative and Qualitative Disclosures about Market Risk	25

Item 4. — Controls and Procedures	25

PART II - OTHER INFORMATION

Item 1. — Legal Proceedings	26

Item 1A. — Risk Factors	26

Item 2. — Unregistered Sales of Equity Securities and Use of Proceeds	26

Item 3. — Defaults Upon Senior Securities	26

Item 4. — Mine Safety Disclosures	26

Item 5. — Other Information	26

Item 6. — Exhibits	26

SIGNATURES	26

ARQULE, INC.

CONDENSED BALANCE SHEETS (Unaudited)

	September 30, 2019			December 31, 2018
	(IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA)
ASSETS
Current assets:
Cash and cash equivalents	$	42,199		$	19,236
Marketable securities – short term		83,014			80,322
Contract receivables		874			5,984
Prepaid expenses		1,952			861
Total current assets		128,039			106,403
Marketable securities – long term		48,900			—
Property and equipment, net		463			69
Operating lease assets		2,691			—
Other assets		249			204
Total assets	$	180,342		$	106,676

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable and accrued expenses	$	9,933		$	12,948
Notes payable – current portion		5,000			1,667
Operating lease liability – current portion		546			—
Total current liabilities		15,479			14,615

Long-term liabilities:
Notes payable – long term		9,582			13,093
Operating lease liability – long term		2,155			—
Total liabilities		27,216			27,708

Commitments and contingencies

Stockholders’ equity:
Preferred stock, $0.01 par value; 1,000,000 shares authorized; no shares issued and outstanding		—			—
Common stock, $0.01 par value; 200,000,000 shares authorized; 120,661,081 and 109,003,637 shares issued and outstanding at September 30, 2019 and December 31, 2018, respectively		1,207			1,090
Additional paid-in capital		729,910			625,993
Accumulated other comprehensive income (loss)		127			(95	)
Accumulated deficit		(578,118	)		(548,020	)
Total stockholders’ equity		153,126			78,968
Total liabilities and stockholders’ equity	$	180,342		$	106,676

The accompanying notes are an integral part of these condensed interim unaudited financial statements.

ARQULE, INC.

CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited)

	THREE MONTHS ENDED September 30,						NINE MONTHS ENDED September 30,
	2019			2018			2019			2018
	(IN THOUSANDS, EXCEPT PER SHARE DATA)
Research and development revenue	$	208		$	4,979		$	1,834		$	22,823

Costs and expenses:
Research and development		8,313			7,261			22,091			19,860
General and administrative		3,170			3,429			10,638			8,014
Total costs and expenses		11,483			10,690			32,729			27,874

Loss from operations		(11,275	)		(5,711	)		(30,895	)		(5,051	)

Interest income		961			514			2,085			843
Interest expense		(425	)		(422	)		(1,288	)		(1,235	)
Other expense		—			—			—			(1,552	)

Net loss		(10,739	)		(5,619	)		(30,098	)		(6,995	)

Unrealized gain (loss) on marketable securities		47			(10	)		222			(16	)
Comprehensive loss	$	(10,692	)	$	(5,629	)	$	(29,876	)	$	(7,011	)

Basic and diluted net loss per share:
Net loss per share	$	(0.09	)	$	(0.05	)	$	(0.27	)	$	(0.07	)


Weighted average basic and diluted common shares outstanding		120,374			107,445			113,126			95,678

The accompanying notes are an integral part of these condensed interim unaudited financial statements.

ARQULE, INC.

CONDENSED STATEMENTS OF STOCKHOLDERS’ EQUITY (Unaudited)

(IN THOUSANDS, EXCEPT SHARE DATA)

	PREFERRED STOCK				COMMON STOCK				ADDITIONAL			ACCUMULATED OTHER						TOTAL STOCK-
	SHARES		AMOUNT		SHARES		PAR VALUE		PAID-IN CAPITAL			COMPREHENSIVE INCOME/(LOSS)			ACCUMULATED DEFICIT			HOLDERS’ EQUITY
Balance at December 31, 2018		—	$	—		109,003,637	$	1,090	$	625,993		$	(95	)	$	(548,020	)	$	78,968
Stock option exercises and issuance of common stock		—		—		92,122		1		143			—			—			144
Stock based compensation expense		—		—		—		—		2,124			—			—			2,124
Change in unrealized gain on marketable securities		—		—		—		—		—			117			—			117
Net loss																(10,267	)		(10,267	)
Balance at March 31, 2019		—	$	—		109,095,759	$	1,091	$	628,260		$	22		$	(558,287	)	$	71,086
Issuance of common stock from stock offering, net		—		—		10,637,500		106		97,234			—			—			97,340
Stock option exercises and issuance of common stock		—		—		527,126		6		1,301			—			—			1,307
Stock based compensation expense		—		—		—		—		917			—			—			917
Change in unrealized gain on marketable securities		—		—		—		—		—			58			—			58
Net loss																(9,092	)		(9,092	)
Balance at June 30, 2019		—	$	—		120,260,385	$	1,203	$	727,712		$	80		$	(567,379	)	$	161,616
Issuance of common stock from stock offering, net		—		—		—		—		(13	)		—			—			(13	)
Stock option exercises and issuance of common stock		—		—		286,410		3		1,004			—			—			1,007
Stock issued upon exercise of Warrants		—		—		114,286		1		199			—			—			200
Stock based compensation expense		—		—		—		—		1,008			—			—			1,008
Change in unrealized gain on marketable securities		—		—		—		—		—			47			—			47
Net loss																(10,739	)		(10,739	)
Balance at September 30, 2019		—	$	—		120,661,081	$	1,207	$	729,910		$	127		$	(578,118	)	$	153,126

The accompanying notes are an integral part of these condensed interim unaudited financial statements.

ARQULE, INC.

CONDENSED STATEMENTS OF STOCKHOLDERS’ EQUITY (Unaudited)

(IN THOUSANDS, EXCEPT SHARE DATA)

	PREFERRED STOCK						COMMON STOCK				ADDITIONAL			ACCUMULATED OTHER						TOTAL STOCK-
	SHARES			AMOUNT			SHARES		PAR VALUE		PAID-IN CAPITAL			COMPREHENSIVE INCOME/(LOSS)			ACCUMULATED DEFICIT			HOLDERS’ EQUITY
Balance at December 31, 2017		8,370		$	8,843			87,110,202	$	871	$	547,364		$	(16	)	$	(534,038	)	$	14,181
Stock option exercises and issuance of common stock		—			—			15,125		—		25			—			—			25
Stock based compensation expense		—			—			—		—		423			—			—			423
Warrants issued upon debt extension		—			—			—		—		120			—			—			120
Change in unrealized loss on marketable securities		—			—			—		—		—			(25	)		—			(25	)
Increase to opening accumulated deficit upon adoption of new accounting standard		—			—			—		—		—			—			1,500			1,500
Net loss																		(6,532	)		(6,532	)
Balance at March 31, 2018		8,370		$	8,843			87,125,327	$	871	$	547,932		$	(41	)	$	(539,070	)	$	9,692
Issuance of common stock and warrants due to conversion of preferred stock to common stock and preferred warrants to common warrants		(8,370	)		(8,843	)		8,370,000		84		11,823			—			—			11,907
Stock option exercises and issuance of common stock		—			—			337,616		3		152			—			—			155
Shares issued from exercise of warrants								269,584		3		(2	)								1
Stock based compensation expense		—			—			—		—		314			—			—			314
Change in unrealized gain on marketable securities		—			—			—		—		—			19			—			19
Net income																		5,156			5,156
Balance at June 30, 2018		—		$	—			96,102,527	$	961	$	560,219		$	(22	)	$	(533,914	)	$	27,244
Stock option exercises and issuance of common stock		—			—			241,020		2		555			—			—			557
Issuance of common stock from stock offering, net								12,650,000		127		64,435									64,562
Stock based compensation expense		—			—			—		—		363			—			—			363
Change in unrealized loss on marketable securities		—			—			—		—		—			(10	)		—			(10	)
Net Loss																		(5,619	)		(5,619	)
Balance at September 30,2018		—		$	—			108,993,547	$	1,090	$	625,572		$	(32	)	$	(539,533	)	$	87,097

The accompanying notes are an integral part of these condensed interim unaudited financial statements.

ARQULE, INC.

CONDENSED STATEMENTS OF CASH FLOWS (Unaudited)

	NINE MONTHS ENDED SEPTEMBER 30,
	2019			2018
	(IN THOUSANDS)
Cash flows from operating activities:
Net loss	$	(30,098	)	$	(6,995	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		82			35
Amortization of premium on marketable securities		533			387
Amortization of debt discount		239			242
Change in fair value of warrant liability		—			1,552
Non-cash stock compensation		4,050			1,100
Changes in operating assets and liabilities:
Contract receivables		5,065			(6,401	)
Prepaid expenses and other, net		(1,081	)		(229	)
Accounts payable and accrued expenses		(3,015	)		2,513
Net cash used in operating activities		(24,225	)		(7,796	)
Cash flows from investing activities:
Purchases of marketable securities		(125,645	)		(100,285	)
Proceeds from sale or maturity of marketable securities		73,742			38,779
Purchases of property and equipment		(476	)		—
Net cash used in investing activities		(52,379	)		(61,506	)
Cash flows from financing activities:
Costs from notes payable and warrants, net		—			(48	)
Proceeds from stock offering, net of offering costs		97,327			64,561
Proceeds from stock option exercises and employee stock plan purchases		2,458			738
Proceeds from warrant exercises		199			—
Principal payments on long-term debt		(417	)		—
Net cash provided by financing activities		99,567			65,251
Net increase (decrease) in cash and cash equivalents		22,963			(4,051	)
Cash and cash equivalents, beginning of period		19,236			20,229
Cash and cash equivalents, end of period	$	42,199		$	16,178

The accompanying notes are an integral part of these condensed interim unaudited financial statements.

ARQULE, INC.

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

(IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA)

1. NATURE OF OPERATIONS AND BASIS OF PRESENTATION

We are a biopharmaceutical company engaged in the research and development of innovative therapeutics to treat cancers and rare diseases. Our mission is to discover, develop and commercialize novel small molecule drugs in areas of high unmet need that will dramatically extend and improve the lives of our patients. These product candidates target biological pathways implicated in a wide range of cancers and certain non-oncology indications. Our discovery and development efforts are guided, when possible, by an understanding of the role of biomarkers, which are indicators of a particular biological condition or process and may predict the clinical benefit of our compounds in defined patient populations. Our clinical-stage pipeline consists of four product candidates, all of which are in targeted patient populations, making ArQule a leader among companies our size in precision medicine.

ArQule has a long history of kinase drug discovery and development, having discovered and introduced ten kinase inhibitors into clinical trials. Our drug discovery efforts have been informed by our historical expertise in chemistry, our work in rational drug design and by our insight into kinase binding and regulation. We have applied this knowledge to produce significant chemical matter for a number of kinase targets and to build an extensive library of proprietary compounds with the potential to target multiple kinases in oncology and other therapeutic areas, such as rare diseases. We may bring further preclinical programs forward and interrogate our library against new targets beyond kinases either directly or with collaborators.

Our proprietary pipeline of orally bioavailable product candidates is directed toward molecular targets and biological processes with demonstrated roles in the development of both human cancers and rare, non-oncology diseases. All of these programs are being developed in targeted, biomarker-defined patient populations. By seeking out subgroups of patients that are most likely to respond to our product candidates, we seek to identify small, often orphan, indications that allow for focused and efficient development. At the same time, in addition to pursuing these potentially fast-to-market strategies, we also pursue development in other indications that could allow us to expand the utility of the product candidates if approved. Our clinical pipeline includes the following product candidates:

•

ARQ 531 is a potent and reversible dual inhibitor of both wild type and C481S-mutant Bruton’s tyrosine kinase (BTK) that is in Phase 1/2 clinical development for B-cell malignancies refractory to other therapeutic options;

•

Miransertib (ARQ 092) is a potent and selective inhibitor of protein kinase B (AKT), a serine/threonine kinase that is in a registrational clinical trial for the treatment of Proteus syndrome and PIK3CA-Related Overgrowth Syndromes (PROS);

•

ARQ 751 is a next-generation, highly potent and selective inhibitor of AKT that is in Phase 1 clinical development for solid tumors harboring AKT, phosphoinositide 3-kinase (PI3K) or phosphatase and tensin homolog (PTEN) loss mutations or that are PTEN null; and

•

Derazantinib (ARQ 087) is a multi-kinase inhibitor designed to preferentially inhibit the fibroblast growth factor receptor (FGFR) family of kinases that is in a registrational clinical trial in intrahepatic cholangiocarcinoma (iCCA) in patients with FGFR2 fusions. Derazantinib was exclusively licensed to Basilea Pharmaceutica Limited (Basilea) in April 2018 in the United States, European Union, Japan and the rest of the world, excluding the People’s Republic of China, Hong Kong, Macau, and Taiwan (collectively, Greater China) where derazantinib was exclusively licensed to Sinovant Sciences Ltd., a subsidiary of Roivant Sciences Ltd. (Sinovant) in February 2018.

Our uses of cash for operating activities have primarily consisted of salaries and wages for our employees, facility and facility-related costs for our offices and laboratories, fees paid in connection with preclinical and clinical studies, laboratory supplies and materials, and professional fees. The sources of our cash flow from operating activities have historically consisted primarily of upfront and other payments received from our collaborators in connection with license agreements. In the nine months ended September 30, 2019 and 2018, our net use of cash was primarily driven by payments for operating expenses which resulted in net cash outflows of $24.2 million and $7.8 million, respectively.

Our cash requirements may vary materially from those now planned depending on the results of our drug discovery and development strategies, our ability to enter into additional corporate collaborations and the terms of such collaborations, results of research and development, unanticipated required capital expenditures, competitive and technological advances, acquisitions and other factors. We cannot guarantee that we will be able to develop any of our product candidates into a commercial product.

In January 2017, we entered into a loan and security agreement with Oxford Finance, LLC (the “Loan Agreement”) with an initial principal balance of $15 million (see Note 8). The terms of the Loan Agreement, which was amended in February 2018, required only payments of interest on a monthly basis through August 2019. As of September 2019, we are required to make payments of principal and interest on a monthly basis through the maturity date of the loan on August 1, 2022.

In November 2017, we entered into definitive securities purchase agreements with certain institutional investors. In conjunction with this stock offering we raised net proceeds of $9.5 million through the sale of 8,370 shares of series A convertible preferred stock (Series A Preferred) and warrants to purchase 2,259 shares of Series A Preferred (Warrants). Each share of Series A Preferred converted into 1,000 shares of common stock and each associated Warrant converted into 1,000 common stock warrants in May 2018. In September 2019, holders of the common stock warrants exercised warrants covering 114,286 shares of common stock, resulting in net proceeds of $0.2 million. The remaining common stock warrants have a post-conversion exercise price of $1.75 per share, are exercisable immediately and expire in May 2022.

In February 2018, we entered into a License Agreement with Sinovant pursuant to which we granted Sinovant an exclusive license to develop and commercialize derazantinib in Greater China. The agreement provided for an upfront payment to ArQule of $3 million and a $2.5 million development milestone that was paid in the first quarter of 2019. We are also eligible for up to an additional $12.0 million in regulatory milestone payments and $70.0 million in commercial milestone payments. Upon commercialization, we are entitled to receive double digit royalties in the low teens from Sinovant on net sales of derazantinib in Greater China. Sinovant will be responsible for all costs and expenses of development, manufacture and commercialization in Greater China. In the three and nine months ended September 30, 2019, we recognized revenue of $0.2 million and $1.6 million, respectively, for providing certain Manufacturing Services (as defined in Note 2) to Sinovant. During the three and nine months ended September 30, 2018, we recognized revenue of $2.9 million and $5.9 million, respectively, related primarily to the transfer of the license to Sinovant and the expected achievement of a development milestone that was ultimately paid in the first quarter of 2019.

In April 2018, we entered into a License Agreement with Basilea pursuant to which we granted Basilea an exclusive license to develop and commercialize derazantinib in the United States, European Union, Japan and the rest of the world, excluding Greater China. Under the terms of the agreement, we received an upfront payment of $10 million and are eligible for up to $63.0 million in development and regulatory milestone payments and up to $262.5 million in commercial milestone payments. Upon commercialization, we are entitled to receive tiered royalties on future net sales of derazantinib ranging from the high-single digits to the mid-teens on direct sales and mid-single digits to low-double digits on indirect sales. Basilea will be responsible for all costs and expenses of development, manufacture and commercialization in its territory. Under certain circumstances, we may have the opportunity to promote derazantinib in the United States directly. In the three and nine months ended September 30, 2019, we recognized revenue of zero and $0.2 million, respectively, for providing R&D Services (as defined in Note 2) to Basilea, recognized as revenue on a “cost-to-cost method”. In the three and nine months ended September 30, 2018 we recognized revenue of $2.0 million and $15.7 million, respectively, related to providing R&D Services to Basilea as well as the transfer of the Basilea License.

In July 2018, we sold 12,650,000 shares of common stock at $5.50 per share for aggregate net proceeds of approximately $64.6 million after commissions and other offering expenses.

In June 2019, we sold 10,637,500 shares of common stock at $9.75 per share for aggregate net proceeds of approximately $97.3 million after commissions and other offering expenses.

We anticipate that our cash, cash equivalents and marketable securities on hand at September 30, 2019 will be sufficient to finance our operations for at least 12 months from the issuance date of these financial statements. We expect that we will need to raise additional capital or incur indebtedness to continue to fund our operations in the future. Our ability to raise additional funds will depend on financial, economic and market conditions, and due to global capital and credit market conditions or for other reasons, we may be unable to raise capital when needed, or on terms favorable to us. If necessary funds are not available, we may have to delay, reduce the scope of, or eliminate some of our development programs, potentially delaying the time to market for any of our product candidates.

2. COLLABORATIONS AND ALLIANCES

Basilea Agreement

In April 2018, we entered into a License Agreement with Basilea (the “Basilea Agreement”) pursuant to which we granted Basilea an exclusive license to develop and commercialize derazantinib in the United States, European Union, Japan and the rest of the world, excluding Greater China (the “Basilea Territory”). Under the terms of the Basilea Agreement, we received an upfront payment of $10.0 million. In addition, we are eligible to receive up to $63.0 million in development and regulatory milestone payments across multiple indications in the United States, European Union and Japan, none of which exceed $12.0 million on an individual basis, and up to $262.5 million in commercial milestone payments based upon the attainment of specified calendar year net sales levels for all indications in the Basilea Territory. Upon commercialization, we are entitled to receive tiered royalties on future net sales of derazantinib ranging from the high-single digits to the mid-teens on direct sales in the Basilea Territory and mid-single digits to low-double digits on indirect sales in the Basilea Territory. Basilea is responsible for all costs and expenses of development, manufacture and commercialization in its territory. Under certain circumstances, we may have the opportunity to promote derazantinib in the United States directly.

We evaluated the Basilea Agreement in accordance with ASC 606, Revenue from Contracts with Customers . We concluded there were two performance obligations under the Basilea Agreement at contract inception: (1) the grant of the exclusive license (the “Basilea License”) to derazantinib in the Basilea Territory and (2) the provision of specified research and development services to Basilea (the “R&D Services”).

The total transaction price for the Basilea Agreement at contract inception was determined to be $19.8 million, which was comprised of the $10.0 million upfront payment and an estimated $9.8 million of variable consideration to be received for the R&D Services. As of June 30, 2019, the R&D Services performance obligation was substantially complete. At contract inception, the variable consideration associated with development and regulatory milestone payments was excluded from the transaction price, and as of September 30, 2019 continued to be excluded from the transaction price, as achievement of the milestones is contingent upon future events and is not considered the most-likely outcome. We update our estimates for development and regulatory milestone variable consideration at each reporting date and will recognize revenue associated with a particular milestone when achieving the milestone is considered the most-likely outcome and it is probable that a significant reversal of cumulative revenue under the contract will not occur. The commercial milestone and royalty consideration were excluded from the transaction price because the Basilea License was determined to be the predominant item in the contract. As a result, we will recognize revenue associated with the commercial milestones and royalties at the later of when (i) the related sales occur or (ii) the performance obligation to which some or all of the applicable commercial milestone and/or royalty has been allocated has been satisfied (or partially satisfied). As of September 30, 2019, we have not recognized any commercial milestone or royalty revenue under the Basilea Agreement.

The total transaction price was allocated to the two performance obligations based on the relative standalone selling price of each performance obligation at contract inception. The standalone selling price for the Basilea License was determined on a discounted cash flow basis. At contract inception, $10.3 million of the total transaction price was allocated to the Basilea License and was recognized when control of the Basilea License was transferred and the license period began. The standalone selling price for the R&D Services was determined based upon a cost-plus margin approach. At contract inception, $9.5 million of the transaction price was allocated to the R&D Services. Revenue related to the R&D Services is recognized on a “cost-to-cost” percentage of completion basis as the services are performed.

For the three and nine months ended September 30, 2019, we recognized revenue of zero and $0.2 million, respectively, under the Basilea Agreement related to R&D Services provided to Basilea. For the three and nine months ended September 30, 2018, we recognized revenue of $2.0 million and $15.7 million, respectively, related to providing R&D Services to Basilea as well as the transfer of the Basilea License.

Sinovant Agreement

In February 2018, we entered into a License Agreement with Sinovant (the “Sinovant Agreement”) pursuant to which we granted Sinovant an exclusive license to develop, manufacture and commercialize derazantinib in Greater China. Under the terms of the Sinovant Agreement, we have received an upfront payment of $3.0 million and recognized a $2.5 million regulatory milestone payment in the third quarter of 2018. We are also eligible to receive up to an additional $12.0 million in regulatory milestone payments across multiple indications in Greater China and $70.0 million in commercial milestone payments based upon the attainment of specified calendar year net sales levels for all indications in Greater China. Upon commercialization, we are entitled to receive double digit royalties in the low teens from Sinovant on net sales of derazantinib in Greater China. Sinovant will be responsible for all costs and expenses of development, manufacture and commercialization in Greater China.

We evaluated the Sinovant Agreement in accordance with ASC 606, Revenue from Contracts with Customers. We concluded that the only performance obligation under the Sinovant Agreement at contract inception was the grant of the exclusive license (the “Sinovant License”) to derazantinib in Greater China. The Sinovant Agreement also contemplated that we might provide certain manufacturing services (the “Manufacturing Services”), which we concluded was not a separate performance obligation at contract inception.

The total transaction price for the Sinovant Agreement at contract inception was determined to be $3.0 million, which was equal to the upfront payment under the Sinovant Agreement. The $3.0 million was fully allocable to the Sinovant License and was recognized as revenue when control was transferred and the license period began. Our right to receive regulatory milestone payments is considered variable consideration. At contract inception, the variable consideration associated with regulatory milestone payments was excluded from the transaction price as achievement of the milestones was contingent upon future events and achievement of the milestones is not considered the most-likely outcome. We update our estimates for regulatory milestones at each reporting date and will recognize revenue associated with a particular milestone when we determine that achieving the milestone is the most-likely outcome and it is probable that a significant reversal of cumulative revenue under the contract will not occur. Based on the above analysis, we recognized $2.5 million in revenue associated with a regulatory milestone in the third quarter of 2018. The commercial milestones and royalty consideration were excluded from the transaction price because the Sinovant License is the only performance obligation and therefore considered the predominant item under the contract. As a result, we recognize revenue associated with the commercial milestones and royalties at the later of when (i) the related sales occur or (ii) the performance obligation to which some or all of the applicable commercial milestone and/or royalty has been allocated has been satisfied (or partially satisfied). As of September 30, 2019, we have not recognized any commercial milestone or royalty revenue under the Sinovant Agreement.

In December 2018, we entered into a Supply Agreement with Sinovant where we agreed to provide the Manufacturing Services to Sinovant beyond the term contemplated for those services under the Sinovant Agreement. The Manufacturing Services are the only performance obligation under the Supply agreement and revenue related to the Supply Agreement is recognized on a “cost-to-cost” percentage of completion basis as the services are performed.

For the three and nine months ended September 30, 2019, we recognized revenue of $0.2 million and $1.6 million, respectively, under the Sinovant Agreement related to the Manufacturing Services that we provided. For the three and nine months ended September 30, 2018, we recognized revenue of $2.9 million and $5.9 million, respectively, related primarily to the transfer of the Sinovant License and the achievement of a regulatory milestone discussed above.

Other Licensing Agreements

In October 2017, we granted a third party a non-exclusive license to certain of our library compounds. The licensed compounds were delivered and were accepted by the third party in 2018. Accordingly, revenue for the three and nine months ended September 30, 2019 was zero. For the three and nine months ended September 30, 2018, we recorded revenue of $0.1 million and $1.3 million, based upon the achievement of the quality and acceptance testing.

3. MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS

We generally classify our marketable securities as available-for-sale at the time of purchase and re-evaluate such designation as of each balance sheet date. Since we generally intend to convert them into cash as necessary to meet our liquidity requirements our marketable securities are classified as cash equivalents if the original maturity, from the date of purchase, is ninety days or less and as short-term investments if the original maturity, from the date of purchase, is in excess of ninety days but less than or equal to one year. Our marketable securities are classified as long-term investments if the maturity date is in excess of one year of the balance sheet date.

We report available-for-sale debt securities at fair value as of each balance sheet date and include any unrealized gains and, to the extent deemed temporary, unrealized losses in stockholders’ equity. Realized gains and losses are determined using the specific identification method and are included in other income (expense) in the statements of operations and comprehensive loss.

We conduct quarterly reviews to determine the fair value of our investment portfolio and to identify and evaluate each investment that has an unrealized loss, in accordance with the meaning of other-than-temporary impairment and its application to certain investments. An unrealized loss exists when the current fair value of an individual security is less than its amortized cost basis. In the event that the cost basis of a security exceeds its fair value, we evaluate, among other factors, the duration of the period that, and extent to which, the fair value is less than cost basis, the financial health of and business outlook for the issuer, including industry and sector performance, and operational and financing cash flow factors, overall market conditions and trends, our intent to sell the investment and if it is more likely than not that we would be required to sell the investment before its anticipated recovery. Unrealized losses on available-for-sale securities that are determined to be temporary, and not related to credit loss, are recorded in accumulated other comprehensive income (loss).

For available-for-sale debt securities with unrealized losses, we perform an analysis to assess whether we intend to sell or whether we would more likely than not be required to sell the security before the expected recovery of the amortized cost basis. Where we intend to sell an available-for-sale debt security, or may be required to do so, the security’s decline in fair value is deemed to be other-than-temporary and the full amount of the unrealized loss is reflected in the statements of operations and comprehensive loss as an impairment loss.

Regardless of our intent to sell a security, we perform additional analysis on all securities with unrealized losses to evaluate losses associated with the creditworthiness of the security. Credit losses are identified where we do not expect to receive cash flows sufficient to recover the amortized cost basis of a security.

We invest our available cash primarily in commercial paper, money market funds, and U.S. Treasury bill funds that have investment grade ratings.

The following is a summary of the fair value of available-for-sale marketable securities we held at September 30, 2019 and December 31, 2018 (in thousands):

September 30, 2019	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
Security type
Corporate debt securities-short term	$	82,929	$	89	$	(4	)	$	83,014
Corporate debt securities-long term		48,857		50		(7	)		48,900
Total available-for-sale marketable securities	$	131,786	$	139	$	(11	)	$	131,914

December 31, 2018	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
Security type
Corporate debt securities-short term	$	80,417	$	2	$	(97	)	$	80,322
Total available-for-sale marketable securities	$	80,417	$	2	$	(97	)	$	80,322

None of our available-for-sale marketable securities were in a continuous unrealized loss position for more than 12 months at September 30, 2019 or December 31, 2018.

The following tables present information about our assets and liabilities that are measured at fair value on a recurring basis for the periods presented and indicates the fair value hierarchy of the valuation techniques we utilized to determine such fair value. There were no transfers in or out of Level 1 or Level 2 measurements for the periods presented (in thousands):

	September 30, 2019		Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Cash equivalents	$	40,662	$	40,662	$	—	$	—
Corporate debt securities-short term		83,014		—		83,014		—
Corporate debt securities-long term		48,900		—		48,900		—
Total	$	172,576	$	40,662	$	131,914	$	—

	December 31, 2018		Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Cash equivalents	$	14,444	$	14,444	$	—	$	—
Corporate debt securities-short term		80,322		—		80,322		—
Total	$	94,766	$	14,444	$	80,322	$	—

4. ACCOUNTS PAYABLE AND ACCRUED EXPENSES

Accounts payable and accrued expenses include the following at September 30, 2019 and December 31, 2018 (in thousands):

	September 30, 2019		December 31, 2018
Accrued outsourced preclinical and clinical fees	$	5,748	$	8,497
Accrued payroll		2,154		1,971
Accrued professional fees		905		666
Accounts payable		801		1,329
Other accrued expenses		325		485
	$	9,933	$	12,948

5. NET LOSS PER SHARE

Net loss per share is computed using the weighted average number of common shares outstanding. Basic and diluted net loss per share amounts are equivalent for the periods presented as the inclusion of potential common shares in the number of shares used for the diluted computation would be anti-dilutive to loss per share. Potential common shares, for the three and nine months ended September 30, 2019, include 12,376,291 shares that would be issued upon the exercise of outstanding employee and Board of Director stock options, 93,168 shares that would be issued upon the exercise of the warrants from our February 2018 amendment to our loan agreement, 3,123,674 shares that would be issued upon the exercise of the warrants from our October 2017 common stock offering and 2,144,714 common shares that would be issued upon the exercise of the warrants from our November 2017 preferred stock offering. Potential common shares, for the three and nine months ended September 30, 2018, include 10,720,022 shares that would be issued upon the exercise of outstanding employee and Board of Director stock options, 93,168 shares that would be issued upon the exercise of the warrants from our February 2018 amendment to our loan agreement, 3,123,674 shares that would be issued upon the exercise of the warrants from our October 2017 common stock offering and 2,259,000 common shares that would be issued upon the exercise of the warrants from our November 2017 preferred stock offering. The preferred shares and warrants from our November 2017 preferred stock offering were converted to common stock and common stock warrants in May 2018.

6. STOCK-BASED COMPENSATION AND STOCK PLANS

Our stock-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense over the employees’ requisite service period (generally the vesting period of the equity grant). We estimate the fair value of stock options using the Black-Scholes valuation model. Key input assumptions used to estimate the fair value of stock options include the exercise price of the award, expected option term, expected volatility of our stock over the option’s expected term, risk-free interest rate over the option’s expected term, and the expected annual dividend yield. We believe that the valuation technique and approach utilized to develop the underlying assumptions are appropriate in calculating the fair values of our stock options granted in the three and nine months ended September 30, 2019 and 2018.

The following table presents stock-based compensation expense included in our condensed statements of operations and comprehensive loss (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2019		2018		2019		2018
Research and development	$	223	$	84	$	741	$	269
General and administrative		785		279		3,308		831
Total stock-based compensation expense	$	1,008	$	363	$	4,049	$	1,100

In the nine months ended September 30, 2019, we recorded stock-based compensation expense of $1.0 million related to the modification of awards to our former Chief Financial Officer in connection with his retirement in March 2019. In the three and nine months ended September 30, 2019 and 2018, no stock-based compensation expense was capitalized and there were no recognized tax benefits associated with the stock-based compensation expense.

Option activity under our stock plans for the nine months ended September 30, 2019 was as follows:

Stock Options	Number of Shares			Weighted Average Exercise Price
Outstanding as of December 31, 2018		10,748,157		$	2.90
Granted		2,666,510			4.07
Exercised		(880,868	)		2.70
Cancelled		(157,508	)		2.44
Outstanding as of September 30, 2019		12,376,291		$	3.17

Exercisable as of September 30, 2019		7,207,088		$	3.26

The aggregate intrinsic value of options outstanding at September 30, 2019 was $50.1 million, including $28.7 million related to exercisable options. The weighted average fair value of options granted in the nine months ended September 30, 2019 and 2018 was $2.54 and $1.70 per share, respectively. The intrinsic value of options exercised in the nine months ended September 30, 2019 was $3.9 million.

	Shares		Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value
Vested and unvested expected to vest at September 30, 2019		12,218,754	$	3.17		6.1	$	49,485
Exercisable at September 30, 2019		7,207,088	$	3.26		4.4	$	28,730

The total compensation cost not yet recognized as of September 30, 2019 related to non-vested option awards was $7.2 million, which will be recognized over a weighted-average period of 2.6 years. During the nine months ended September 30, 2019, 28,350 shares expired and 129,158 shares were forfeited. The weighted average remaining contractual life for options exercisable at September 30, 2019 was 4.37 years.

7. COMMON STOCK OFFERINGS

In June 2019, we sold 10,637,500 shares of common stock at $9.75 per share for aggregate net proceeds of approximately $97.3 million after commissions and other offering expenses.

In July 2018, we sold 12,650,000 shares of common stock at $5.50 per share for aggregate net proceeds of approximately $64.6 million after commissions and other offering expenses.

8. LOAN AGREEMENT

In January 2017, we entered into a loan and security agreement (the “Loan Agreement”) with Oxford Finance LLC, as collateral agent and a lender (the “Lender”), and any additional lenders that may become parties thereto.

Pursuant to the terms of the Loan Agreement, the Lender issued us a loan with an initial principal amount of $15.0 million. The loan bears interest at the rate equal to (a) the greater of (i) the 30 day U.S. LIBOR rate reported in the Wall Street Journal on the date occurring on the last business day of the month that immediately precedes the month in which the interest will accrue or (ii) 0.65% (b) plus 6.85%. The applicable interest rate on the loan at September 30, 2019 was 8.94%. The Loan Agreement required interest-only payments through August 2019, followed by an amortization period of monthly principal and interest payments of 36 months. The original maturity date of the loan was August 1, 2021 and in February 2018 we signed an amendment with the Lender which extended the maturity date by one year to August 1, 2022.

The expected remaining repayment of the $14.583 million loan principal at September 30, 2019 is as follows (in thousands):

2019	$	1,250
2020		5,000
2021		5,000
2022		3,333
	$	14,583

Upon prepayment of the loan or on the maturity date, we will pay to the Lender a final payment of 6% of the full principal amount of the loan. We may elect to prepay all amounts owed prior to the maturity date, provided that a prepayment fee also is paid equal to 1% of the outstanding principal balance.

Pursuant to the terms of the Loan Agreement, we are bound by certain affirmative covenants setting forth actions that are required during the term of the Loan Agreement, including, without limitation, certain information delivery requirements, obligations to maintain certain insurance, and certain notice requirements. Additionally, we are bound by certain negative covenants setting forth actions that are not permitted to be taken during the term of the Loan Agreement without consent, including, without limitation, incurring certain additional indebtedness, entering into certain mergers, acquisitions or other business combination transactions, or incurring any non-permitted lien or other encumbrance on our assets. We were in compliance with the loan covenants at September 30, 2019.

Upon the occurrence of an event of default under the Loan Agreement (subject to cure periods for certain events of default), all amounts owed by us thereunder will begin to bear interest at a rate that is 5% higher than the rate that is otherwise applicable and may be declared immediately due and payable by the Lender. Events of default under the Loan Agreement include, among other things, the following: the occurrence of certain bankruptcy events; the failure to make payments under the Loan Agreement when due; the occurrence of a material adverse change in our business, operations or financial condition; the rendering of certain types of fines or judgments against us; any breach by us of any covenant (subject to cure for certain covenants only) made in the Loan Agreement; and the failure of any representation or warranty made by us in connection with the Loan Agreement to be correct in all material respects when made.

We have granted the Lender, a security interest in substantially all of our personal property, rights and assets, other than intellectual property, to secure the payment of all amounts owed to the Lender under the Loan Agreement. We have also agreed not to encumber any of our intellectual property without the Lender’s prior written consent.

In February 2018, the Loan Agreement was amended to extend the maturity date and to require payments of interest on a monthly basis through August 2019 and payments of interest and principal from September 2019 to August 2022. In connection with entering into the amendment we issued to the Lender warrants to purchase an aggregate of 93,168 shares of our common stock. The warrants are exercisable immediately, have a per-share exercise price of $1.61 and have a term of ten years. The amendment was determined to be a modification of debt in accordance with ASC 470 Debt. We have recorded the relative fair value of the additional warrants as a discount to the carrying value of the notes payable with a corresponding increase to additional paid in capital.

9. PREFERRED STOCK AND WARRANT LIABILITY

Our Restated Certificate of Incorporation, as amended, authorizes the issuance of up to 1 million shares of $0.01 par value preferred stock.

The terms of the Series A Preferred for which the warrants were exercisable required that the fair value allocated to the warrants at the date of issuance be recorded as a liability on our balance sheet. The warrant liability was marked to market value through the statement of operations and comprehensive loss as a non-cash gain or loss at each reporting period until the conversion of the Series A Preferred to common stock in May 2018. Upon conversion, the warrant liability of $3.1 million was extinguished with an offsetting amount included as additional paid-in capital in stockholders’ equity. Accordingly, at each of December 31, 2018 and September 30, 2019, the warrant liability was zero. In the three and nine months ended September 30, 2018, we recognized a non-cash expense of zero and $1.5 million, respectively, recorded in other expense on the statement of operations and comprehensive loss related to the change in the fair value of the warrant liability.

10. RECENT ACCOUNTING PRONOUNCEMENTS

Recently Adopted Accounting Pronouncements

In February 2016 the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) No. 2016-02, Leases (Topic 842). This standard established a right-of-use model that requires all lessees to recognize right-of-use assets and liabilities on their balance sheet that arise from leases with terms longer than 12 months as well as provide disclosures with respect to certain qualitative and quantitative information related to their leasing arrangements. This standard became effective for us on January 1, 2019 (“the Effective Date”).

The FASB has subsequently issued the following amendments to ASU 2016-02, which also became effective on January 1, 2019, and which we collectively refer to as the new leasing standards:

•

ASU No. 2018-01, Leases (Topic 842): Land Easement Practical Expedient for Transition to Topic 842, which permits an entity to elect an optional transition practical expedient to not evaluate under Topic 842 land easements that exist or expired prior to adoption of Topic 842 and that were not previously accounted for as leases under the prior standard, ASC 840, Leases.

•

ASU No. 2018-10, Codification Improvements to Topic 842, Leases, which amends certain narrow aspects of the guidance issued in ASU 2016-02.

•

ASU No. 2018-11, Leases (Topic 842): Targeted Improvements, which allows for a transition approach to initially apply ASU 2016-02 at the adoption date and recognize a cumulative-effect adjustment to the opening balance of accumulated deficit in the period of adoption as well as an additional practical expedient for lessors to not separate non-lease components from the associated lease component.

•

ASU No. 2018-20, Narrow-Scope Improvements for Lessors, which contains certain narrow scope improvements to the guidance issued in ASU 2016-02.

We adopted the new lease accounting standard on January 1, 2019, using a modified retrospective transition approach of applying the new standard to all leases existing as of, or entered into after, the Effective Date and with remaining terms of 12 months or more. Our assessment included the lease of our headquarters in Burlington, MA which commenced in May 2015 and, prior to our October 2019 amendment discussed below, was scheduled to expire in July 2020 and our laboratory space in Woburn, MA which commenced in March 2019 and expires in April 2024.

The adoption of the new standard on January 1, 2019 resulted in the recording of a right-of-use asset and lease liability of $0.7 million related to the lease of our headquarters in Burlington, MA that existed on the Effective Date. The lease liability is based on the present value of the remaining minimum lease payments, discounted using our secured incremental borrowing rate at the Effective Date. As permitted under ASC 842, we elected several practical expedients and therefore did not reassess at the Effective Date (1) whether any existing contract is or contains a lease, (2) the classification of existing leases, and (3) whether previously capitalized costs continue to qualify as initial indirect costs. We also elected the practical expedient to not separate lease and non-lease components. The application of the practical expedients did not have a significant impact on the measurement of the operating lease liability. In addition, we implemented internal controls to enable the preparation of financial information on adoption. The adoption did not have a material impact on our condensed financial statements related to the existing lease of our headquarters in Burlington, MA for the three and nine months ended September 30, 2019. As a result, there was no cumulative-effect adjustment.

For contracts entered into on or after the Effective Date, at the inception of a contract we assess whether the contract is, or contains, a lease. Our assessment is based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether we obtain the right to substantially all the economic benefit from the use of the asset throughout the period, and (3) whether we have the right to direct the use of the asset. At inception of a lease, we allocate the consideration in the contract to each lease component based on its relative stand-alone price to determine the lease payments.

Leases are classified as either finance leases or operating leases. A lease is classified as a finance lease if any one of the following criteria are met: (1) the lease transfers ownership of the asset by the end of the lease term, (2) the lease contains an option to purchase the asset that is reasonably certain to be exercised, (3) the lease term is for a major part of the remaining useful life of the asset or (4) the present value of the lease payments equals or exceeds substantially all of the fair value of the asset. A lease is classified as an operating lease if it does not meet any one of these criteria. Our leases are comprised of operating leases related to our headquarters in Burlington, MA and laboratory space in Woburn, MA.

For all leases at the lease commencement date, a right-of-use asset and a lease liability are recognized. The right-of-use asset represents the right to use the leased asset for the lease term. The lease liability represents the present value of the lease payments under the lease.

The right-of-use asset is initially measured at cost, which primarily comprises the initial amount of the lease liability, plus any initial direct costs incurred, consisting mainly of brokerage commissions, less any lease incentives received. All right-of-use assets are reviewed for impairment. The lease liability is initially measured at the present value of the lease payments, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the secured incremental borrowing rate. For our operating leases, we use our secured incremental borrowing rate if the implicit lease rate cannot be determined.

Lease payments included in the measurement of the lease liability comprise the following: the fixed noncancelable lease payments, payments for optional renewal periods where it is reasonably certain the renewal period will be exercised, and payments for early termination options unless it is reasonably certain the lease will not be terminated early.

Lease expense for operating leases consists of the lease payments plus any initial direct costs and is recognized on a straight-line basis over the lease term. Certain leases contain rent escalation clauses and variable lease payments that require additional rental payments in later years of the term, including payments based on an index or inflation rate. Payments based on the change in an index or inflation rate, or payments based on a change in our portion of the operating expenses, including real estate taxes and insurance, are not included in the initial lease liability and are recorded as a period expense when incurred. Our operating leases may include an option to renew the lease term for various renewal periods and/or to terminate the leases early. As an option to exercise the renewal or early termination of our operating leases were either non-existent or not reasonably certain as of the ASC 842 Effective Date for our headquarters in Burlington, MA and the lease commencement date of our laboratory space in Woburn, MA, we did not include such options in our initial lease liability. Subsequent to the Effective Date and during the quarter ending September 30, 2019, the option to renew the lease term of our headquarters in Burlington, MA became reasonably certain. This resulted in a $1.98 million increase of our right-of-use asset and lease liability of as of September 30, 2019.

As of September 30, 2019, we recognized right-of-use assets related to our headquarters in Burlington, MA and laboratory space in Woburn, MA of $2.7 million and the related net lease liabilities of $2.7 million, which represents the net present value of the remaining lease payments of approximately $3.7 million, discounted using the Company’s incremental borrowing rate of 8.87%. We have included the right-of-use assets and lease liabilities in the condensed balance sheet as of September 30, 2019.

The following table summarizes future minimum lease payments for our operating leases as of September 30, 2019 (in thousands):

Year Ending December 31,
2019 (three months ending December 31, 2019)	$	152
2020		619
2021		642
2022		657
2023		672
Thereafter		963
Total minimum lease payments	$	3,705

In October 2019, we entered into an amendment to the lease of our headquarters in Burlington, MA that increased the amount of space subject to the lease and extended the term of the lease until July 2025.

As previously disclosed in our 2018 Annual Report on Form 10-K and under the previous lease accounting standard, ASC 840, Leases , the total commitment for our non-cancelable operating lease was $0.8 million as of December 31, 2018 (in thousands):

Year Ending December 31,
2019	$	523
2020		296
Thereafter		—
Total minimum lease payments	$	819

Recently Issued Accounting Pronouncements

In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement, (“ASU 2018-13”). The new standard removes certain disclosures, modifies certain disclosures and adds additional disclosures related to fair value measurement. The new standard will be effective beginning January 1, 2020. We are currently evaluating the impact that the adoption of ASU 2018-13 will have on our consolidated financial statements.

In August 2018, the FASB issued ASU 2018-15, Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract, (“ASU 2018-15”). The amendments in this update align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). The accounting for the service element of a hosting arrangement that is a service contract is not affected by the amendments in this update. The new standard will be effective beginning January 1, 2020. The amendments in this update should be applied either retrospectively or prospectively to all implementation costs incurred after the date of adoption. We are currently evaluating the impact that the adoption of ASU 2018-15 will have on our consolidated financial statements.

In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments”. This ASU will require that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard will require allowances to be recorded instead of reducing the amortized cost of the investment. ASU 2016-13 will limit the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which the carrying value exceeds the fair value and requires the reversal of previously recognized credit losses if fair value increases. ASU 2016-13 will be effective for fiscal years beginning after December 15, 2019 with early adoption permitted, and requires adoption using a modified retrospective approach, with certain exceptions. Based on the composition of the Company’s investment portfolio, current market conditions and historical credit loss activity, we are currently evaluating the impact of the adoption of this standard on the Company’s financial statements.

11. INCOME TAXES

As of December 31, 2018, we had federal net operating losses (“NOL”), state NOL, and research and development credit carryforwards of approximately $422,045, $240,916 and $28,378 respectively, which expire at various dates through 2037.

As of September 30, 2019, and December 31, 2018 we had no unrecognized tax benefits. We do not expect that the total amount of unrecognized tax benefits will significantly increase in the next twelve months. Our policy is to recognize interest and penalties related to uncertain tax positions in income tax expense. As of September 30, 2019, and December 31, 2018, we had no accrued interest or penalties related to uncertain tax positions. Our U.S. federal tax returns for the tax years 2015 through 2018 and our state tax returns for the tax years 2015 through 2018 remain open to examination. Prior tax years remain open to the extent of NOL and tax credit carryforwards.

Utilization of NOL and research and development credit carryforwards may be subject to a substantial annual limitation in the event of an ownership change that has occurred previously or could occur in the future pursuant to Section 382 and 383 of the Internal Revenue Code of 1986, as amended, as well as similar state provisions. An ownership change may limit the amount of NOL and research and development credit carryforwards that can be utilized annually to offset future taxable income, and may, in turn, result in the expiration of a portion of those carryforwards before utilization. In general, an ownership change, as defined by Section 382, results from transactions that increase the ownership of certain stockholders or public groups in the stock of a corporation by more than 50 percentage points over a three-year period. We undertook a detailed study of our NOL and research and development credit carryforwards through January 31, 2019, to determine whether such amounts are likely to be limited by Sections 382 or 383. As a result of this analysis, we currently do not believe any Sections 382 or 383 limitations will significantly impact our ability to offset income with available NOL and research and development credit carryforwards. However, future ownership changes under Section 382 may limit our ability to fully utilize these tax benefits.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion should be read in conjunction with our condensed financial statements and accompanying notes contained in this quarterly report on Form 10-Q and our audited financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2018.

Our pipeline of orally bioavailable product candidates is directed toward molecular targets and biological processes with demonstrated roles in the development of both human cancers and rare, non-oncology diseases. All of these programs are being developed in targeted, biomarker-defined patient populations. By seeking out subgroups of patients that are most likely to respond to our product candidates, we seek to identify small, often orphan, indications that allow for focused and efficient development. At the same time, in addition to pursuing these potentially fast-to-market strategies, we also pursue development in other indications that could allow us to expand the utility of the product candidates if approved. Our clinical pipeline includes the following product candidates:

•

We have incurred a cumulative deficit of approximately $578 million from inception through September 30, 2019. We recorded a net loss for 2018 and expect a net loss for 2019.

LIQUIDITY AND CAPITAL RESOURCES

	September 30,		December 31,		Increase (decrease)
	2019		2018		$		%
	(in millions)
Cash, cash equivalents and marketable securities	$	174.1	$	99.6	$	74.5		75	%
Working capital		112.6		91.8		20.8		23	%

	Nine Months Ended
	September 30,			September 30,			Increase
	2019			2018			(decrease)
	(in millions)
Cash flow from:
Operating activities	$	(24.2	)	$	(7.8	)	$	(16.4	)
Investing activities		(52.4	)		(61.5	)		9.1
Financing activities		99.6			65.3			34.3

Cash flow from operating activities. Our uses of cash for operating activities have primarily consisted of salaries and wages for our employees, facility and facility-related costs for our offices and laboratories, fees paid in connection with preclinical and clinical studies, laboratory supplies and materials and professional fees. The sources of our cash flow from operating activities have consisted primarily of upfront and other payments received from our collaborators in connection with license agreements. In the nine months ended September 30, 2019 and 2018, our net use of cash was primarily driven by the difference between cash received from our collaborations and payments for operating expenses which resulted in net cash outflows of $24.2 million and $7.8 million, respectively.

Cash flow from investing activities. Our net cash used by investing activities of $52.4 million and $61.5 million for the nine months ended September 30, 2019 and 2018, respectively, was comprised of net purchases of marketable securities. The composition and mix of cash, cash equivalents and marketable securities may change frequently as a result of our constant evaluation of conditions in financial markets, the maturity of specific investments, and our near-term liquidity needs.

Our cash equivalents and marketable securities typically include commercial paper, money market funds, and U.S. Treasury bill funds, which have investment grade ratings. Our cash equivalents and our portfolio of marketable securities are subject to market risk due to changes in interest rates. Fixed rate interest securities may have their market value adversely impacted due to a rise in interest rates, while floating rate securities may produce less income than expected if interest rates fall. Due in part to these factors, our future investment income may fall short of expectation due to changes in interest rates or we may suffer losses in principal if we are forced to sell securities that decline in market value due to changes in interest rates.

Cash flow from financing activities. Our net cash provided by financing activities of $99.6 million for the nine months ended September 30, 2019, was primarily comprised of $97.3 million in net proceeds from our June 2019 stock offering, $2.5 million from stock option exercises, $0.2 million from warrant exercises partially offset by a $0.4 million principal payment on long term debt. Our net cash provided by financing activities of $65.3 million for the nine months ended September 30, 2018 was principally comprised of $64.6 million in net proceeds from our July 2018 stock offering and $0.7 million from stock option exercises.

Our cash requirements may vary materially from those now planned depending upon the results of our drug discovery and development strategies, our ability to enter into additional corporate collaborations and the terms of such collaborations, results of research and development, unanticipated required capital expenditures, competitive and technological advances, acquisitions and other factors. We cannot guarantee that we will be able to develop any of our drug candidates into a commercial product. In January 2017, we entered into Loan Agreement with an initial principal balance of $15 million (see Note 8). The terms of the Loan Agreement require payments of interest and principal on a monthly basis through August 2022.

In November 2017, we entered into definitive securities purchase agreements with certain institutional investors. In conjunction with this stock offering, we raised net proceeds of $9.5 million through the sale of 8,370 shares of series A convertible preferred stock (Series A Preferred) and warrants to purchase 2,259 shares of Series A Preferred (Warrants). Each share of Series A Preferred converted into 1,000 shares of common stock and each associated Warrant converted into 1,000 common stock warrants in May 2018. In September 2019, holders of the common stock warrants exercised warrants covering 114,286 shares of common stock, resulting in net proceeds of $0.2 million. The remaining common stock warrants have a post-conversion exercise price of $1.75 per share, are exercisable immediately and expire in May 2022.

In February 2018, we entered into a License Agreement with Sinovant pursuant to which we granted Sinovant an exclusive license to develop and commercialize derazantinib in Greater China. The agreement provided for an upfront payment to ArQule of $3 million and a $2.5 million development milestone that was paid in the first quarter of 2019. We are also eligible for up to an additional $12.0 million in regulatory milestone payments and $70.0 million in commercial milestone payments. Upon commercialization, we are entitled to receive double digit royalties in the low teens from Sinovant on net sales of derazantinib in Greater China. Sinovant will be responsible for all costs and expenses of development, manufacture and commercialization in Greater China. For the three and nine months ended September 30, 2019, we recognized revenue of $0.2 million and $1.6 million, respectively, for providing certain manufacturing services to Sinovant. For the three and nine months ended September 30, 2018, we recognized revenue of $2.9 million and $5.9 million, respectively, related to the transfer of the license to Sinovant and the expected achievement of a regulatory milestone that was ultimately paid in the first quarter of 2019.

In April 2018, we entered into a License Agreement with Basilea pursuant to which we granted Basilea an exclusive license to develop and commercialize derazantinib in the United States, European Union, Japan and the rest of the world, excluding Greater China. Under the terms of the agreement, we received an upfront payment of $10 million and are eligible for up to $63.0 million in development and regulatory milestone payments and up to $262.5 million in commercial milestone payments. Upon commercialization, we are entitled to receive tiered royalties on future net sales of derazantinib ranging from the high-single digits to the mid-teens on direct sales and mid-single digits to low-double digits on indirect sales. Basilea will be responsible for all costs and expenses of development, manufacture and commercialization in its territory. Under certain circumstances, we may have the opportunity to promote derazantinib in the United States directly. For the three and nine months ended September 30, 2019, we recognized revenue of zero and $0.2 million, respectively, for providing certain research and development services to Basilea, recognized as revenue on a “cost-to-cost” method. Revenue for the three months ended September 30, 2018 totaled $2.0 million for providing certain research and development services to Basilea, recognized as revenue on a “cost-to-cost” method. Revenue for the nine months ended September 30, 2018 totaled $15.7 million related to the transfer of the license to Basilea as well as the provision of certain research and development services to Basilea, recognized as revenue on a “cost-to-cost” method.

In July 2018, we sold 12,650,000 shares of common stock at $5.50 per share for aggregate net proceeds of approximately $64.6 million after commissions and other offering expenses.

In June 2019, we sold 10,637,500 shares of common stock at $9.75 per share for aggregate net proceeds of approximately $97.3 million after commissions and other offering expenses.

We anticipate that our cash, cash equivalents and marketable securities on hand at September 30, 2019 and the financial support from our licensing agreements will be sufficient to finance our operations into 2022 which is in excess of at least 12 months from the issuance date of these financial statements.

We expect that we will need to raise additional capital or incur indebtedness to continue to fund our operations in the future. Our ability to raise additional funds will depend on financial, economic and market conditions, and due to global capital and credit market conditions or for other reasons, we may be unable to raise capital when needed, or on terms favorable to us. If necessary funds are not available, we may have to delay, reduce the scope of, or eliminate some of our development programs, potentially delaying the time to market for any of our product candidates.

Our contractual obligations were comprised of the following as of September 30, 2019 (in thousands):

	Payment due by period
Contractual Obligations	Total		Less than 1 year		1 - 3 years		3 - 5 years		More than 5 years
Notes payable	$	15,483	$	5,000	$	10,483	$	—	$	—
Interest on notes payable		1,692		952		740		—		—
Operating lease obligations		3,705		611		1,292		1,304		498
Purchase obligations		5,748		5,748		—		—		—
Total	$	26,628	$	12,311	$	12,515	$	1,304	$	498

In January 2015, we entered into a lease agreement for our headquarters facility in Burlington, MA. The lease commenced on May 1, 2015 for a term of five years and three months with an average annual rental rate of $0.5 million and included an option to extend the lease for a renewal term of five years commencing in August, 2020. As of September 30, 2019, it was reasonably certain that the option to renew the lease term would be exercised. This resulted in a $1.98 million increase of our right-of-use asset and lease liability of as of September 30, 2019. In October 2019, we entered into an amendment to the lease of our headquarters in Burlington, MA that increased the amount of space subject to the lease and extended the term of the lease until July 2025. In January 2019, we entered into a lease agreement for our laboratory space in Woburn, MA. The lease commenced on March 6, 2019 for a term of five years and one month. The lease agreement for the laboratory space includes a rent escalation clause, and accordingly, rent expense is being recognized on a straight-line basis over the lease term. The obligations for our operating leases are included in the table above.

Purchase obligations are comprised primarily of outsourced preclinical and clinical trial expenses and payments to license certain intellectual property to support our research efforts.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

A “critical accounting policy” is one which is both important to the portrayal of our financial condition and results and requires management’s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. For additional information, please see the discussion of our significant accounting policies in Note 2 to the Financial Statements included in our Annual Report for the fiscal year ended December 31, 2018 on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 7, 2019.

RESULTS OF OPERATIONS

The following are the results of operations for the three and nine months ended September 30, 2019 and 2018:

Revenue

					Increase (decrease)
	2019		2018		$			%
	(in millions)
For the three months ended September 30:
Research and development revenue	$	0.2	$	5.0	$	(4.8	)		(96	)%

For the nine months ended September 30:
Research and development revenue	$	1.8	$	22.8	$	(21.0	)		(92	)%

Research and development revenue in the three months ended September 30, 2019 consisted of $0.2 million from our Sinovant licensing and supply agreements. Research and development revenue in the three months ended September 30, 2018 consisted of $2.8 million from our Sinovant licensing agreement, $2.0 million from our Basilea licensing agreement and $0.1 million from a non-exclusive license agreement for certain of our library compounds.

Research and development revenue in the nine months ended September 30, 2019 consisted of $1.6 million from our Sinovant licensing and supply agreements and $0.2 million from our Basilea licensing agreement. Research and development revenue in the nine months ended September 30, 2018 consisted of $5.9 million from our Sinovant licensing agreement, $15.7 million from our Basilea licensing agreement, and $1.3 million from a non-exclusive license agreement for certain of our library compounds.

Costs and Expenses

Research and development

					Increase (decrease)
	2019		2018		$		%
	(in millions)
For the three months ended September 30:
Research and development	$	8.3	$	7.3	$	1.0		14	%

For the nine months ended September 30:
Research and development	$	22.1	$	19.9	$	2.2		11	%

Research and development expense in the three months ended September 30, 2019 increased by $1.0 million as compared to the three months ended September 30, 2018, primarily due to higher labor related costs and higher outsourced preclinical, clinical and product development costs. Research and development expense in the nine months ended September 30, 2019 increased by $2.2 million as compared to the nine months ended September 30, 2018, primarily due to higher labor related costs and higher outsourced preclinical, clinical and product development costs. At September 30, 2019 we had 24 employees dedicated to our research and development program compared to 19 employees at September 30, 2018.

Overview

Our research and development expense consists primarily of salaries and related expenses for personnel, costs of contract manufacturing services, costs of facilities and equipment, fees paid to professional service providers in conjunction with our clinical trials, fees paid to research organizations in conjunction with preclinical animal studies, costs of materials used in research and development, consulting, license, and sponsored research fees paid to third parties and depreciation of associated laboratory equipment. We expect our research and development expense to remain significant, as we continue to develop our portfolio of oncology and rare disease programs.

We have not accumulated and tracked our internal historical research and development costs or our personnel and personnel-related costs on a program-by-program basis. Our employee and infrastructure resources are allocated across several projects, and many of our costs are directed to broadly applicable research endeavors. As a result, we cannot state the costs incurred for each of our programs on a program-by-program basis.

Our future research and development expenses in support of our current and future programs will be subject to numerous uncertainties in timing and cost to completion. We test potential products in numerous preclinical studies for safety, toxicology, and efficacy. We may conduct multiple clinical trials for each product. As we obtain results from trials, we may elect to discontinue or delay clinical trials for certain products in order to focus our resources on more promising products. Completion of clinical trials may take several years or more, and the length of time and cost of development generally varies substantially according to the type, complexity, novelty, and intended use of a product.

We estimate that clinical trials of the type generally needed to secure new drug approval are typically completed over the following timelines:

Clinical Phase		Estimated Completion Period
Phase 1		1–2 years
Phase 2		2–3 years
Phase 3		2–4 years

The duration and the cost of clinical trials may vary significantly over the life of a project as a result of differences arising during clinical development, including, among others, the following:

•

the number of clinical sites included in the trials;

•

the length of time required to enroll suitable patients;

•

the number of patients that ultimately participate in the trials;

•

the duration of patient follow-up to ensure the absence of long-term product-related adverse events; and

•

the efficacy and safety profile of the product.

An element of our business strategy is to pursue the research and development of a broad pipeline of products. This is intended to allow us to diversify the risks associated with our research and development expenditures. To the extent we are unable to build and maintain a broad pipeline of products, our dependence on the success of one or a few products increases.

Our strategy includes entering into alliance arrangements with third parties to participate in the development and commercialization of our products, such as our collaboration agreements with Basilea and Sinovant. In the event that third parties have control over the clinical trial process for a product, the estimated completion date would be under control of that third party rather than under our control. We cannot forecast with any degree of certainty whether our products will be subject to future collaborative arrangements or how such arrangements would affect our development plans or capital requirements.

As a result of the uncertainties discussed above, we make significant estimates in determining the duration and completion costs of our programs or when and to what extent we will receive cash inflows from the commercialization and sale of a product. Our inability to complete our programs in a timely manner or our failure to enter into appropriate collaborative agreements could significantly increase our capital requirements and could adversely impact our liquidity. These uncertainties could force us to seek additional, external sources of financing from time-to-time in order to continue with our product development strategy. Our inability to raise additional capital, or to do so on terms reasonably acceptable to us, would jeopardize the future success of our business.

General and administrative

					Increase (decrease)
	2019		2018		$			%
	(in millions)
For the three months ended September 30:
General and administrative	$	3.2	$	3.4	$	(0.2	)		(8	)%

For the nine months ended September 30:
General and administrative	$	10.6	$	8.0	$	2.6			33	%

General and administrative expense decreased by $0.2 million in the three months ended September 30, 2019 as compared to the three months ended September 30, 2018, principally due to lower consulting fees.

General and administrative expense increased by $2.6 million in the nine months ended September 30, 2019 as compared to the nine months ended September 30, 2018, principally due to a $1.3 million increase in labor related and other costs and $1.3 million of non-recurring executive retirement costs.

General and administrative headcount was 14 employees at each of September 30, 2019 and 2018.

Interest income, interest expense and other expense

					Increase (decrease)
	2019		2018		$			%
	(in thousands)
For the three months ended September 30:
Interest income	$	961	$	514	$	447			87	%
Interest expense		425		422		3			1	%

For the nine months ended September 30:
Interest income	$	2,085	$	843	$	1,242			147	%
Interest expense		1,288		1,235		53			4	%
Other expense		—		1,552		(1,552	)		(100	)%

Interest income is derived from our portfolio of cash, cash equivalents and investments and increased in the three and nine months ended September 30, 2019 as compared to the three and nine months ended September 30, 2018, respectively, primarily due to an increase in our portfolio balance resulting from net proceeds from our June 2019 public stock offering and increased interest rates.

Interest expense is related to our loan agreement with the Lender (see Note 8).

Other expense was zero in the three and nine months ended September 30, 2019 due to the elimination of our preferred stock warrant liability upon the conversion of the preferred shares into common shares in May 2018. Other expense in the nine months ended September 30, 2018 was $1.6 million which reflected a non-cash expense resulting from the change in the fair value of our preferred stock warrant liability.

RECENT ACCOUNTING PRONOUNCEMENTS

For a discussion of new accounting pronouncements please read Note 10, Recent Accounting Pronouncements to our financial statements included in this report.

FORWARD LOOKING STATEMENTS

In addition to historical information, this report contains forward-looking statements. You can identify these forward-looking statements by their use of words such as “anticipate,” “assume,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “project,” “target,” “will”, “potential” , “goal”, and other words and terms of similar meaning. You also can identify them by the fact that they do not relate strictly to historical or current facts. All statements which address operating performance, events or developments that we expect or anticipate will occur in the future, such as projections about our future results of operations, our financial condition, research, development and commercialization of our products and anticipated trends in our business are forward-looking statements.

In this report we make forward-looking statements regarding our drug development pipeline and our existing and planned clinical trials as well as future milestones and royalty payments, projected financial results and our ability to fund operations with current cash, cash equivalents and marketable securities.

Drug development involves a high degree of risk. Only a small number of research and development programs result in the commercialization of a product. For example, preclinical efforts associated with our product pipeline may fail or prove disappointing because our technology platform did not produce candidates with the desired characteristics. Animal preclinical studies may be unpredictive of human response. Positive information about early stage clinical trial results will not ensure that later stage or larger scale clinical trials will be successful or will satisfy applicable regulatory standards. Furthermore, our drugs may not demonstrate appropriate safety profiles in ongoing or later stage or larger scale clinical trials as a result of known or as yet unidentified side effects. Problems or delays may arise during clinical trials or in the course of developing, testing or manufacturing our drugs that could lead us or our collaborators to delay of discontinue development.

The planned timing of initiation of clinical trials and the duration and conclusion of such trials for our drugs are subject to the ability of the company to enroll patients, enter into agreements with clinical trial sites and investigators, and other technical hurdles and issues that may not be resolved.

We also make forward-looking statements regarding the adequacy of our financial resources. Our capital resources may not be adequate because our cash requirements may vary materially from those now planned depending upon the results of our drug discovery and development strategies, the outcomes of our clinical trials, our ability to enter into additional corporate collaborations in the future and the terms of such collaborations, results of research and development, the need for currently unanticipated capital expenditures, competitive and technological advances, acquisitions, financial market conditions and other factors. Additionally, our collaborators may terminate their agreements with us, thereby eliminating that source of funding.

We cannot guarantee that we will be able to develop any of our drug candidates into a commercial product generating revenues. If we experience increased losses, we may have to seek additional financing from public and private sales of our securities, including equity securities. There can be no assurance that additional funding will be available when needed or on acceptable terms.

The factors, risks and uncertainties referred to above and others are more fully described under the heading “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2018 filed with the SEC on March 7, 2019, as updated from time to time in our subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The forward-looking statements contained herein represent our judgment as of the date of this report. We are not under any obligation, and we expressly disclaim any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent required by law.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We own financial instruments that are sensitive to market risk as part of our investment portfolio. We have implemented policies regarding the amount and credit ratings of investments. Our investment portfolio is used to preserve our capital until it is used to fund operations, including our research and development activities. Our investments are evaluated quarterly to determine the fair value of the portfolio.

Our cash equivalents and marketable securities typically include commercial paper, money market funds, and U.S. Treasury bill funds that have investment grade ratings.

Our cash equivalents and our portfolio of marketable securities are subject to market risk due to changes in interest rates. Fixed rate interest securities may have their market value adversely impacted due to a rise in interest rates, while floating rate securities may produce less income than expected if interest rates fall. Due in part to these factors, our future investment income may fall short of expectation due to changes in interest rates or we may suffer losses in principal if we are forced to sell securities that decline in market value due to changes in interest rates. Based on the type of securities we hold, we do not believe a change in interest rates would have a material impact on our financial statements. If interest rates were to increase or decrease by 1%, this would not result in a material change in the fair value of our investment portfolio.

ITEM 4. CONTROLS AND PROCEDURES

Our management, with the participation of our Chief Executive Officer (Principal Executive Officer) and President and Chief Operating Officer (Principal Financial Officer), evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2019. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (“Exchange Act”), means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and financial officer, as appropriate to allow timely decisions regarding required disclosure. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of September 30, 2019, our Chief Executive Officer (Principal Executive Officer) and President and Chief Operating Officer (Principal Financial Officer) concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.

There have been no changes in our internal control over financial reporting during the most recently completed fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

ITEM 1. — LEGAL PROCEEDINGS. None.

ITEM 1A. — RISK FACTORS. For information regarding factors that could affect our results of operations, financial condition and liquidity, see the risk factors discussion provided under “Risk Factors” in Item 1A of ArQule’s Annual Report on Form 10-K for the year ended December 31, 2018 filed with the SEC on March 7, 2019, as updated from time to time in our subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. See also, “Forward-Looking Statements” included in this Quarterly Report on Form 10-Q.

ITEM 2. — UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS. None.

ITEM 3. — DEFAULTS UPON SENIOR SECURITIES. None.

ITEM 4. — MINE SAFETY DISCLOSURES. Not applicable.

ITEM 5. — OTHER INFORMATION. None.

ITEM 6. — EXHIBITS.

EXHIBIT NO.		DESCRIPTION

31.1		Rule 13a-14(a) Certificate of Chief Executive Officer, filed herewith.
31.2		Rule 13a-14(a) Certificate of Principal Financial Officer, filed herewith.
32		Rule 13a-14(b) Certificate of Chief Executive Officer and Principal Financial Officer, filed herewith.
101		Interactive Data File

*	Indicates a management contract or compensatory plan.

ARQULE, INC.

SIGNATURES

Pursuant to the requirements of the Securities Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	ArQule, Inc.

Date: October 30, 2019	/s/ PETER S. LAWRENCE
	Peter S. Lawrence
	President and Chief Operating Officer
	(Duly Authorized Officer and Principal Financial Officer)

EX-31.1 2 tm19194741_ex31-1.htm EXHIBIT 31.1

Exhibit 31.1

CERTIFICATE OF THE CHIEF EXECUTIVE OFFICER

I, Paolo Pucci, certify that:

I have reviewed this quarterly report on Form 10-Q of ArQule, Inc.;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: October 30, 2019

	/s/ PAOLO PUCCI
	Paolo Pucci
	Chief Executive Officer
	(Principal Executive Officer)

EX-31.2 3 tm19194741_ex31-2.htm EXHIBIT 31.2

Exhibit 31.2

CERTIFICATE OF THE PRINCIPAL FINANCIAL OFFICER

I, Peter S. Lawrence, certify that:

I have reviewed this quarterly report on Form 10-Q of ArQule, Inc.;

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: October 30, 2019

		/s/ PETER S. LAWRENCE
		Peter S. Lawrence
		President and Chief Operating Officer
		(Principal Financial Officer)

EX-32 4 tm19194741_ex32.htm EXHIBIT 32

Exhibit 32

ARQULE, INC.

CERTIFICATE OF THE CHIEF EXECUTIVE OFFICER AND

PRINCIPAL FINANCIAL OFFICER

The undersigned, Paolo Pucci Chief Executive Officer (Principal Executive Officer) of ArQule, Inc. (the “Company”) and Peter S. Lawrence, President and Chief Operating Officer (Principal Financial Officer), of the Company, both duly elected and currently serving, hereby certify that, to the best of his or her knowledge:

the quarterly report on Form 10-Q for the period ending September 30, 2019, filed on behalf of the Company pursuant to the Securities Exchange Act of 1934 (the “Exchange Act”) and containing the financial statements of the Company, fully complies with the requirements of section 13(a) of the Exchange Act; and

the information contained in such quarterly report fairly presents, in all material respects, the financial condition and results of operations of the Company for the dates and periods covered by such quarterly report.

This certification accompanies the Company’s Quarterly Report on Form 10-Q for the period ended September 30, 2019, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (the “2002 Act”) and shall not be deemed filed by the Company for purposes of Section 18 of the Exchange Act.

This certification is being made for the exclusive purpose of compliance by the Principal Executive Officer and Principal Financial Officer of the Company with the requirements of Section 906 of the 2002 Act, and may not be disclosed, distributed or used by any person for any reason other than as specifically required by law.

IN WITNESS WHEREOF, the undersigned have executed this Certificate as of the 30th day of October 2019.

/s/ PAOLO PUCCI
Name:	Paolo Pucci
Title:	Chief Executive Officer
	(Principal Executive Officer)

/s/ PETER S. LAWRENCE
Name:	Peter S. Lawrence
Title:	President and Chief Operating Officer
	(Principal Financial Officer)

EX-101.INS 5 arql-20190930.xml XBRL INSTANCE DOCUMENT 0001019695 us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 2019-09-30 0001019695 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0001019695 us-gaap:CommonStockMember 2018-01-01 2018-03-31 0001019695 us-gaap:SeriesAPreferredStockMember arql:DefinitiveStockPurchaseAgreementsMember 2017-11-01 2017-11-30 0001019695 us-gaap:RetainedEarningsMember 2019-09-30 0001019695 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0001019695 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-30 0001019695 us-gaap:RetainedEarningsMember 2019-06-30 0001019695 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001019695 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0001019695 us-gaap:RetainedEarningsMember 2019-03-31 0001019695 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001019695 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0001019695 2019-03-31 0001019695 us-gaap:RetainedEarningsMember 2018-12-31 0001019695 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001019695 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001019695 us-gaap:RetainedEarningsMember 2018-09-30 0001019695 us-gaap:AdditionalPaidInCapitalMember 2018-09-30 0001019695 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-09-30 0001019695 us-gaap:RetainedEarningsMember 2018-06-30 0001019695 us-gaap:AdditionalPaidInCapitalMember 2018-06-30 0001019695 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-06-30 0001019695 2018-06-30 0001019695 us-gaap:RetainedEarningsMember 2018-03-31 0001019695 us-gaap:AdditionalPaidInCapitalMember 2018-03-31 0001019695 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-03-31 0001019695 2018-03-31 0001019695 us-gaap:RetainedEarningsMember 2017-12-31 0001019695 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001019695 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0001019695 us-gaap:EmployeeStockOptionMember 2018-12-31 0001019695 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-09-30 0001019695 2019-06-01 2019-06-30 0001019695 2019-01-01 2019-06-30 0001019695 2018-07-01 2018-07-31 0001019695 arql:SeriesAConvertiblePreferredStockAndWarrantsMember arql:DefinitiveStockPurchaseAgreementsMember 2017-11-01 2017-11-30 0001019695 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-07-01 2019-09-30 0001019695 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-04-01 2019-06-30 0001019695 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0001019695 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-07-01 2018-09-30 0001019695 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-04-01 2018-06-30 0001019695 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-03-31 0001019695 us-gaap:StateAndLocalJurisdictionMember 2018-12-31 0001019695 us-gaap:ResearchMember 2018-12-31 0001019695 us-gaap:DomesticCountryMember 2018-12-31 0001019695 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0001019695 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0001019695 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001019695 us-gaap:RetainedEarningsMember 2018-07-01 2018-09-30 0001019695 us-gaap:RetainedEarningsMember 2018-04-01 2018-06-30 0001019695 us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 2019-01-01 0001019695 arql:October2017CommonStockOfferingMember 2019-07-01 2019-09-30 0001019695 arql:ExerciseOfWarrantsFromNovember2017PreferredStockOfferingMember 2019-07-01 2019-09-30 0001019695 arql:ExerciseOfOptionsFromFebruary2018LoanAgreementMember 2019-07-01 2019-09-30 0001019695 arql:EmployeeAndBoardOfDirectorMember 2019-07-01 2019-09-30 0001019695 arql:October2017CommonStockOfferingMember 2019-01-01 2019-09-30 0001019695 arql:ExerciseOfWarrantsFromNovember2017PreferredStockOfferingMember 2019-01-01 2019-09-30 0001019695 arql:ExerciseOfOptionsFromFebruary2018LoanAgreementMember 2019-01-01 2019-09-30 0001019695 arql:EmployeeAndBoardOfDirectorMember 2019-01-01 2019-09-30 0001019695 arql:October2017CommonStockOfferingMember 2018-07-01 2018-09-30 0001019695 arql:ExerciseOfWarrantsFromNovember2017PreferredStockOfferingMember 2018-07-01 2018-09-30 0001019695 arql:ExerciseOfOptionsFromFebruary2018LoanAgreementMember 2018-07-01 2018-09-30 0001019695 arql:EmployeeAndBoardOfDirectorMember 2018-07-01 2018-09-30 0001019695 arql:October2017CommonStockOfferingMember 2018-01-01 2018-09-30 0001019695 arql:ExerciseOfWarrantsFromNovember2017PreferredStockOfferingMember 2018-01-01 2018-09-30 0001019695 arql:ExerciseOfOptionsFromFebruary2018LoanAgreementMember 2018-01-01 2018-09-30 0001019695 arql:EmployeeAndBoardOfDirectorMember 2018-01-01 2018-09-30 0001019695 us-gaap:EmployeeStockOptionMember 2019-09-30 0001019695 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-09-30 0001019695 arql:BasileaPharmaceuticaInternationalLimitedMember arql:ResearchAndDevelopmentMember 2018-04-30 0001019695 arql:BasileaPharmaceuticaInternationalLimitedMember arql:BasileaPharmaceuticaInternationalLicensingAgreementMember 2018-04-30 0001019695 arql:LoanAgreementMember arql:OxfordFinanceLlcMember 2019-01-01 2019-09-30 0001019695 arql:OxfordFinanceLlcMember arql:LoanAgreementMember 2019-09-30 0001019695 arql:LoanAgreementMember arql:OxfordFinanceLlcMember 2019-09-30 0001019695 us-gaap:SeriesAPreferredStockMember arql:DefinitiveStockPurchaseAgreementsMember 2017-11-30 0001019695 arql:SeriesAPreferredWarrantsMember arql:DefinitiveStockPurchaseAgreementsMember 2017-11-30 0001019695 us-gaap:CommonStockMember 2019-09-30 0001019695 us-gaap:CommonStockMember 2019-06-30 0001019695 us-gaap:CommonStockMember 2019-03-31 0001019695 us-gaap:CommonStockMember 2018-12-31 0001019695 us-gaap:CommonStockMember 2018-09-30 0001019695 us-gaap:CommonStockMember 2018-06-30 0001019695 us-gaap:PreferredStockMember 2018-03-31 0001019695 us-gaap:CommonStockMember 2018-03-31 0001019695 us-gaap:PreferredStockMember 2017-12-31 0001019695 us-gaap:CommonStockMember 2017-12-31 0001019695 2019-06-30 0001019695 2018-07-31 0001019695 arql:LoanAgreementMember arql:OxfordFinanceLlcMember us-gaap:CommonStockMember 2018-02-28 0001019695 2018-09-30 0001019695 2017-12-31 0001019695 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ShortTermDebtMember 2019-09-30 0001019695 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:LongTermDebtMember 2019-09-30 0001019695 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ShortTermDebtMember 2019-09-30 0001019695 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:LongTermDebtMember 2019-09-30 0001019695 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ShortTermDebtMember 2019-09-30 0001019695 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:LongTermDebtMember 2019-09-30 0001019695 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ShortTermDebtMember 2019-09-30 0001019695 us-gaap:FairValueMeasurementsRecurringMember us-gaap:LongTermDebtMember 2019-09-30 0001019695 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ShortTermDebtMember 2018-12-31 0001019695 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ShortTermDebtMember 2018-12-31 0001019695 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ShortTermDebtMember 2018-12-31 0001019695 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ShortTermDebtMember 2018-12-31 0001019695 us-gaap:ShortTermDebtMember 2019-09-30 0001019695 us-gaap:LongTermDebtMember 2019-09-30 0001019695 us-gaap:ShortTermDebtMember 2018-12-31 0001019695 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-09-30 0001019695 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-09-30 0001019695 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-09-30 0001019695 us-gaap:FairValueMeasurementsRecurringMember 2019-09-30 0001019695 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001019695 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001019695 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001019695 us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001019695 us-gaap:ResearchAndDevelopmentExpenseMember 2019-07-01 2019-09-30 0001019695 us-gaap:GeneralAndAdministrativeExpenseMember 2019-07-01 2019-09-30 0001019695 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-09-30 0001019695 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-09-30 0001019695 us-gaap:ResearchAndDevelopmentExpenseMember 2018-07-01 2018-09-30 0001019695 us-gaap:GeneralAndAdministrativeExpenseMember 2018-07-01 2018-09-30 0001019695 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-09-30 0001019695 us-gaap:GeneralAndAdministrativeExpenseMember 2018-01-01 2018-09-30 0001019695 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001019695 2019-01-01 2019-03-31 0001019695 2019-10-16 0001019695 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-03-31 0001019695 2018-01-01 2018-09-30 0001019695 arql:SeriesAPreferredWarrantsMember arql:DefinitiveStockPurchaseAgreementsMember 2019-01-01 2019-09-30 0001019695 us-gaap:CommonStockMember 2019-07-01 2019-09-30 0001019695 arql:BasileaPharmaceuticalLimitedMember arql:BasileaPharmaceuticaInternationalLicensingAgreementMember 2018-04-01 2018-04-30 0001019695 arql:BasileaPharmaceuticaInternationalLimitedMember arql:BasileaPharmaceuticaInternationalLicensingAgreementMember 2018-04-01 2018-04-30 0001019695 arql:RoivantSciencesMember arql:RoivantSciencesLicensingAgreementMember 2018-02-01 2018-02-28 0001019695 arql:RoivantSciencesMember arql:RoivantSciencesLicensingAgreementMember 2019-07-01 2019-09-30 0001019695 arql:BasileaPharmaceuticaInternationalLimitedMember arql:BasileaPharmaceuticaInternationalLicensingAgreementMember 2019-07-01 2019-09-30 0001019695 arql:OtherLicensingAgreementsMember 2019-07-01 2019-09-30 0001019695 arql:RoivantSciencesMember arql:RoivantSciencesLicensingAgreementMember 2019-01-01 2019-09-30 0001019695 arql:BasileaPharmaceuticaInternationalLimitedMember arql:BasileaPharmaceuticaInternationalLicensingAgreementMember 2019-01-01 2019-09-30 0001019695 arql:OtherLicensingAgreementsMember 2019-01-01 2019-09-30 0001019695 arql:RoivantSciencesMember arql:RoivantSciencesLicensingAgreementMember 2018-07-01 2018-09-30 0001019695 arql:BasileaPharmaceuticaInternationalLimitedMember arql:BasileaPharmaceuticaInternationalLicensingAgreementMember 2018-07-01 2018-09-30 0001019695 arql:OtherLicensingAgreementsMember 2018-07-01 2018-09-30 0001019695 arql:RoivantSciencesMember arql:RoivantSciencesLicensingAgreementMember 2018-01-01 2018-09-30 0001019695 arql:BasileaPharmaceuticaInternationalLimitedMember arql:BasileaPharmaceuticaInternationalLicensingAgreementMember 2018-01-01 2018-09-30 0001019695 arql:OtherLicensingAgreementsMember 2018-01-01 2018-09-30 0001019695 arql:BasileaPharmaceuticaInternationalLimitedMember arql:ResearchAndDevelopmentMember 2018-04-01 2018-04-30 0001019695 us-gaap:AdditionalPaidInCapitalMember 2018-04-01 2018-06-30 0001019695 2018-04-01 2018-06-30 0001019695 us-gaap:PreferredStockMember 2018-04-01 2018-06-30 0001019695 us-gaap:CommonStockMember 2018-04-01 2018-06-30 0001019695 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0001019695 2019-07-01 2019-09-30 0001019695 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0001019695 2019-04-01 2019-06-30 0001019695 us-gaap:AdditionalPaidInCapitalMember 2018-07-01 2018-09-30 0001019695 2018-07-01 2018-09-30 0001019695 us-gaap:CommonStockMember 2019-04-01 2019-06-30 0001019695 us-gaap:CommonStockMember 2018-07-01 2018-09-30 0001019695 us-gaap:RetainedEarningsMember 2018-01-01 2018-03-31 0001019695 2018-01-01 2018-03-31 0001019695 us-gaap:AccountingStandardsUpdate201602Member 2019-09-30 0001019695 arql:LoanAgreementMember arql:OxfordFinanceLlcMember 2017-01-01 2017-01-31 0001019695 arql:LoanAgreementMember arql:OxfordFinanceLlcMember 2018-02-01 2018-02-28 0001019695 2019-01-01 2019-09-30 0001019695 arql:SeriesAPreferredWarrantsMember arql:DefinitiveStockPurchaseAgreementsMember 2017-11-01 2017-11-30 0001019695 arql:LoanAgreementMember arql:OxfordFinanceLlcMember us-gaap:CommonStockMember 2018-02-01 2018-02-28 0001019695 2019-09-30 0001019695 2018-12-31 xbrli:shares xbrli:pure iso4217:USD xbrli:shares iso4217:USD 8497000 5748000 P10Y 1.75 <div> <div> 7. COMMON STOCK OFFERINGS In June 2019, we sold 10,637,500 shares of common stock at $9.75 per share for aggregate net proceeds of approximately $97.3 million after commissions and other offering expenses. In July 2018, we sold 12,650,000 shares of common stock at $5.50 per share for aggregate net proceeds of approximately $64.6 million after commissions and other offering expenses. <div /></div> </div> Monthly basis through August 2019 September 2019 to August 2022 0.05 0.06 0.0065 0.01 1980000 1980000 1500000 1500000 12650000 10637500 64562000 64435000 127000 97340000 97234000 106000 -13000 -13000 8370000 -8370 11907000 11823000 84000 -8843000 9800000 700000 2691000 more than 50 percentage points P3Y <div> <div> 9. PREFERRED STOCK AND WARRANT LIABILITY Our Restated Certificate of Incorporation , as amended, authorizes the issuance of up to 1 million shares of $0.01 par value preferred stock. In November 2017, we entered into definitive securities purchase agreements with certain institutional investors. In conjunction with this stock offering we raised net proceeds of $9.5 million through the sale of 8,370 shares of series A convertible preferred stock (Series A Preferred) and warrants covering 2,259 shares of Series A Preferred (Warrants). Each share of Series A Preferred converted into 1,000 shares of common stock and each associated Warrant converted into 1,000 common stock warrants in May 2018. The terms of the Series A Preferred for which the warrants were exercisable required that the fair value allocated to the warrants at the date of issuance be recorded as a liability on our balance sheet. The warrant liability was marked to market value through the statement of operations and comprehensive loss as a non-cash gain or loss at each reporting period until the conversion of the Series A Preferred to common stock in May  2018. Upon conversion, the warrant liability of $3.1 million was extinguished with an offsetting amount included as additional paid-in capital in stockholders’ equity. Accordingly, at each of December 31, 2018 and September 30, 2019, the warrant liability was zero. In the three and nine months ended September 30, 2018, we recognized a non-cash expense of zero and $1.5 million , respectively, recorded in other expense on the statement of operations and comprehensive loss related to the change in the fair value of the warrant liability. <div /></div> </div> 1300000 15700000 15700000 5900000 5900000 10300000 100000 2000000 2000000 2900000 2900000 0 200000 200000 1600000 1600000 0 0 0 200000 200000 70000000 70000000 262500000 262500000 2500000 2500000 2500000 12000000 12000000 63000000 63000000 3000000 3000000 10000000 10000000 10000000 269584 114286 114286 1000 -2000 3000 200000 199000 1000 200000 0 0 3100000 1500000 0 120000 120000 false --12-31 Q3 2019 2019-09-30 10-Q 0001019695 120733695 Yes false Accelerated Filer Yes ARQULE INC false true arql

12948000

9933000

<div> <div> 4. ACCOUNTS PAYABLE AND ACCRUED EXPENSES Accounts payable and accrued expenses include the following at September 30, 2019 and December 31, 2018 (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:70.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:70.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:13.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> September 30,  </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31,  </td> </tr> <tr> <td valign="bottom" style="width:70.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> </tr> <tr> <td valign="bottom" style="width:70.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Accrued outsourced preclinical and clinical fees </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 5,748 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 8,497 </td> </tr> <tr> <td valign="bottom" style="width:70.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Accrued payroll </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,154 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,971 </td> </tr> <tr> <td valign="bottom" style="width:70.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Accrued professional fees </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 905 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 666 </td> </tr> <tr> <td valign="bottom" style="width:70.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Accounts payable </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 801 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,329 </td> </tr> <tr> <td valign="bottom" style="width:70.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Other accrued expenses </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 325 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 485 </td> </tr> <tr> <td valign="bottom" style="width:70.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 9,933 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 12,948 </td> </tr> </table></div>   <div /></div> </div>

1329000

801000

-387000

-533000

666000

905000

1971000

2154000

-95000

127000

625993000

729910000

423000

314000

363000

2124000

917000

1008000

1100000

831000

269000

363000

279000

84000

4049000

3308000

741000

1008000

785000

223000

242000

239000

106676000

180342000

106403000

128039000

94766000

14444000

80322000

172576000

40662000

131914000

2000

139000

50000

89000

97000

11000

7000

4000

80417000

131786000

48857000

82929000

80322000

48900000

83014000

48900000

83014000

80322000

131914000

48900000

83014000

<div> <div> 1. NATURE OF OPERATIONS AND BASIS OF PRESENTATION We are a biopharmaceutical company engaged in the research and development of innovative therapeutics to treat cancers and rare diseases. Our mission is to discover, develop and commercialize novel small molecule drugs in areas of high unmet need that will dramatically extend and improve the lives of our patients. These product candidates target biological pathways implicated in a wide range of cancers and certain non-oncology indications. Our discovery and development efforts are guided, when possible, by an understanding of the role of biomarkers, which are indicators of a particular biological condition or process and may predict the clinical benefit of our compounds in defined patient populations. Our clinical-stage pipeline consists of four product candidates, all of which are in targeted patient populations, making ArQule a leader among companies our size in precision medicine. ArQule has a long history of kinase drug discovery and development, having discovered and introduced ten kinase inhibitors into clinical trials. Our drug discovery efforts have been informed by our historical expertise in chemistry, our work in rational drug design and by our insight into kinase binding and regulation. We have applied this knowledge to produce significant chemical matter for a number of kinase targets and to build an extensive library of proprietary compounds with the potential to target multiple kinases in oncology and other therapeutic areas, such as rare diseases. We may bring further preclinical programs forward and interrogate our library against new targets beyond kinases either directly or with collaborators. Our proprietary pipeline of orally bioavailable product candidates is directed toward molecular targets and biological processes with demonstrated roles in the development of both human cancers and rare, non-oncology diseases. All of these programs are being developed in targeted, biomarker-defined patient populations. By seeking out subgroups of patients that are most likely to respond to our product candidates, we seek to identify small, often orphan, indications that allow for focused and efficient development. At the same time, in addition to pursuing these potentially fast-to-market strategies, we also pursue development in other indications that could allow us to expand the utility of the product candidates if approved. Our clinical pipeline includes the following product candidates: <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"></td><td valign="top" align="left" style="width: 17.00pt;"> · </td><td style="width:1pt;"></td><td align="left" valign="top"> ARQ 531 is a potent and reversible dual inhibitor of both wild type and C481S-mutant Bruton’s tyrosine kinase (BTK) that is in Phase 1/2 clinical development for B-cell malignancies refractory to other therapeutic options;</td></tr></table></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"></td><td valign="top" align="left" style="width: 17.00pt;"> · </td><td style="width:1pt;"></td><td align="left" valign="top"> Miransertib (ARQ 092) is a potent and selective inhibitor of protein kinase B (AKT), a serine/threonine kinase that is in a registrational clinical trial for the treatment of Proteus syndrome and PIK3CA-Related Overgrowth Syndromes (PROS);</td></tr></table></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"></td><td valign="top" align="left" style="width: 17.00pt;"> · </td><td style="width:1pt;"></td><td align="left" valign="top"> ARQ 751 is a next-generation, highly potent and selective inhibitor of AKT that is in Phase 1 clinical development for solid tumors harboring AKT, phosphoinositide 3‑kinase (PI3K) or phosphatase and tensin homolog (PTEN) loss mutations or that are PTEN null; and</td></tr></table></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"></td><td valign="top" align="left" style="width: 17.00pt;"> · </td><td style="width:1pt;"></td><td align="left" valign="top"> Derazantinib (ARQ 087) is a multi-kinase inhibitor designed to preferentially inhibit the fibroblast growth factor receptor (FGFR) family of kinases that is in a registrational clinical trial in intrahepatic cholangiocarcinoma (iCCA) in patients with FGFR2 fusions. Derazantinib was exclusively licensed to Basilea Pharmaceutica Limited (Basilea) in April 2018 in the United States, European Union, Japan and the rest of the world, excluding the People’s Republic of China, Hong Kong, Macau, and Taiwan (collectively, Greater China) where derazantinib was exclusively licensed to Sinovant Sciences Ltd., a subsidiary of Roivant Sciences Ltd. (Sinovant) in February 2018.</td></tr></table></div> Our uses of cash for operating activities have primarily consisted of salaries and wages for our employees, facility and facility-related costs for our offices and laboratories, fees paid in connection with preclinical and clinical studies, laboratory supplies and materials, and professional fees. The sources of our cash flow from operating activities have historically consisted primarily of upfront and other payments received from our collaborators in connection with license agreements. In the nine months ended September 30, 2019 and 2018, our net use of cash was primarily driven by payments for operating expenses which resulted in net cash outflows of $24.2 million and $7.8 million, respectively. Our cash requirements may vary materially from those now planned depending on the results of our drug discovery and development strategies, our ability to enter into additional corporate collaborations and the terms of such collaborations, results of research and development, unanticipated required capital expenditures, competitive and technological advances, acquisitions and other factors. We cannot guarantee that we will be able to develop any of our product candidates into a commercial product. In January 2017, we entered into a loan and security agreement with Oxford Finance, LLC (the “Loan Agreement”) with an initial principal balance of $15 million (see Note 8). The terms of the Loan Agreement, which was amended in February 2018, required only payments of interest on a monthly basis through August 2019 . As of September 2019, we are required to make payments of principal and interest on a monthly basis through the maturity date of the loan on August 1, 2022. In November 2017, we entered into definitive securities purchase agreements with certain institutional investors. In conjunction with this stock offering we raised net proceeds of  $9.5 million through the sale of 8,370 shares of series A convertible preferred stock (Series A Preferred) and warrants to purchase 2,259 shares of Series A Preferred (Warrants). Each share of Series A Preferred converted into 1,000 shares of common stock and each associated Warrant converted into 1,000 common stock warrants in May  2018. In September 2019, holders of the common stock warrants exercised warrants covering 114,286 shares of common stock, resulting in net proceeds of $0.2 million. The remaining common stock warrants have a post-conversion exercise price of  $1.75 per share, are exercisable immediately and expire in May 2022. In February 2018, we entered into a License Agreement with Sinovant pursuant to which we granted Sinovant an exclusive license to develop and commercialize derazantinib in Greater China. The agreement provided for an upfront payment to ArQule of $3 million and a $2.5 million development milestone that was paid in the first quarter of 2019. We are also eligible for up to an additional $12.0 million in regulatory milestone payments and $70.0 million in commercial milestone payments. Upon commercialization, we are entitled to receive double digit royalties in the low teens from Sinovant on net sales of derazantinib in Greater China. Sinovant will be responsible for all costs and expenses of development, manufacture and commercialization in Greater China. In the three and nine months ended September 30, 2019 , we recognized revenue of $0.2 million and $1.6 million, respectively, for providing certain Manufacturing Services (as defined in Note 2) to Sinovant. During the three and nine months ended September 30, 2018, we recognized revenue of $2.9 million and $5.9 million, respectively, related primarily to the transfer of the license to Sinovant and the expected achievement of a development milestone that was ultimately paid in the first quarter of 2019. In April 2018, we entered into a License Agreement with Basilea pursuant to which we granted Basilea an exclusive license to develop and commercialize derazantinib in the United States, European Union, Japan and the rest of the world, excluding Greater China. Under the terms of the agreement, we received an upfront payment of  $10 million and are eligible for up to $63.0 million in development and regulatory milestone payments and up to $262.5 million in commercial milestone payments. Upon commercialization, we are entitled to receive tiered royalties on future net sales of derazantinib ranging from the high-single digits to the mid-teens on direct sales and mid-single digits to low-double digits on indirect sales. Basilea will be responsible for all costs and expenses of development, manufacture and commercialization in its territory. Under certain circumstances, we may have the opportunity to promote derazantinib in the United States directly. In the three and nine months ended September 30, 2019, we recognized revenue of zero and $0.2 million, respectively, for providing R&D Services (as defined in Note 2) to Basilea, recognized as revenue on a “cost-to-cost method". In the three and nine months ended September 30, 2018 we recognized revenue of $2.0 million and $15.7 million, respectively, related to providing R&D Services to Basilea as well as the transfer of the Basilea License. In July 2018, we sold 12,650,000 shares of common stock at $5.50 per share for aggregate net proceeds of approximately $64.6 million after commissions and other offering expenses. In June 2019, we sold 10,637,500 shares of common stock at $9.75 per share for aggregate net proceeds of approximately $97.3 million after commissions and other offering expenses. We anticipate that our cash, cash equivalents and marketable securities on hand at  September 30, 2019 will be sufficient to finance our operations for at least 12 months from the issuance date of these financial statements. We expect that we will need to raise additional capital or incur indebtedness to continue to fund our operations in the future. Our ability to raise additional funds will depend on financial, economic and market conditions, and due to global capital and credit market conditions or for other reasons, we may be unable to raise capital when needed, or on terms favorable to us. If necessary funds are not available, we may have to delay, reduce the scope of, or eliminate some of our development programs, potentially delaying the time to market for any of our product candidates. <div /></div> </div>

20229000

16178000

19236000

42199000

14444000

40662000

-4051000

22963000

1.61

93168

<div> <div> 2. COLLABORATIONS AND ALLIANCES Basilea Agreement In April 2018, we entered into a License Agreement with Basilea (the "Basilea Agreement") pursuant to which we granted Basilea an exclusive license to develop and commercialize derazantinib in the United States, European Union, Japan and the rest of the world, excluding Greater China (the "Basilea Territory"). Under the terms of the Basilea Agreement, we received an upfront payment of $10.0 million . In addition, we are eligible to receive up to $63.0 million in development and regulatory milestone payments across multiple indications in the United States, European Union and Japan, none of which exceed $12.0 million on an individual basis, and up to $262.5 million in commercial milestone payments based upon the attainment of specified calendar year net sales levels for all indications in the Basilea Territory. Upon commercialization, we are entitled to receive tiered royalties on future net sales of derazantinib ranging from the high-single digits to the mid-teens on direct sales in the Basilea Territory and mid-single digits to low-double digits on indirect sales in the Basilea Territory. Basilea is responsible for all costs and expenses of development, manufacture and commercialization in its territory. Under certain circumstances, we may have the opportunity to promote derazantinib in the United States directly. We evaluated the Basilea Agreement in accordance with ASC 606, Revenue from Contracts with Customers . We concluded there were two performance obligations under the Basilea Agreement at contract inception: (1) the grant of the exclusive license (the "Basilea License") to derazantinib in the Basilea Territory and (2) the provision of specified research and development services to Basilea (the "R&D Services"). The total transaction price for the Basilea Agreement at contract inception was determined to be $19.8 million, which was comprised of the $10.0 million upfront payment and an estimated $9.8 million of variable consideration to be received for the R&D Services. As of June 30, 2019, the R&D Services performance obligation was substantially complete. At contract inception, the variable consideration associated with development and regulatory milestone payments was excluded from the transaction price, and as of September 30, 2019 continued to be excluded from the transaction price, as achievement of the milestones is contingent upon future events and is not considered the most-likely outcome. We update our estimates for development and regulatory milestone variable consideration at each reporting date and will recognize revenue associated with a particular milestone when achieving the milestone is considered the most-likely outcome and it is probable that a significant reversal of cumulative revenue under the contract will not occur. The commercial milestone and royalty consideration were excluded from the transaction price because the Basilea License was determined to be the predominant item in the contract. As a result, we will recognize revenue associated with the commercial milestones and royalties at the later of when (i) the related sales occur or (ii) the performance obligation to which some or all of the applicable commercial milestone and/or royalty has been allocated has been satisfied (or partially satisfied). As of September 30, 2019, we have not recognized any commercial milestone or royalty revenue under the Basilea Agreement. The total transaction price was allocated to the two performance obligations based on the relative standalone selling price of each performance obligation at contract inception. The standalone selling price for the Basilea License was determined on a discounted cash flow basis. At contract inception, $10.3 million of the total transaction price was allocated to the Basilea License and was recognized when control of the Basilea License was transferred and the license period began. The standalone selling price for the R&D Services was determined based upon a cost-plus margin approach. At contract inception, $9.5 million of the transaction price was allocated to the R&D Services. Revenue related to the R&D Services is recognized on a “cost-to-cost” percentage of completion basis as the services are performed. For the three and nine months ended September 30, 2019, we recognized revenue of zero and $0.2 million, respectively, under the Basilea Agreement related to R&D Services provided to Basilea. For the three and nine months ended September 30, 2018, we recognized revenue of $2.0 million and $15.7 million, respectively, related to providing R&D Services to Basilea as well as the transfer of the Basilea License. Sinovant Agreement In February 2018, we entered into a License Agreement with Sinovant (the "Sinovant Agreement") pursuant to which we granted Sinovant an exclusive license to develop, manufacture and commercialize derazantinib in Greater China. Under the terms of the Sinovant Agreement, we have received an upfront payment of  $3.0 million and recognized a $2.5 million regulatory milestone payment in the third quarter of 2018. We are also eligible to receive up to an additional $12.0 million in regulatory milestone payments across multiple indications in Greater China and $70.0 million in commercial milestone payments based upon the attainment of specified calendar year net sales levels for all indications in Greater China. Upon commercialization, we are entitled to receive double digit royalties in the low teens from Sinovant on net sales of derazantinib in Greater China. Sinovant will be responsible for all costs and expenses of development, manufacture and commercialization in Greater China. We evaluated the Sinovant Agreement in accordance with ASC 606, Revenue from Contracts with Customers. We concluded that the only performance obligation under the Sinovant Agreement at contract inception was the grant of the exclusive license (the “Sinovant License”) to derazantinib in Greater China. The Sinovant Agreement also contemplated that we might provide certain manufacturing services (the “Manufacturing Services”), which we concluded was not a separate performance obligation at contract inception. The total transaction price for the Sinovant Agreement at contract inception was determined to be $3.0 million, which was equal to the upfront payment under the Sinovant Agreement. The $3.0 million was fully allocable to the Sinovant License and was recognized as revenue when control was transferred and the license period began. Our right to receive regulatory milestone payments is considered variable consideration. At contract inception, the variable consideration associated with regulatory milestone payments was excluded from the transaction price as achievement of the milestones was contingent upon future events and achievement of the milestones is not considered the most-likely outcome. We update our estimates for regulatory milestones at each reporting date and will recognize revenue associated with a particular milestone when we determine that achieving the milestone is the most-likely outcome and it is probable that a significant reversal of cumulative revenue under the contract will not occur. Based on the above analysis, we recognized $2.5 million in revenue associated with a regulatory milestone in the third quarter of 2018. The commercial milestones and royalty consideration were excluded from the transaction price because the Sinovant License is the only performance obligation and therefore considered the predominant item under the contract. As a result, we recognize revenue associated with the commercial milestones and royalties at the later of when (i) the related sales occur or (ii) the performance obligation to which some or all of the applicable commercial milestone and/or royalty has been allocated has been satisfied (or partially satisfied). As of September 30, 2019, we have not recognized any commercial milestone or royalty revenue under the Sinovant Agreement. In December 2018, we entered into a Supply Agreement with Sinovant where we agreed to provide the Manufacturing Services to Sinovant beyond the term contemplated for those services under the Sinovant Agreement. The Manufacturing Services are the only performance obligation under the Supply agreement and revenue related to the Supply Agreement is recognized on a “cost-to-cost” percentage of completion basis as the services are performed. For the three and nine months ended September 30, 2019, we recognized revenue of  $0.2 million and  $1.6 million, respectively, under the Sinovant Agreement related to the Manufacturing Services that we provided. For the three and nine months ended September 30, 2018, we recognized revenue of $2.9 million and $5.9 million, respectively, related primarily to the transfer of the Sinovant License and the achievement of a regulatory milestone discussed above. Other Licensing Agreements In October 2017, we granted a third party a non-exclusive license to certain of our library compounds. The licensed compounds were delivered and were accepted by the third party in 2018. Accordingly, revenue for the three and nine months ended September 30, 2019 was zero. For the three and nine months ended September 30, 2018, we recorded revenue of $0.1 million and $1.3 million, based upon the achievement of the quality and acceptance testing. <div /></div> </div>

0.01

200000000

12650000

109003637

10637500

120661081

87110202

8370

87125327

8370

96102527

108993547

109003637

109095759

120260385

120661081

1090000

1207000

-7011000

-5629000

-29876000

-10692000

1000

27874000

10690000

32729000

11483000

0.0085

P36M

15000000

0.0894

(a) the greater of (i) the 30 day U.S. LIBOR rate reported in the Wall Street Journal on the date occurring on the last business day of the month that immediately precedes the month in which the interest will accrue or (ii) 0.65% (b) plus 6.85%.

2021-08-01

2022-08-01

<div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:58.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:58.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Gross </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Gross </td> <td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:58.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Amortized </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Unrealized </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Unrealized </td> <td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Fair </td> </tr> <tr> <td valign="bottom" style="width:58.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> September 30, 2019 </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Cost </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Gains </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Losses </td> <td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Value </td> </tr> <tr> <td valign="bottom" style="width:58.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Security type </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> </tr> <tr> <td valign="bottom" style="width:58.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Corporate debt securities-short term </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 82,929 </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 89 </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (4) </td> <td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 83,014 </td> </tr> <tr> <td valign="bottom" style="width:58.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Corporate debt securities-long term </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 48,857 </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 50 </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (7) </td> <td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 48,900 </td> </tr> <tr> <td valign="bottom" style="width:58.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total available-for-sale marketable securities </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 131,786 </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 139 </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (11) </td> <td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 131,914 </td> </tr> </table></div>   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Gross </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Gross </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Amortized </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Unrealized </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Unrealized </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Fair </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31, 2018 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Cost </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Gains </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Losses </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Value </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Security type </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Corporate debt securities-short term </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 80,417 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  2 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (97) </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 80,322 </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total available-for-sale marketable securities </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 80,417 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  2 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (97) </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 80,322 </td> </tr> </table></div>   <div /></div> </div>

19800000

9500000

35000

82000

<div> <div> 6. STOCK-BASED COMPENSATION AND STOCK PLANS Our stock-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense over the employees’ requisite service period (generally the vesting period of the equity grant). We estimate the fair value of stock options using the Black-Scholes valuation model. Key input assumptions used to estimate the fair value of stock options include the exercise price of the award, expected option term, expected volatility of our stock over the option’s expected term, risk-free interest rate over the option’s expected term, and the expected annual dividend yield. We believe that the valuation technique and approach utilized to develop the underlying assumptions are appropriate in calculating the fair values of our stock options granted in the three and nine months ended September 30, 2019 and 2018. The following table presents stock-based compensation expense included in our condensed statements of operations and comprehensive loss (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:57.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:57.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="5" valign="bottom" style="width:18.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Three Months Ended </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="5" valign="bottom" style="width:19.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Nine Months Ended </td> </tr> <tr> <td valign="bottom" style="width:57.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:18.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> September 30,  </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:19.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> September 30,  </td> </tr> <tr> <td valign="bottom" style="width:57.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> </tr> <tr> <td valign="bottom" style="width:57.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Research and development </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 223 </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 84 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 741 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 269 </td> </tr> <tr> <td valign="bottom" style="width:57.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> General and administrative </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 785 </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 279 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3,308 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 831 </td> </tr> <tr> <td valign="bottom" style="width:57.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total stock-based compensation expense </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,008 </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 363 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 4,049 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,100 </td> </tr> </table></div>   In the nine months ended September 30, 2019, we recorded stock-based compensation expense of $1.0 million related to the modification of awards to our former Chief Financial Officer in connection with his retirement in March 2019. In the three and nine months ended September 30, 2019 and 2018, no stock-based compensation expense was capitalized and there were no recognized tax benefits associated with the stock-based compensation expense. Option activity under our stock plans for the nine months ended September 30, 2019 was as follows:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:70.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:70.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted </td> </tr> <tr> <td valign="bottom" style="width:70.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Number of </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Average </td> </tr> <tr> <td valign="bottom" style="width:70.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Stock Options </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Shares </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Exercise Price </td> </tr> <tr> <td valign="bottom" style="width:70.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Outstanding as of December 31, 2018 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 10,748,157 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2.90 </td> </tr> <tr> <td valign="bottom" style="width:70.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Granted </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,666,510 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4.07 </td> </tr> <tr> <td valign="bottom" style="width:70.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Exercised </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(880,868) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2.70 </td> </tr> <tr> <td valign="bottom" style="width:70.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Cancelled </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (157,508) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2.44 </td> </tr> <tr> <td valign="bottom" style="width:70.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Outstanding as of September 30, 2019 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12,376,291 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3.17 </td> </tr> <tr> <td valign="bottom" style="width:70.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:70.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Exercisable as of September 30, 2019 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 7,207,088 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3.26 </td> </tr> </table></div>   The aggregate intrinsic value of options outstanding at September 30, 2019 was $50.1 million, including $28.7 million related to exercisable options. The weighted average fair value of options granted in the nine months ended September 30, 2019 and 2018 was $2.54 and $1.70 per share, respectively. The intrinsic value of options exercised in the nine months ended September 30, 2019 was $3.9 million.   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:54.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:54.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted- </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:06.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:54.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Average </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:06.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:54.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted- </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Remaining </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Aggregate </td> </tr> <tr> <td valign="bottom" style="width:54.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Average </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Contractual </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Intrinsic </td> </tr> <tr> <td valign="bottom" style="width:54.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Shares </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Exercise Price </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Term (in years) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Value </td> </tr> <tr> <td valign="bottom" style="width:54.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Vested and unvested expected to vest at September 30, 2019 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 12,218,754 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3.17 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6.1 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 49,485 </td> </tr> <tr> <td valign="bottom" style="width:54.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Exercisable at September 30, 2019 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 7,207,088 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3.26 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4.4 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 28,730 </td> </tr> </table></div>   The total compensation cost not yet recognized as of September 30, 2019 related to non-vested option awards was $7.2 million, which will be recognized over a weighted-average period of 2.6 years. During the nine months ended September 30, 2019,  28,350 shares expired and 129,158 shares were forfeited. The weighted average remaining contractual life for options exercisable at September 30, 2019 was 4.37 years. <div /></div> </div>

-0.07

-0.05

-0.27

-0.09

<div> <div> 5. NET LOSS PER SHARE Net loss per share is computed using the weighted average number of common shares outstanding. Basic and diluted net loss per share amounts are equivalent for the periods presented as the inclusion of potential common shares in the number of shares used for the diluted computation would be anti-dilutive to loss per share. Potential common shares, for the three and nine months ended September 30, 2019, include 12,376,291 shares that would be issued upon the exercise of outstanding employee and Board of Director stock options, 93,168 shares that would be issued upon the exercise of the warrants from our February 2018 amendment to our loan agreement, 3,123,674 shares that would be issued upon the exercise of the warrants from our October 2017 common stock offering and 2,144,714 common shares that would be issued upon the exercise of the warrants from our November 2017 preferred stock offering. Potential common shares, for the three and nine months ended September 30, 2018, include 10,720,022 shares that would be issued upon the exercise of outstanding employee and Board of Director stock options, 93,168 shares that would be issued upon the exercise of the warrants from our February 2018 amendment to our loan agreement, 3,123,674 shares that would be issued upon the exercise of the warrants from our October 2017 common stock offering and 2,259,000 common shares that would be issued upon the exercise of the warrants from our November 2017 preferred stock offering. The preferred shares and warrants from our November 2017 preferred stock offering were converted to common stock and common stock warrants in May 2018. <div /></div> </div>

P2Y7M6D

7200000

1552000

<div> <div> 3. MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS We generally classify our marketable securities as available-for-sale at the time of purchase and re-evaluate such designation as of each balance sheet date. Since we generally intend to convert them into cash as necessary to meet our liquidity requirements our marketable securities are classified as cash equivalents if the original maturity, from the date of purchase, is ninety days or less and as short-term investments if the original maturity, from the date of purchase, is in excess of ninety days but less than or equal to one year. Our marketable securities are classified as long-term investments if the maturity date is in excess of one year of the balance sheet date. We report available-for-sale debt securities at fair value as of each balance sheet date and include any unrealized gains and, to the extent deemed temporary, unrealized losses in stockholders’ equity. Realized gains and losses are determined using the specific identification method and are included in other income (expense) in the statements of operations and comprehensive loss. We conduct quarterly reviews to determine the fair value of our investment portfolio and to identify and evaluate each investment that has an unrealized loss, in accordance with the meaning of other-than-temporary impairment and its application to certain investments. An unrealized loss exists when the current fair value of an individual security is less than its amortized cost basis. In the event that the cost basis of a security exceeds its fair value, we evaluate, among other factors, the duration of the period that, and extent to which, the fair value is less than cost basis, the financial health of and business outlook for the issuer, including industry and sector performance, and operational and financing cash flow factors, overall market conditions and trends, our intent to sell the investment and if it is more likely than not that we would be required to sell the investment before its anticipated recovery. Unrealized losses on available-for-sale securities that are determined to be temporary, and not related to credit loss, are recorded in accumulated other comprehensive income (loss). For available-for-sale debt securities with unrealized losses, we perform an analysis to assess whether we intend to sell or whether we would more likely than not be required to sell the security before the expected recovery of the amortized cost basis. Where we intend to sell an available-for-sale debt security, or may be required to do so, the security’s decline in fair value is deemed to be other-than-temporary and the full amount of the unrealized loss is reflected in the statements of operations and comprehensive loss as an impairment loss. Regardless of our intent to sell a security, we perform additional analysis on all securities with unrealized losses to evaluate losses associated with the creditworthiness of the security. Credit losses are identified where we do not expect to receive cash flows sufficient to recover the amortized cost basis of a security. We invest our available cash primarily in commercial paper, money market funds, and U.S. Treasury bill funds that have investment grade ratings. The following is a summary of the fair value of available-for-sale marketable securities we held at September 30, 2019 and December 31, 2018 (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:58.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:58.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Gross </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Gross </td> <td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:58.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Amortized </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Unrealized </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Unrealized </td> <td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Fair </td> </tr> <tr> <td valign="bottom" style="width:58.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> September 30, 2019 </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Cost </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Gains </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Losses </td> <td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Value </td> </tr> <tr> <td valign="bottom" style="width:58.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Security type </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> </tr> <tr> <td valign="bottom" style="width:58.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Corporate debt securities-short term </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 82,929 </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 89 </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (4) </td> <td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 83,014 </td> </tr> <tr> <td valign="bottom" style="width:58.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Corporate debt securities-long term </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 48,857 </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 50 </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (7) </td> <td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 48,900 </td> </tr> <tr> <td valign="bottom" style="width:58.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total available-for-sale marketable securities </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 131,786 </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 139 </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (11) </td> <td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 131,914 </td> </tr> </table></div>   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Gross </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Gross </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Amortized </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Unrealized </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Unrealized </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Fair </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31, 2018 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Cost </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Gains </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Losses </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Value </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Security type </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Corporate debt securities-short term </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 80,417 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  2 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (97) </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 80,322 </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total available-for-sale marketable securities </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 80,417 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  2 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (97) </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 80,322 </td> </tr> </table></div>   None of our available-for-sale marketable securities were in a continuous unrealized loss position for more than 12 months at September 30, 2019 or December 31, 2018. The following tables present information about our assets and liabilities that are measured at fair value on a recurring basis for the periods presented and indicates the fair value hierarchy of the valuation techniques we utilized to determine such fair value. There were no transfers in or out of Level 1 or Level 2 measurements for the periods presented (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:56.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Quoted </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Significant </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Prices in </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Other </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Significant </td> </tr> <tr> <td valign="bottom" style="width:56.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Active </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Observable </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Unobservable </td> </tr> <tr> <td valign="bottom" style="width:56.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> September 30,  </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Markets </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Inputs </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Inputs </td> </tr> <tr> <td valign="bottom" style="width:56.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 1) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 2) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 3) </td> </tr> <tr> <td valign="bottom" style="width:56.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Cash equivalents </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 40,662 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 40,662 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:56.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Corporate debt securities-short term </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 83,014 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> — </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 83,014 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:56.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Corporate debt securities-long term </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 48,900 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 48,900 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:56.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 172,576 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 40,662 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 131,914 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> </tr> </table></div>   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:57.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:57.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Quoted </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Significant </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:57.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Prices in </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Other </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Significant </td> </tr> <tr> <td valign="bottom" style="width:57.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Active </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Observable </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Unobservable </td> </tr> <tr> <td valign="bottom" style="width:57.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31,  </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Markets </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Inputs </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Inputs </td> </tr> <tr> <td valign="bottom" style="width:57.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 1) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 2) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 3) </td> </tr> <tr> <td valign="bottom" style="width:57.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Cash equivalents </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 14,444 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 14,444 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:57.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Corporate debt securities-short term </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 80,322 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 80,322 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:57.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 94,766 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 14,444 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 80,322 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> </tr> </table></div>   <div /></div> </div>

8014000

3429000

10638000

3170000

<div> <div> 11. INCOME TAXES As of December 31, 2018, we had federal net operating losses (“NOL”), state NOL, and research and development credit carryforwards of approximately $422,045,  $240,916 and $28,378 respectively, which expire at various dates through 2037. As of September 30, 2019, and December 31, 2018 we had no unrecognized tax benefits. We do not expect that the total amount of unrecognized tax benefits will significantly increase in the next twelve months. Our policy is to recognize interest and penalties related to uncertain tax positions in income tax expense. As of September 30, 2019, and December 31, 2018, we had no accrued interest or penalties related to uncertain tax positions. Our U.S. federal tax returns for the tax years 2015 through 2018 and our state tax returns for the tax years 2015 through 2018 remain open to examination. Prior tax years remain open to the extent of NOL and tax credit carryforwards. Utilization of NOL and research and development credit carryforwards may be subject to a substantial annual limitation in the event of an ownership change that has occurred previously or could occur in the future pursuant to Section 382 and 383 of the Internal Revenue Code of 1986, as amended, as well as similar state provisions. An ownership change may limit the amount of NOL and research and development credit carryforwards that can be utilized annually to offset future taxable income, and may, in turn, result in the expiration of a portion of those carryforwards before utilization. In general, an ownership change, as defined by Section 382, results from transactions that increase the ownership of certain stockholders or public groups in the stock of a corporation by more than 50 percentage points over a three-year period. We undertook a detailed study of our NOL and research and development credit carryforwards through January 31, 2019, to determine whether such amounts are likely to be limited by Sections 382 or 383. As a result of this analysis, we currently do not believe any Sections 382 or 383 limitations will significantly impact our ability to offset income with available NOL and research and development credit carryforwards. However, future ownership changes under Section 382 may limit our ability to fully utilize these tax benefits. <div /></div> </div>

2513000

-3015000

6401000

-5065000

229000

1081000

10720022

93168

2259000

3123674

10720022

93168

2259000

3123674

12376291

93168

2144714

3123674

12376291

93168

2144714

3123674

1235000

422000

1288000

425000

843000

514000

2085000

961000

false

819000

3705000

3700000

963000

672000

657000

642000

619000

152000

27708000

27216000

106676000

180342000

14615000

15479000

14583000

3333000

5000000

1250000

<div> <div> 8. LOAN AGREEMENT In January 2017, we entered into a loan and security agreement (the “Loan Agreement”) with Oxford Finance LLC, as collateral agent and a lender (the “Lender”), and any additional lenders that may become parties thereto. Pursuant to the terms of the Loan Agreement, the Lender issued us a loan with an initial principal amount of $15.0 million. The loan bears interest at the rate equal to (a) the greater of (i) the 30 day U.S. LIBOR rate reported in the Wall Street Journal on the date occurring on the last business day of the month that immediately precedes the month in which the interest will accrue or (ii) 0.65% (b) plus 6.85%. The applicable interest rate on the loan at September 30, 2019 was 8.94%. The Loan Agreement required interest-only payments through August 2019, followed by an amortization period of monthly principal and interest payments of  36 months. The original maturity date of the loan was August 1, 2021 and in February 2018 we signed an amendment with the Lender which extended the maturity date by one year to August 1, 2022. The expected remaining repayment of the $14.583 million loan principal at September 30, 2019 is as follows (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">      </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,250 </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 5,000 </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2021 </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 5,000 </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2022 </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3,333 </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 14,583 </td> </tr> </table></div>   Upon prepayment of the loan or on the maturity date, we will pay to the Lender a final payment of 6% of the full principal amount of the loan. We may elect to prepay all amounts owed prior to the maturity date, provided that a prepayment fee also is paid equal to 1% of the outstanding principal balance. Pursuant to the terms of the Loan Agreement, we are bound by certain affirmative covenants setting forth actions that are required during the term of the Loan Agreement, including, without limitation, certain information delivery requirements, obligations to maintain certain insurance, and certain notice requirements. Additionally, we are bound by certain negative covenants setting forth actions that are not permitted to be taken during the term of the Loan Agreement without consent, including, without limitation, incurring certain additional indebtedness, entering into certain mergers, acquisitions or other business combination transactions, or incurring any non-permitted lien or other encumbrance on our assets. We were in compliance with the loan covenants at September 30, 2019. Upon the occurrence of an event of default under the Loan Agreement (subject to cure periods for certain events of default), all amounts owed by us thereunder will begin to bear interest at a rate that is 5% higher than the rate that is otherwise applicable and may be declared immediately due and payable by the Lender. Events of default under the Loan Agreement include, among other things, the following: the occurrence of certain bankruptcy events; the failure to make payments under the Loan Agreement when due; the occurrence of a material adverse change in our business, operations or financial condition; the rendering of certain types of fines or judgments against us; any breach by us of any covenant (subject to cure for certain covenants only) made in the Loan Agreement; and the failure of any representation or warranty made by us in connection with the Loan Agreement to be correct in all material respects when made. We have granted the Lender, a security interest in substantially all of our personal property, rights and assets, other than intellectual property, to secure the payment of all amounts owed to the Lender under the Loan Agreement. We have also agreed not to encumber any of our intellectual property without the Lender’s prior written consent. In February 2018, the Loan Agreement was amended to extend the maturity date and to require  payments of interest on a monthly basis through August 2019 and payments of interest and principal from September 2019 to August 2022. In connection with entering into the amendment we issued to the Lender warrants to purchase an aggregate of 93,168 shares of our common stock. The warrants are exercisable immediately, have a per-share exercise price of $1.61 and have a term of ten years. The amendment was determined to be a modification of debt in accordance with ASC 470 Debt. We have recorded the relative fair value of the additional warrants as a discount to the carrying value of the notes payable with a corresponding increase to additional paid in capital. <div /></div> </div>

13093000

9582000

80322000

83014000

48900000

65251000

99567000

-61506000

-52379000

-7796000

-24225000

-6532000

-6995000

5156000

-5619000

-10267000

-30098000

-9092000

-10739000

<div> <div> 10. RECENT ACCOUNTING PRONOUNCEMENTS Recently Adopted Accounting Pronouncements In February 2016 the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) No. 2016‑02, Leases (Topic 842). This standard established a right-of-use model that requires all lessees to recognize right-of-use assets and liabilities on their balance sheet that arise from leases with terms longer than 12 months as well as provide disclosures with respect to certain qualitative and quantitative information related to their leasing arrangements. This standard became effective for us on January 1, 2019 (“the Effective Date”). The FASB has subsequently issued the following amendments to ASU 2016‑02, which also became effective on January 1, 2019, and which we collectively refer to as the new leasing standards: ASU No. 2018‑01, Leases (Topic 842): Land Easement Practical Expedient for Transition to Topic 842, which permits an entity to elect an optional transition practical expedient to not evaluate under Topic 842 land easements that exist or expired prior to adoption of Topic 842 and that were not previously accounted for as leases under the prior standard, ASC 840, Leases. ASU No. 2018‑10, Codification Improvements to Topic 842, Leases, which amends certain narrow aspects of the guidance issued in ASU 2016‑02. ASU No. 2018‑11, Leases (Topic 842): Targeted Improvements, which allows for a transition approach to initially apply ASU 2016‑02 at the adoption date and recognize a cumulative-effect adjustment to the opening balance of accumulated deficit in the period of adoption as well as an additional practical expedient for lessors to not separate non-lease components from the associated lease component. ASU No. 2018‑20, Narrow-Scope Improvements for Lessors, which contains certain narrow scope improvements to the guidance issued in ASU 2016‑02. We adopted the new lease accounting standard on January 1, 2019, using a modified retrospective transition approach of applying the new standard to all leases existing as of, or entered into after, the Effective Date and with remaining terms of 12 months or more. Our assessment included the lease of our headquarters in Burlington, MA which commenced in May 2015 and , prior to our October 2019 amendment discussed below, was scheduled to expire in July 2020 and our laboratory space in Woburn, MA which commenced in March 2019 and expires in April 2024. The adoption of the new standard on January 1, 2019 resulted in the recording of a right-of-use asset and lease liability of $0.7 million related to the lease of our headquarters in Burlington, MA that existed on the Effective Date. The lease liability is based on the present value of the remaining minimum lease payments, discounted using our secured incremental borrowing rate at the Effective Date. As permitted under ASC 842, we elected several practical expedients and therefore did not reassess at the Effective Date (1) whether any existing contract is or contains a lease, (2) the classification of existing leases, and (3) whether previously capitalized costs continue to qualify as initial indirect costs. We also elected the practical expedient to not separate lease and non-lease components. The application of the practical expedients did not have a significant impact on the measurement of the operating lease liability. In addition, we implemented internal controls to enable the preparation of financial information on adoption. The adoption did not have a material impact on our condensed financial statements related to the existing lease of our headquarters in Burlington, MA for the three and nine months ended September 30, 2019. As a result, there was no cumulative-effect adjustment. For contracts entered into on or after the Effective Date, at the inception of a contract we assess whether the contract is, or contains, a lease. Our assessment is based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether we obtain the right to substantially all the economic benefit from the use of the asset throughout the period, and (3) whether we have the right to direct the use of the asset. At inception of a lease, we allocate the consideration in the contract to each lease component based on its relative stand-alone price to determine the lease payments. Leases are classified as either finance leases or operating leases. A lease is classified as a finance lease if any one of the following criteria are met: (1) the lease transfers ownership of the asset by the end of the lease term, (2) the lease contains an option to purchase the asset that is reasonably certain to be exercised, (3) the lease term is for a major part of the remaining useful life of the asset or (4) the present value of the lease payments equals or exceeds substantially all of the fair value of the asset. A lease is classified as an operating lease if it does not meet any one of these criteria. Our leases are comprised of operating leases related to our headquarters in Burlington, MA and laboratory space in Woburn, MA. For all leases at the lease commencement date, a right-of-use asset and a lease liability are recognized. The right-of-use asset represents the right to use the leased asset for the lease term. The lease liability represents the present value of the lease payments under the lease. The right-of-use asset is initially measured at cost, which primarily comprises the initial amount of the lease liability, plus any initial direct costs incurred, consisting mainly of brokerage commissions, less any lease incentives received. All right-of-use assets are reviewed for impairment. The lease liability is initially measured at the present value of the lease payments, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the secured incremental borrowing rate. For our operating leases, we use our secured incremental borrowing rate if the implicit lease rate cannot be determined. Lease payments included in the measurement of the lease liability comprise the following: the fixed noncancelable lease payments, payments for optional renewal periods where it is reasonably certain the renewal period will be exercised, and payments for early termination options unless it is reasonably certain the lease will not be terminated early. Lease expense for operating leases consists of the lease payments plus any initial direct costs and is recognized on a straight-line basis over the lease term. Certain leases contain rent escalation clauses and variable lease payments that require additional rental payments in later years of the term, including payments based on an index or inflation rate. Payments based on the change in an index or inflation rate, or payments based on a change in our portion of the operating expenses, including real estate taxes and insurance, are not included in the initial lease liability and are recorded as a period expense when incurred. Our operating leases may include an option to renew the lease term for various renewal periods and/or to terminate the leases early. As an option to exercise the renewal or early termination of our operating leases were either non-existent or not reasonably certain as of the ASC 842 Effective Date for our headquarters in Burlington, MA and the lease commencement date of our laboratory space in Woburn, MA, we did not include such options in our initial lease liability. Subsequent to the Effective Date and during the quarter ending September 30, 2019, the option to renew the lease term of our headquarters in Burlington, MA became reasonably certain. This resulted in a $1.98 million increase of our right-of-use asset and lease liability of as of September 30, 2019. As of September 30, 2019, we recognized right-of-use assets related to our headquarters in Burlington, MA and laboratory space in Woburn, MA of $2.7 million and the related net lease liabilities of $2.7 million, which represents the net present value of the remaining lease payments of approximately $3.7 million, discounted using the Company’s incremental borrowing rate of 8.87%. We have included the right-of-use assets and lease liabilities in the condensed balance sheet as of September 30, 2019. The following table summarizes future minimum lease payments for our operating leases as of September 30, 2019 (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Year Ending December 31, </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2019 (three months ending December 31, 2019) </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 152 </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 619 </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2021 </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 642 </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2022 </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 657 </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2023 </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 672 </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Thereafter </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 963 </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total minimum lease payments </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,705 </td> </tr> </table></div>   In October 2019, we entered into an amendment to the lease of our headquarters in Burlington, MA that increased the amount of space subject to the lease and extended the term of the lease until July 2025. As previously disclosed in our 2018 Annual Report on Form 10‑K and under the previous lease accounting standard, ASC 840, Leases, the total commitment for our non-cancelable operating lease was $0.8 million as of December 31, 2018 (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Year Ending December 31,  </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 523 </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 296 </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Thereafter </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total minimum lease payments </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 819 </td> </tr> </table></div>   Recently Issued Accounting Pronouncements In August 2018, the FASB issued ASU 2018‑13, Fair Value Measurement (Topic 820): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement, (“ASU 2018‑13”). The new standard removes certain disclosures, modifies certain disclosures and adds additional disclosures related to fair value measurement. The new standard will be effective beginning January 1, 2020. We are currently evaluating the impact that the adoption of ASU 2018‑13 will have on our consolidated financial statements. In August 2018, the FASB issued ASU 2018‑15, Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350‑40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract, (“ASU 2018‑15”). The amendments in this update align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). The accounting for the service element of a hosting arrangement that is a service contract is not affected by the amendments in this update. The new standard will be effective beginning January 1, 2020. The amendments in this update should be applied either retrospectively or prospectively to all implementation costs incurred after the date of adoption. We are currently evaluating the impact that the adoption of ASU 2018‑15 will have on our consolidated financial statements. In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments”. This ASU will require that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard will require allowances to be recorded instead of reducing the amortized cost of the investment. ASU 2016-13 will limit the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which the carrying value exceeds the fair value and requires the reversal of previously recognized credit losses if fair value increases. ASU 2016-13 will be effective for fiscal years beginning after December 15, 2019 with early adoption permitted, and requires adoption using a modified retrospective approach, with certain exceptions. Based on the composition of the Company’s investment portfolio, current market conditions and historical credit loss activity, we are currently evaluating the impact of the adoption of this standard on the Company’s financial statements. <div /></div> </div>

<div> <div> Recently Adopted Accounting Pronouncements In February 2016 the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) No. 2016‑02, Leases (Topic 842). This standard established a right-of-use model that requires all lessees to recognize right-of-use assets and liabilities on their balance sheet that arise from leases with terms longer than 12 months as well as provide disclosures with respect to certain qualitative and quantitative information related to their leasing arrangements. This standard became effective for us on January 1, 2019 (“the Effective Date”). The FASB has subsequently issued the following amendments to ASU 2016‑02, which also became effective on January 1, 2019, and which we collectively refer to as the new leasing standards: ASU No. 2018‑01, Leases (Topic 842): Land Easement Practical Expedient for Transition to Topic 842, which permits an entity to elect an optional transition practical expedient to not evaluate under Topic 842 land easements that exist or expired prior to adoption of Topic 842 and that were not previously accounted for as leases under the prior standard, ASC 840, Leases. ASU No. 2018‑10, Codification Improvements to Topic 842, Leases, which amends certain narrow aspects of the guidance issued in ASU 2016‑02. ASU No. 2018‑11, Leases (Topic 842): Targeted Improvements, which allows for a transition approach to initially apply ASU 2016‑02 at the adoption date and recognize a cumulative-effect adjustment to the opening balance of accumulated deficit in the period of adoption as well as an additional practical expedient for lessors to not separate non-lease components from the associated lease component. ASU No. 2018‑20, Narrow-Scope Improvements for Lessors, which contains certain narrow scope improvements to the guidance issued in ASU 2016‑02. We adopted the new lease accounting standard on January 1, 2019, using a modified retrospective transition approach of applying the new standard to all leases existing as of, or entered into after, the Effective Date and with remaining terms of 12 months or more. Our assessment included the lease of our headquarters in Burlington, MA which commenced in May 2015 and , prior to our October 2019 amendment discussed below, was scheduled to expire in July 2020 and our laboratory space in Woburn, MA which commenced in March 2019 and expires in April 2024. The adoption of the new standard on January 1, 2019 resulted in the recording of a right-of-use asset and lease liability of $0.7 million related to the lease of our headquarters in Burlington, MA that existed on the Effective Date. The lease liability is based on the present value of the remaining minimum lease payments, discounted using our secured incremental borrowing rate at the Effective Date. As permitted under ASC 842, we elected several practical expedients and therefore did not reassess at the Effective Date (1) whether any existing contract is or contains a lease, (2) the classification of existing leases, and (3) whether previously capitalized costs continue to qualify as initial indirect costs. We also elected the practical expedient to not separate lease and non-lease components. The application of the practical expedients did not have a significant impact on the measurement of the operating lease liability. In addition, we implemented internal controls to enable the preparation of financial information on adoption. The adoption did not have a material impact on our condensed financial statements related to the existing lease of our headquarters in Burlington, MA for the three and nine months ended September 30, 2019. As a result, there was no cumulative-effect adjustment. For contracts entered into on or after the Effective Date, at the inception of a contract we assess whether the contract is, or contains, a lease. Our assessment is based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether we obtain the right to substantially all the economic benefit from the use of the asset throughout the period, and (3) whether we have the right to direct the use of the asset. At inception of a lease, we allocate the consideration in the contract to each lease component based on its relative stand-alone price to determine the lease payments. Leases are classified as either finance leases or operating leases. A lease is classified as a finance lease if any one of the following criteria are met: (1) the lease transfers ownership of the asset by the end of the lease term, (2) the lease contains an option to purchase the asset that is reasonably certain to be exercised, (3) the lease term is for a major part of the remaining useful life of the asset or (4) the present value of the lease payments equals or exceeds substantially all of the fair value of the asset. A lease is classified as an operating lease if it does not meet any one of these criteria. Our leases are comprised of operating leases related to our headquarters in Burlington, MA and laboratory space in Woburn, MA. For all leases at the lease commencement date, a right-of-use asset and a lease liability are recognized. The right-of-use asset represents the right to use the leased asset for the lease term. The lease liability represents the present value of the lease payments under the lease. The right-of-use asset is initially measured at cost, which primarily comprises the initial amount of the lease liability, plus any initial direct costs incurred, consisting mainly of brokerage commissions, less any lease incentives received. All right-of-use assets are reviewed for impairment. The lease liability is initially measured at the present value of the lease payments, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the secured incremental borrowing rate. For our operating leases, we use our secured incremental borrowing rate if the implicit lease rate cannot be determined. Lease payments included in the measurement of the lease liability comprise the following: the fixed noncancelable lease payments, payments for optional renewal periods where it is reasonably certain the renewal period will be exercised, and payments for early termination options unless it is reasonably certain the lease will not be terminated early. Lease expense for operating leases consists of the lease payments plus any initial direct costs and is recognized on a straight-line basis over the lease term. Certain leases contain rent escalation clauses and variable lease payments that require additional rental payments in later years of the term, including payments based on an index or inflation rate. Payments based on the change in an index or inflation rate, or payments based on a change in our portion of the operating expenses, including real estate taxes and insurance, are not included in the initial lease liability and are recorded as a period expense when incurred. Our operating leases may include an option to renew the lease term for various renewal periods and/or to terminate the leases early. As an option to exercise the renewal or early termination of our operating leases were either non-existent or not reasonably certain as of the ASC 842 Effective Date for our headquarters in Burlington, MA and the lease commencement date of our laboratory space in Woburn, MA, we did not include such options in our initial lease liability. Subsequent to the Effective Date and during the quarter ending September 30, 2019, the option to renew the lease term of our headquarters in Burlington, MA became reasonably certain. This resulted in a $1.98 million increase of our right-of-use asset and lease liability of as of September 30, 2019. As of September 30, 2019, we recognized right-of-use assets related to our headquarters in Burlington, MA and laboratory space in Woburn, MA of $2.7 million and the related net lease liabilities of $2.7 million, which represents the net present value of the remaining lease payments of approximately $3.7 million, discounted using the Company’s incremental borrowing rate of 8.87%. We have included the right-of-use assets and lease liabilities in the condensed balance sheet as of September 30, 2019. The following table summarizes future minimum lease payments for our operating leases as of September 30, 2019 (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Year Ending December 31, </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2019 (three months ending December 31, 2019) </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 152 </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 619 </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2021 </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 642 </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2022 </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 657 </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2023 </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 672 </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Thereafter </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 963 </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total minimum lease payments </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,705 </td> </tr> </table></div>   In October 2019, we entered into an amendment to the lease of our headquarters in Burlington, MA that increased the amount of space subject to the lease and extended the term of the lease until July 2025. As previously disclosed in our 2018 Annual Report on Form 10‑K and under the previous lease accounting standard, ASC 840, Leases, the total commitment for our non-cancelable operating lease was $0.8 million as of December 31, 2018 (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Year Ending December 31,  </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 523 </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 296 </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Thereafter </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total minimum lease payments </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 819 </td> </tr> </table></div>   Recently Issued Accounting Pronouncements In August 2018, the FASB issued ASU 2018‑13, Fair Value Measurement (Topic 820): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement, (“ASU 2018‑13”). The new standard removes certain disclosures, modifies certain disclosures and adds additional disclosures related to fair value measurement. The new standard will be effective beginning January 1, 2020. We are currently evaluating the impact that the adoption of ASU 2018‑13 will have on our consolidated financial statements. In August 2018, the FASB issued ASU 2018‑15, Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350‑40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract, (“ASU 2018‑15”). The amendments in this update align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). The accounting for the service element of a hosting arrangement that is a service contract is not affected by the amendments in this update. The new standard will be effective beginning January 1, 2020. The amendments in this update should be applied either retrospectively or prospectively to all implementation costs incurred after the date of adoption. We are currently evaluating the impact that the adoption of ASU 2018‑15 will have on our consolidated financial statements. <div /></div> </div>

1667000

5000000

-5051000

-5711000

-30895000

-11275000

2700000

546000

2155000

2700000

523000

296000

422045000

28378000

240916000

485000

325000

204000

249000

-25000

19000

-10000

117000

58000

47000

-16000

-10000

222000

47000

1552000

48000

100285000

125645000

476000

0.01

1000000

861000

1952000

9500000

64561000

97327000

64600000

97300000

38779000

73742000

738000

2458000

199000

69000

463000

5984000

874000

417000

19860000

7261000

22091000

8313000

-548020000

-578118000

22823000

4979000

1834000

208000

5.50

9.75

<div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:70.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:70.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:13.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> September 30,  </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31,  </td> </tr> <tr> <td valign="bottom" style="width:70.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> </tr> <tr> <td valign="bottom" style="width:70.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Accrued outsourced preclinical and clinical fees </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 5,748 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 8,497 </td> </tr> <tr> <td valign="bottom" style="width:70.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Accrued payroll </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,154 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,971 </td> </tr> <tr> <td valign="bottom" style="width:70.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Accrued professional fees </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 905 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 666 </td> </tr> <tr> <td valign="bottom" style="width:70.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Accounts payable </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 801 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,329 </td> </tr> <tr> <td valign="bottom" style="width:70.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Other accrued expenses </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 325 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 485 </td> </tr> <tr> <td valign="bottom" style="width:70.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 9,933 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 12,948 </td> </tr> </table></div>   <div /></div> </div>

<div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:57.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:57.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="5" valign="bottom" style="width:18.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Three Months Ended </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="5" valign="bottom" style="width:19.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Nine Months Ended </td> </tr> <tr> <td valign="bottom" style="width:57.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:18.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> September 30,  </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:19.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> September 30,  </td> </tr> <tr> <td valign="bottom" style="width:57.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> </tr> <tr> <td valign="bottom" style="width:57.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Research and development </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 223 </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 84 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 741 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 269 </td> </tr> <tr> <td valign="bottom" style="width:57.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> General and administrative </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 785 </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 279 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3,308 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 831 </td> </tr> <tr> <td valign="bottom" style="width:57.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total stock-based compensation expense </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,008 </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 363 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 4,049 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,100 </td> </tr> </table></div>   <div /></div> </div>

<div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:56.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Quoted </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Significant </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Prices in </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Other </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Significant </td> </tr> <tr> <td valign="bottom" style="width:56.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Active </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Observable </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Unobservable </td> </tr> <tr> <td valign="bottom" style="width:56.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> September 30,  </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Markets </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Inputs </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Inputs </td> </tr> <tr> <td valign="bottom" style="width:56.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 1) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 2) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 3) </td> </tr> <tr> <td valign="bottom" style="width:56.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Cash equivalents </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 40,662 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 40,662 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:56.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Corporate debt securities-short term </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 83,014 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> — </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 83,014 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:56.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Corporate debt securities-long term </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 48,900 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 48,900 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:56.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 172,576 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 40,662 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 131,914 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> </tr> </table></div>   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:57.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:57.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Quoted </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Significant </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:57.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Prices in </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Other </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Significant </td> </tr> <tr> <td valign="bottom" style="width:57.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Active </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Observable </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Unobservable </td> </tr> <tr> <td valign="bottom" style="width:57.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31,  </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Markets </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Inputs </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Inputs </td> </tr> <tr> <td valign="bottom" style="width:57.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 1) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 2) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 3) </td> </tr> <tr> <td valign="bottom" style="width:57.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Cash equivalents </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 14,444 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 14,444 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:57.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Corporate debt securities-short term </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 80,322 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 80,322 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:57.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 94,766 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 14,444 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 80,322 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> </tr> </table></div>   <div /></div> </div>

<div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:70.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:70.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted </td> </tr> <tr> <td valign="bottom" style="width:70.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Number of </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Average </td> </tr> <tr> <td valign="bottom" style="width:70.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Stock Options </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Shares </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Exercise Price </td> </tr> <tr> <td valign="bottom" style="width:70.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Outstanding as of December 31, 2018 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 10,748,157 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2.90 </td> </tr> <tr> <td valign="bottom" style="width:70.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Granted </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,666,510 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4.07 </td> </tr> <tr> <td valign="bottom" style="width:70.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Exercised </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(880,868) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2.70 </td> </tr> <tr> <td valign="bottom" style="width:70.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Cancelled </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (157,508) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2.44 </td> </tr> <tr> <td valign="bottom" style="width:70.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Outstanding as of September 30, 2019 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12,376,291 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3.17 </td> </tr> <tr> <td valign="bottom" style="width:70.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:70.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Exercisable as of September 30, 2019 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 7,207,088 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3.26 </td> </tr> </table></div>   <div /></div> </div>

1100000

4050000

1000000

28700000

7207088

3.26

P4Y4M13D

3900000

28350

157508

2666510

1.70

2.54

129158

50100000

10748157

12376291

2.90

3.17

28730000

7207088

3.26

P4Y4M24D

49485000

12218754

3.17

P6Y1M6D

2.70

2.44

4.07

14181000

-16000

547364000

871000

8843000

-534038000

9692000

-41000

547932000

871000

8843000

-539070000

27244000

-22000

560219000

961000

-533914000

87097000

-32000

625572000

1090000

-539533000

78968000

-95000

625993000

1090000

-548020000

71086000

22000

628260000

1091000

-558287000

161616000

80000

727712000

1203000

-567379000

153126000

127000

729910000

1207000

-578118000

2259

8370

15125

337616

241020

92122

880868

527126

286410

25000

155000

152000

3000

557000

555000

2000

144000

143000

1000

1307000

1301000

6000

1007000

1004000

3000

0.0887

0.01

1000000

95678

107445

113126

120374

EX-101.SCH 6 arql-20190930.xsd XBRL TAXONOMY EXTENSION SCHEMA 00100 - Statement - CONDENSED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00400 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Summary of fair value of available-for-sale securities (Details) link:presentationLink link:calculationLink link:definitionLink 40302 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Assets measured at fair value on a recurring basis (Details) link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES - Summary of accounts payable and accrued expenses (Details) link:presentationLink link:calculationLink link:definitionLink 40801 - Disclosure - LOAN AGREEMENT - Expected remaining repayment (Details) link:presentationLink link:calculationLink link:definitionLink 41001 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS - Total minimum lease payments (Details) link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) link:presentationLink link:calculationLink link:definitionLink 40101 - Disclosure - NATURE OF OPERATIONS AND BASIS OF PRESENTATION (Details) link:presentationLink link:calculationLink link:definitionLink 40201 - Disclosure - COLLABORATIONS AND ALLIANCES (Details) link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - NET LOSS PER SHARE (Details) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - STOCK-BASED COMPENSATION AND STOCK PLANS - Stock-based compensation expense (Details) link:presentationLink link:calculationLink link:definitionLink 40602 - Disclosure - STOCK-BASED COMPENSATION AND STOCK PLANS - Option activity (Details) link:presentationLink link:calculationLink link:definitionLink 40603 - Disclosure - STOCK-BASED COMPENSATION AND STOCK PLANS - Shares vested, expected to vest and exercisable (Details) link:presentationLink link:calculationLink link:definitionLink 40604 - Disclosure - STOCK-BASED COMPENSATION AND STOCK PLANS - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - COMMON STOCK OFFERINGS (Details) link:presentationLink link:calculationLink link:definitionLink 40802 - Disclosure - LOAN AGREEMENT (Details) link:presentationLink link:calculationLink link:definitionLink 40901 - Disclosure - PREFERRED STOCK AND WARRANT LIABILITY (Details) link:presentationLink link:calculationLink link:definitionLink 41002 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS - Additional information (Details) link:presentationLink link:calculationLink link:definitionLink 41101 - Disclosure - INCOME TAXES (Details) link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00105 - Statement - CONDENSED BALANCE SHEETS (Parentheticals) link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - NATURE OF OPERATIONS AND BASIS OF PRESENTATION link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - COLLABORATIONS AND ALLIANCES link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - NET LOSS PER SHARE link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - STOCK-BASED COMPENSATION AND STOCK PLANS link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - COMMON STOCK OFFERINGS link:presentationLink link:calculationLink link:definitionLink 10801 - Disclosure - LOAN AGREEMENT link:presentationLink link:calculationLink link:definitionLink 10901 - Disclosure - PREFERRED STOCK AND WARRANT LIABILITY link:presentationLink link:calculationLink link:definitionLink 11001 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS link:presentationLink link:calculationLink link:definitionLink 11101 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 20202 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS (Policies) link:presentationLink link:calculationLink link:definitionLink 30303 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 30403 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables) link:presentationLink link:calculationLink link:definitionLink 30603 - Disclosure - STOCK-BASED COMPENSATION AND STOCK PLANS (Tables) link:presentationLink link:calculationLink link:definitionLink 30803 - Disclosure - LOAN AGREEMENT (Tables) link:presentationLink link:calculationLink link:definitionLink 31003 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 arql-20190930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 arql-20190930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 arql-20190930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document and Entity Information [Abstract] Entity Registrant Name Entity Central Index Key Trading Symbol Current Fiscal Year End Date Entity Filer Category Entity Current Reporting Status Entity Interactive Data Current Entity Common Stock, Shares Outstanding Document Type Document Period End Date Entity Shell Company Amendment Flag Document Fiscal Year Focus Document Fiscal Period Focus Entity Small Business Entity Emerging Growth Company CONDENSED BALANCE SHEETS Assets [Abstract] ASSETS Assets, Current [Abstract] Current assets: Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents, end of period Cash and cash equivalents, beginning of period Cash and cash equivalents Marketable Securities, Current Marketable securities - short term Receivables, Long-term Contracts or Programs Contract receivables Prepaid Expense, Current Prepaid expenses Assets, Current Total current assets Marketable Securities, Noncurrent Marketable securities - long term Property, Plant and Equipment, Net Property and equipment, net Present value of operating leases assets. Operating Lease Assets Operating lease assets Other Assets, Noncurrent Other assets Assets Total assets Liabilities and Equity [Abstract] LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities, Current [Abstract] Current liabilities: Accounts Payable and Accrued Liabilities, Current Accounts payable and accrued expenses, Total Accounts payable and accrued expenses Notes Payable, Current Notes payable - current portion Operating Lease, Liability, Current Operating lease liability - current portion Liabilities, Current Total current liabilities Long-term liabilities: Notes Payable, Noncurrent Notes payable - long term Operating Lease, Liability, Noncurrent Operating lease liability - long term Liabilities Total liabilities Commitments and Contingencies Commitments and contingencies Stockholders Equity Attributable To Parent [Abstract] Stockholders' equity: Preferred Stock, Value, Issued Preferred stock, $0.01 par value; 1,000,000 shares authorized; no shares issued and outstanding Common Stock, Value, Issued Common stock, $0.01 par value; 200,000,000 shares authorized; 120,661,081 and 109,003,637 shares issued and outstanding at September 30, 2019 and December 31, 2018, respectively Additional Paid In Capital, Common Stock Additional paid-in capital Accumulated Other Comprehensive Income (Loss), Net Of Tax Accumulated other comprehensive income (loss) Retained Earnings (Accumulated Deficit) Accumulated deficit Stockholders' Equity Attributable To Parent Balance Balance Total stockholders' equity Liabilities and Equity Total liabilities and stockholders' equity Preferred Stock, Par or Stated Value Per Share Preferred Stock, par value (in dollars per share) Preferred Stock, Shares Authorized Preferred Stock, Shares Authorized Preferred Stock, Shares Issued Preferred Stock, Shares Issued Preferred Stock, Shares Outstanding Preferred Stock, Shares Outstanding Common Stock, Par Or Stated Value Per Share Common stock, par value (in dollars per share) Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Balance (in shares) Balance (in shares) Common stock, shares outstanding Income Statement [Abstract] Revenues [Abstract] Revenue: Revenue from Contract with Customer, Including Assessed Tax Research and development revenue Costs and Expenses [Abstract] Costs and expenses: Research and Development Expense Research and development General and Administrative Expense General and administrative Costs and Expenses Total costs and expenses Operating Income (Loss) Loss from operations Investment Income, Interest Interest income Interest Expense Interest expense Other expense Other expense Net Income (Loss) Attributable To Parent Net loss Net income/loss Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax Unrealized gain (loss) on marketable securities Comprehensive Income (Loss), Net Of Tax, Attributable To Parent Comprehensive loss Earnings Per Share, Basic and Diluted [Abstract] Basic and diluted net loss per share: Earnings Per Share, Basic and Diluted Net loss per share (in dollars per share) Weighted Average Number of Shares Outstanding, Basic and Diluted Weighted average basic and diluted common shares outstanding (in shares) Statement Of Stockholders' Equity [Abstract] Statement [Table] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Preferred Stock [Member] PREFERRED STOCK Common Stock [Member] Common Stock Additional Paid In Capital [Member] ADDITIONAL PAID-IN CAPITAL Accumulated Other Comprehensive Income [Member] ACCUMULATED OTHER COMPREHENSIVE INCOME/(LOSS) Retained Earnings [Member] ACCUMULATED DEFICIT Statement [Line Items] Increase (Decrease) In Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Represents amount for issuance of common stock and warrants due to conversion of preferred stock to common stock and preferred warrants to common warrants Issuance Of Common Stock And Warrants Due To Conversion Of Preferred Stock To Common Stock And Preferred Warrants To Common Warrants Value Issuance of common stock and warrants due to conversion of preferred stock to common stock and preferred warrants to common warrants Represents information about issuance of common stock and warrants due to conversion of preferred stock to common stock and preferred warrants to common warrants. Issuance Of Common Stock And Warrants Due To Conversion Of Preferred Stock To Common Stock And Preferred Warrants To Common Warrants Shares Issuance of common stock and warrants due to conversion of preferred stock to common stock and preferred warrants to common warrants ( in shares) Represents amount related to issuance of common stock and warrants from stock offering, net. Issuance Of Common Stock And Options From Stock Offering Net Value Issuance of common stock from stock offering, net Represents shares related to issuance of common stock and options from stock offering. Issuance Of Common Stock And Options From Stock Offering Net Issuance of common stock from stock offering, net (in shares) Stock Issued During Period, Value, Stock Options Exercised Stock option exercises and issuance of common stock Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Exercised Stock option exercises and issuance of common stock (in shares) Represent amount for stock issued during period shares exercise of warrants. Stock Issued During Period Value Exercise Of Warrants Shares issued from exercise of warrants Represents share for shares issued from exercise of warrants. Stock Issued During Period Shares Exercise Of Warrants Shares issued from exercise of warrants (in shares) Adjustments To Additional Paid In Capital, Share-Based Compensation, Requisite Service Period Recognition Stock based compensation expense Represent information related to warrants issued upon debt extension. Warrants Issued Upon Debt Extension Warrants issued upon debt extension Other Comprehensive Income (Loss), Available-For-Sale Securities Adjustment, Net Of Tax Change in unrealized gain on marketable securities Represents amount for increase to opening accumulated deficit upon adoption of new accounting standard. Increase To Opening Accumulated Deficit Upon Adoption Of New Accounting Standard Increase to opening accumulated deficit upon adoption of new accounting standard Statement Of Cash Flows [Abstract] Net Cash Provided by (Used in) Operating Activities [Abstract] Cash flows from operating activities: Adjustments To Reconcile Net Income (Loss) To Cash Provided By (Used In) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Depreciation, Depletion and Amortization Depreciation and amortization Accretion (Amortization) Of Discounts and Premiums, Investments Amortization of premium on marketable securities Amortization of Debt Discount (Premium) Amortization of debt discount Fair Value Adjustment of Warrants Change in fair value of warrant liability Share-Based Compensation Non-cash stock compensation Increase (Decrease) In Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Contract with Customer, Asset Contract receivables Increase (Decrease) In Prepaid Expense and Other Assets Prepaid expenses and others, net Increase (Decrease) In Accounts Payable and Accrued Liabilities Accounts payable and accrued expenses Net Cash Provided by (Used in) Operating Activities, Total Net cash outflows driven by payments for operating expenses Net cash used in operating activities Net Cash Provided by (Used in) Investing Activities [Abstract] Cash flows from investing activities: Payments To Acquire Marketable Securities Purchases of marketable securities Proceeds From Sale and Maturity Of Marketable Securities Proceeds from sale or maturity of marketable securities Payments to Acquire Property, Plant, and Equipment Purchases of property and equipment Net Cash Provided by (Used in) Investing Activities, Total Net cash used in investing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Cash flows from financing activities: Payments of Stock Issuance Costs Costs from notes payable and warrants, net Proceeds from Issuance Initial Public Offering Proceeds from stock offering, net of offering costs Proceeds from stock offering Proceeds From Stock Options Exercised Proceeds from stock option exercises and employee stock plan purchases Proceeds from Warrant Exercises Proceeds from warrant exercises Repayments of Long-term Debt Principal payments on long-term debt Net Cash Provided by (Used in) Financing Activities, Total Net cash provided by financing activities Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Net increase (decrease) in cash and cash equivalents NATURE OF OPERATIONS AND BASIS OF PRESENTATION Business Description and Basis of Presentation [Text Block] NATURE OF OPERATIONS AND BASIS OF PRESENTATION COLLABORATIONS AND ALLIANCES Collaborative Arrangement Disclosure [Text Block] COLLABORATIONS AND ALLIANCES MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS Financial Instruments Disclosure [Text Block] MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS ACCOUNTS PAYABLE AND ACCRUED EXPENSES Accounts Payable and Accrued Liabilities Disclosure [Text Block] ACCOUNTS PAYABLE AND ACCRUED EXPENSES NET LOSS PER SHARE Earnings Per Share [Text Block] NET LOSS PER SHARE Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Text Block] STOCK-BASED COMPENSATION AND STOCK PLANS COMMON STOCK OFFERINGS The entire disclosure for common stock Common Stock [Text Block] COMMON STOCK OFFERINGS LOAN AGREEMENT Long-term Debt [Text Block] LOAN AGREEMENT PREFERRED STOCK AND WARRANT LIABILITY The entire disclosure for preferred stock and warrant liability Preferred Stock And Warrant Liability [Text Block] PREFERRED STOCK AND WARRANT LIABILITY RECENT ACCOUNTING PRONOUNCEMENTS New Accounting Pronouncements and Changes in Accounting Principles [Text Block] RECENT ACCOUNTING PRONOUNCEMENTS INCOME TAXES Income Tax Disclosure [Text Block] INCOME TAXES Accounting Policies [Abstract] New Accounting Pronouncements, Policy [Policy Text Block] RECENT ACCOUNTING PRONOUNCEMENTS Available-For-Sale Securities [Table Text Block] Schedule of fair value of available-for-sale marketable securities Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Schedule of assets and liabilities that are measured at fair value on recurring basis Schedule Of Accounts Payable and Accrued Liabilities [Table Text Block] Schedule of accounts payable and accrued expenses Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block] Schedule of stock-based compensation expense Schedule Of Share-Based Compensation, Shares Authorized Under Stock Option Plans, By Exercise Price Range [Table Text Block] Schedule of stock option activity Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Vested and Expected To Vest, Exercisable [Table Text Block] Schedule of options vested, expected to vest and exercisable Schedule of Long-term Debt Instruments [Table Text Block] Schedule of expected remaining repayment Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] Schedule of future minimum operating leases Schedule of organization and nature of operations. Organization And Nature Of Operations [Table] Type of Arrangement and Non-arrangement Transactions [Axis] Arrangements And Nonarrangement Transactions [Member] Arrangements and Non-arrangement Transactions [Domain] Represents definitive stock purchase agreements. Definitive Stock Purchase Agreements [Member] Definitive stock purchase agreements Contractual agreement of the company. Roivant Sciences Licensing Agreement [Member] Roivant Sciences Licensing Agreement Contractual agreement of the company. Basilea Pharmaceutica International Licensing Agreement [Member] Basilea Licensing Agreement Represents loan agreement . Loan Agreement [Member] Loan and security agreement Class of Stock [Axis] Class Of Stock [Domain] Class of Stock [Domain] Series A convertible preferred stock and warrants. Series A Convertible Preferred Stock And Warrants [Member] Series A convertible preferred stock and warrants Series A Preferred Stock [Member] Series A convertible preferred stock Series A Preferred Warrants. Series A Preferred Warrants [Member] Series A Preferred Warrants Legal Entity [Axis] Entity [Domain] Entity [Domain] Represents details of legal entity. Roivant Sciences [Member] Roivant Sciences Ltd. (Sinovant) Represents information about Basilea Pharmaceutical International Limited ("Basilea"). Basilea Pharmaceutica International Limited [Member] Basilea Pharmaceutical International Limited Represents details of legal entity. Oxford Finance Llc [Member] Oxford Finance, LLC (the "Loan Agreement") Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Organization And Nature Of Operations [Line Items] Debt Instrument, Face Amount Loan principal amount Loan principal amount Revenue for completing performance obligation. Revenue For Completing Performance Obligation Revenue for completing performance obligation Stock Issued During Period, Shares, New Issues Number of stock issued under agreement Number of stock issued under agreement Convertible Preferred Stock, Shares Issued upon Conversion Number of common stock issued upon conversion Number of common stock issued upon conversion Common stock conversion price. Common Stock Conversion Price Post-conversion price of common stock Represents amount related to commercial milestone payment. Revenue Recognition Commercial Milestone Method Revenue Expected Regulatory and sales commercial milestones Class of Warrant or Right, Number of Securities Called by Warrants or Rights Number of warrants issued to purchase common stock Number of warrants issued to purchase common stock Number of warrants exercised during the current period. Stock Issued During Period, Shares, Warrants Exercised Common stock warrants exercised Value of stock issued as a result of the exercise of warrants. Stock Issued During Period, Value, Warrants Exercised Net proceeds from common stock warrants Class of Warrant or Right, Exercise Price of Warrants or Rights Pre-share exercise price of warrants or rights Exercise price of warrants or rights Represents upfront payment. Revenue Recognition, Milestone Method, Upfront Payment Upfront payment Represents additional development milestone. Revenue Recognition, Milestone Method, Additional Development Milestone Additional development milestone Additional development milestone Represents regulatory and sales milestones. Revenue Recognition, Milestone Method, Revenue Expected Regulatory and sales milestones Sale of Stock, Price Per Share Share price Proceeds from Issuance of Common Stock Aggregate net proceeds from common stock issued Debt Instrument, Convertible, Remaining Discount Amortization Period Amortization period Debt Instrument, Maturity Date Maturity date Schedule Of Collaborative Arrangements and Non-Collaborative Arrangement Transactions [Table] Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Represents the amount of net research and development revenue related to non-Phase collaboration costs. Net Research And Development Revenue Research and development revenue Deferred Revenue Total transaction price EX-101.PRE 10 arql-20190930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 R35.htm IDEA: XBRL DOCUMENT

LOAN AGREEMENT - Expected remaining repayment (Details) $ in Thousands	Sep. 30, 2019 USD ($)
LOAN AGREEMENT
2019	$ 1,250
2020	5,000
2021	5,000
2022	3,333
Loan principal amount	$ 14,583

XML 12 R31.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION AND STOCK PLANS - Option activity (Details) - Stock Options	9 Months Ended
	Sep. 30, 2019 $ / shares shares
Number of Shares
Outstanding as of December 31, 2018 \| shares	10,748,157
Granted \| shares	2,666,510
Exercised \| shares	(880,868)
Cancelled \| shares	(157,508)
Outstanding as of March 31, 2019 \| shares	12,376,291
Exercisable as of March 31, 2019 \| shares	7,207,088
Weighted Average Exercise Price
Outstanding as of December 31, 2018 \| $ / shares	$ 2.90
Granted \| $ / shares	4.07
Exercised \| $ / shares	2.70
Cancelled \| $ / shares	2.44
Outstanding as of March 31, 2019 \| $ / shares	3.17
Exercisable as of March 31, 2019 \| $ / shares	$ 3.26

XML 13 R39.htm IDEA: XBRL DOCUMENT

RECENT ACCOUNTING PRONOUNCEMENTS - Additional information (Details) - USD ($) $ in Thousands		9 Months Ended
	Jan. 01, 2019	Sep. 30, 2019	Dec. 31, 2018
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Present value of the remaining lease payments		$ 3,705	$ 819
Accounting Standards Update 2016-02
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative impact for accounting changes to recognize a lease liability		700
Increase in right-of-use asset		1,980
Increase in lease liability		1,980
Right-of-use asset		2,700
Net lease liabilities		2,700
Present value of the remaining lease payments		$ 3,700
Incremental borrowing rate		8.87%
Lease, Practical Expedient, Land Easement [true false]	false

XML 14 R5.htm IDEA: XBRL DOCUMENT

CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) - USD ($) $ in Thousands	PREFERRED STOCK	Common Stock	ADDITIONAL PAID-IN CAPITAL	ACCUMULATED OTHER COMPREHENSIVE INCOME/(LOSS)	ACCUMULATED DEFICIT	Total
Balance at Dec. 31, 2017	$ 8,843	$ 871	$ 547,364	$ (16)	$ (534,038)	$ 14,181
Balance (in shares) at Dec. 31, 2017	8,370	87,110,202
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock option exercises and issuance of common stock			25			25
Stock option exercises and issuance of common stock (in shares)		15,125
Stock based compensation expense			423			423
Warrants issued upon debt extension			120			120
Change in unrealized gain on marketable securities				(25)		(25)
Increase to opening accumulated deficit upon adoption of new accounting standard					1,500	1,500
Net income/loss					(6,532)	(6,532)
Balance at Mar. 31, 2018	$ 8,843	$ 871	547,932	(41)	(539,070)	9,692
Balance (in shares) at Mar. 31, 2018	8,370	87,125,327
Balance at Dec. 31, 2017	$ 8,843	$ 871	547,364	(16)	(534,038)	14,181
Balance (in shares) at Dec. 31, 2017	8,370	87,110,202
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income/loss						(6,995)
Balance at Sep. 30, 2018		$ 1,090	625,572	(32)	(539,533)	87,097
Balance (in shares) at Sep. 30, 2018		108,993,547
Balance at Mar. 31, 2018	$ 8,843	$ 871	547,932	(41)	(539,070)	9,692
Balance (in shares) at Mar. 31, 2018	8,370	87,125,327
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock and warrants due to conversion of preferred stock to common stock and preferred warrants to common warrants	$ (8,843)	$ 84	11,823			11,907
Issuance of common stock and warrants due to conversion of preferred stock to common stock and preferred warrants to common warrants ( in shares)	(8,370)	8,370,000
Stock option exercises and issuance of common stock		$ 3	152			155
Stock option exercises and issuance of common stock (in shares)		337,616
Shares issued from exercise of warrants		$ 3	(2)			1
Shares issued from exercise of warrants (in shares)		269,584
Stock based compensation expense			314			314
Change in unrealized gain on marketable securities				19		19
Net income/loss					5,156	5,156
Balance at Jun. 30, 2018		$ 961	560,219	(22)	(533,914)	27,244
Balance (in shares) at Jun. 30, 2018		96,102,527
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock from stock offering, net		$ 127	64,435			64,562
Issuance of common stock from stock offering, net (in shares)		12,650,000
Stock option exercises and issuance of common stock		$ 2	555			557
Stock option exercises and issuance of common stock (in shares)		241,020
Stock based compensation expense			363			363
Change in unrealized gain on marketable securities				(10)		(10)
Net income/loss					(5,619)	(5,619)
Balance at Sep. 30, 2018		$ 1,090	625,572	(32)	(539,533)	87,097
Balance (in shares) at Sep. 30, 2018		108,993,547
Balance at Dec. 31, 2018		$ 1,090	625,993	(95)	(548,020)	$ 78,968
Balance (in shares) at Dec. 31, 2018		109,003,637				109,003,637
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock option exercises and issuance of common stock		$ 1	143	0	0	$ 144
Stock option exercises and issuance of common stock (in shares)		92,122
Stock based compensation expense			2,124			2,124
Change in unrealized gain on marketable securities				117		117
Net income/loss					(10,267)	(10,267)
Balance at Mar. 31, 2019		$ 1,091	628,260	22	(558,287)	71,086
Balance (in shares) at Mar. 31, 2019		109,095,759
Balance at Dec. 31, 2018		$ 1,090	625,993	(95)	(548,020)	$ 78,968
Balance (in shares) at Dec. 31, 2018		109,003,637				109,003,637
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income/loss						$ (30,098)
Balance at Sep. 30, 2019		$ 1,207	729,910	127	(578,118)	$ 153,126
Balance (in shares) at Sep. 30, 2019		120,661,081				120,661,081
Balance at Mar. 31, 2019		$ 1,091	628,260	22	(558,287)	$ 71,086
Balance (in shares) at Mar. 31, 2019		109,095,759
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock from stock offering, net		$ 106	97,234			97,340
Issuance of common stock from stock offering, net (in shares)		10,637,500
Stock option exercises and issuance of common stock		$ 6	1,301			1,307
Stock option exercises and issuance of common stock (in shares)		527,126
Stock based compensation expense			917			917
Change in unrealized gain on marketable securities				58		58
Net income/loss					(9,092)	(9,092)
Balance at Jun. 30, 2019		$ 1,203	727,712	80	(567,379)	161,616
Balance (in shares) at Jun. 30, 2019		120,260,385
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock from stock offering, net			(13)			(13)
Stock option exercises and issuance of common stock		$ 3	1,004			1,007
Stock option exercises and issuance of common stock (in shares)		286,410
Shares issued from exercise of warrants		$ 1	199			200
Shares issued from exercise of warrants (in shares)		114,286
Stock based compensation expense			1,008			1,008
Change in unrealized gain on marketable securities				47		47
Net income/loss					(10,739)	(10,739)
Balance at Sep. 30, 2019		$ 1,207	$ 729,910	$ 127	$ (578,118)	$ 153,126
Balance (in shares) at Sep. 30, 2019		120,661,081				120,661,081

XML 15 R12.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION AND STOCK PLANS

9 Months Ended

Sep. 30, 2019

Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]

STOCK-BASED COMPENSATION AND STOCK PLANS

6. STOCK-BASED COMPENSATION AND STOCK PLANS

The following table presents stock-based compensation expense included in our condensed statements of operations and comprehensive loss (in thousands):


	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2019		2018		2019		2018
Research and development	$	223	$	84	$	741	$	269
General and administrative		785		279		3,308		831
Total stock-based compensation expense	$	1,008	$	363	$	4,049	$	1,100

Option activity under our stock plans for the nine months ended September 30, 2019 was as follows:


		Weighted
	Number of	Average
Stock Options	Shares	Exercise Price
Outstanding as of December 31, 2018	10,748,157	$	2.90
Granted	2,666,510		4.07
Exercised	(880,868)		2.70
Cancelled	(157,508)		2.44
Outstanding as of September 30, 2019	12,376,291	$	3.17

Exercisable as of September 30, 2019	7,207,088	$	3.26


				Weighted-
				Average
		Weighted-		Remaining	Aggregate
		Average		Contractual	Intrinsic
	Shares	Exercise Price		Term (in years)	Value
Vested and unvested expected to vest at September 30, 2019	12,218,754	$	3.17	6.1	$	49,485
Exercisable at September 30, 2019	7,207,088	$	3.26	4.4	$	28,730

XML 16 R16.htm IDEA: XBRL DOCUMENT

RECENT ACCOUNTING PRONOUNCEMENTS

9 Months Ended

Sep. 30, 2019

RECENT ACCOUNTING PRONOUNCEMENTS

RECENT ACCOUNTING PRONOUNCEMENTS

10. RECENT ACCOUNTING PRONOUNCEMENTS

Recently Adopted Accounting Pronouncements

In February 2016 the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) No. 2016‑02, Leases (Topic 842). This standard established a right-of-use model that requires all lessees to recognize right-of-use assets and liabilities on their balance sheet that arise from leases with terms longer than 12 months as well as provide disclosures with respect to certain qualitative and quantitative information related to their leasing arrangements. This standard became effective for us on January 1, 2019 (“the Effective Date”).

The FASB has subsequently issued the following amendments to ASU 2016‑02, which also became effective on January 1, 2019, and which we collectively refer to as the new leasing standards:

ASU No. 2018‑01, Leases (Topic 842): Land Easement Practical Expedient for Transition to Topic 842, which permits an entity to elect an optional transition practical expedient to not evaluate under Topic 842 land easements that exist or expired prior to adoption of Topic 842 and that were not previously accounted for as leases under the prior standard, ASC 840, Leases.

ASU No. 2018‑10, Codification Improvements to Topic 842, Leases, which amends certain narrow aspects of the guidance issued in ASU 2016‑02.

ASU No. 2018‑11, Leases (Topic 842): Targeted Improvements, which allows for a transition approach to initially apply ASU 2016‑02 at the adoption date and recognize a cumulative-effect adjustment to the opening balance of accumulated deficit in the period of adoption as well as an additional practical expedient for lessors to not separate non-lease components from the associated lease component.

ASU No. 2018‑20, Narrow-Scope Improvements for Lessors, which contains certain narrow scope improvements to the guidance issued in ASU 2016‑02.

We adopted the new lease accounting standard on January 1, 2019, using a modified retrospective transition approach of applying the new standard to all leases existing as of, or entered into after, the Effective Date and with remaining terms of 12 months or more. Our assessment included the lease of our headquarters in Burlington, MA which commenced in May 2015 and , prior to our October 2019 amendment discussed below, was scheduled to expire in July 2020 and our laboratory space in Woburn, MA which commenced in March 2019 and expires in April 2024.

The following table summarizes future minimum lease payments for our operating leases as of September 30, 2019 (in thousands):


Year Ending December 31,
2019 (three months ending December 31, 2019)	$	152
2020		619
2021		642
2022		657
2023		672
Thereafter		963
Total minimum lease payments	$	3,705

As previously disclosed in our 2018 Annual Report on Form 10‑K and under the previous lease accounting standard, ASC 840, Leases, the total commitment for our non-cancelable operating lease was $0.8 million as of December 31, 2018 (in thousands):


Year Ending December 31,
2019	$	523
2020		296
Thereafter		—
Total minimum lease payments	$	819

Recently Issued Accounting Pronouncements

In August 2018, the FASB issued ASU 2018‑13, Fair Value Measurement (Topic 820): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement, (“ASU 2018‑13”). The new standard removes certain disclosures, modifies certain disclosures and adds additional disclosures related to fair value measurement. The new standard will be effective beginning January 1, 2020. We are currently evaluating the impact that the adoption of ASU 2018‑13 will have on our consolidated financial statements.

In August 2018, the FASB issued ASU 2018‑15, Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350‑40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract, (“ASU 2018‑15”). The amendments in this update align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). The accounting for the service element of a hosting arrangement that is a service contract is not affected by the amendments in this update. The new standard will be effective beginning January 1, 2020. The amendments in this update should be applied either retrospectively or prospectively to all implementation costs incurred after the date of adoption. We are currently evaluating the impact that the adoption of ASU 2018‑15 will have on our consolidated financial statements.

In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments”. This ASU will require that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard will require allowances to be recorded instead of reducing the amortized cost of the investment. ASU 2016-13 will limit the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which the carrying value exceeds the fair value and requires the reversal of previously recognized credit losses if fair value increases. ASU 2016-13 will be effective for fiscal years beginning after December 15, 2019 with early adoption permitted, and requires adoption using a modified retrospective approach, with certain exceptions. Based on the composition of the Company’s investment portfolio, current market conditions and historical credit loss activity, we are currently evaluating the impact of the adoption of this standard on the Company’s financial statements.

XML 17 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2019	Oct. 16, 2019
Document and Entity Information [Abstract]
Entity Registrant Name	ARQULE INC
Entity Central Index Key	0001019695
Trading Symbol	arql
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding		120,733,695
Document Type	10-Q
Document Period End Date	Sep. 30, 2019
Entity Shell Company	false
Amendment Flag	false
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q3
Entity Small Business	true
Entity Emerging Growth Company	false

XML 18 R9.htm IDEA: XBRL DOCUMENT

MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS

9 Months Ended

Sep. 30, 2019

MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS

MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS

3. MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS

We invest our available cash primarily in commercial paper, money market funds, and U.S. Treasury bill funds that have investment grade ratings.

The following is a summary of the fair value of available-for-sale marketable securities we held at September 30, 2019 and December 31, 2018 (in thousands):


			Gross		Gross
	Amortized		Unrealized		Unrealized		Fair
September 30, 2019	Cost		Gains		Losses		Value
Security type
Corporate debt securities-short term	$	82,929	$	89	$	(4)	$	83,014
Corporate debt securities-long term		48,857		50		(7)		48,900
Total available-for-sale marketable securities	$	131,786	$	139	$	(11)	$	131,914


			Gross		Gross
	Amortized		Unrealized		Unrealized		Fair
December 31, 2018	Cost		Gains		Losses		Value
Security type
Corporate debt securities-short term	$	80,417	$	2	$	(97)	$	80,322
Total available-for-sale marketable securities	$	80,417	$	2	$	(97)	$	80,322

None of our available-for-sale marketable securities were in a continuous unrealized loss position for more than 12 months at September 30, 2019 or December 31, 2018.


			Quoted		Significant
			Prices in		Other		Significant
			Active		Observable		Unobservable
	September 30,		Markets		Inputs		Inputs
	2019		(Level 1)		(Level 2)		(Level 3)
Cash equivalents	$	40,662	$	40,662	$	—	$	—
Corporate debt securities-short term		83,014		—		83,014		—
Corporate debt securities-long term		48,900		—		48,900		—
Total	$	172,576	$	40,662	$	131,914	$	—


			Quoted		Significant
			Prices in		Other		Significant
			Active		Observable		Unobservable
	December 31,		Markets		Inputs		Inputs
	2018		(Level 1)		(Level 2)		(Level 3)
Cash equivalents	$	14,444	$	14,444	$	—	$	—
Corporate debt securities-short term		80,322		—		80,322		—
Total	$	94,766	$	14,444	$	80,322	$	—

XML 19 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 20 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.3 html 168 294 1 false 36 0 false 4 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.arqule.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00100 - Statement - CONDENSED BALANCE SHEETS Sheet http://www.arqule.com/role/StatementCondensedBalanceSheets CONDENSED BALANCE SHEETS Statements 2 false false R3.htm 00105 - Statement - CONDENSED BALANCE SHEETS (Parentheticals) Sheet http://www.arqule.com/role/StatementCondensedBalanceSheetsParentheticals CONDENSED BALANCE SHEETS (Parentheticals) Statements 3 false false R4.htm 00200 - Statement - CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) Sheet http://www.arqule.com/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) Statements 4 false false R5.htm 00300 - Statement - CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) Sheet http://www.arqule.com/role/StatementCondensedStatementsOfStockholdersEquityUnaudited CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) Statements 5 false false R6.htm 00400 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (Unaudited) Sheet http://www.arqule.com/role/StatementCondensedStatementsOfCashFlowsUnaudited CONDENSED STATEMENTS OF CASH FLOWS (Unaudited) Statements 6 false false R7.htm 10101 - Disclosure - NATURE OF OPERATIONS AND BASIS OF PRESENTATION Sheet http://www.arqule.com/role/DisclosureNatureOfOperationsAndBasisOfPresentation NATURE OF OPERATIONS AND BASIS OF PRESENTATION Notes 7 false false R8.htm 10201 - Disclosure - COLLABORATIONS AND ALLIANCES Sheet http://www.arqule.com/role/DisclosureCollaborationsAndAlliances COLLABORATIONS AND ALLIANCES Notes 8 false false R9.htm 10301 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS Sheet http://www.arqule.com/role/DisclosureMarketableSecuritiesAndFairValueMeasurements MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS Notes 9 false false R10.htm 10401 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES Sheet http://www.arqule.com/role/DisclosureAccountsPayableAndAccruedExpenses ACCOUNTS PAYABLE AND ACCRUED EXPENSES Notes 10 false false R11.htm 10501 - Disclosure - NET LOSS PER SHARE Sheet http://www.arqule.com/role/DisclosureNetLossPerShare NET LOSS PER SHARE Notes 11 false false R12.htm 10601 - Disclosure - STOCK-BASED COMPENSATION AND STOCK PLANS Sheet http://www.arqule.com/role/DisclosureStockBasedCompensationAndStockPlans STOCK-BASED COMPENSATION AND STOCK PLANS Notes 12 false false R13.htm 10701 - Disclosure - COMMON STOCK OFFERINGS Sheet http://www.arqule.com/role/DisclosureCommonStockOfferings COMMON STOCK OFFERINGS Notes 13 false false R14.htm 10801 - Disclosure - LOAN AGREEMENT Sheet http://www.arqule.com/role/DisclosureLoanAgreement LOAN AGREEMENT Notes 14 false false R15.htm 10901 - Disclosure - PREFERRED STOCK AND WARRANT LIABILITY Sheet http://www.arqule.com/role/DisclosurePreferredStockAndWarrantLiability PREFERRED STOCK AND WARRANT LIABILITY Notes 15 false false R16.htm 11001 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS Sheet http://www.arqule.com/role/DisclosureRecentAccountingPronouncements RECENT ACCOUNTING PRONOUNCEMENTS Notes 16 false false R17.htm 11101 - Disclosure - INCOME TAXES Sheet http://www.arqule.com/role/DisclosureIncomeTaxes INCOME TAXES Notes 17 false false R18.htm 20202 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS (Policies) Sheet http://www.arqule.com/role/DisclosureRecentAccountingPronouncementsPolicies RECENT ACCOUNTING PRONOUNCEMENTS (Policies) Policies 18 false false R19.htm 30303 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS (Tables) Sheet http://www.arqule.com/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsTables MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS (Tables) Tables http://www.arqule.com/role/DisclosureMarketableSecuritiesAndFairValueMeasurements 19 false false R20.htm 30403 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables) Sheet http://www.arqule.com/role/DisclosureAccountsPayableAndAccruedExpensesTables ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables) Tables http://www.arqule.com/role/DisclosureAccountsPayableAndAccruedExpenses 20 false false R21.htm 30603 - Disclosure - STOCK-BASED COMPENSATION AND STOCK PLANS (Tables) Sheet http://www.arqule.com/role/DisclosureStockBasedCompensationAndStockPlansTables STOCK-BASED COMPENSATION AND STOCK PLANS (Tables) Tables http://www.arqule.com/role/DisclosureStockBasedCompensationAndStockPlans 21 false false R22.htm 30803 - Disclosure - LOAN AGREEMENT (Tables) Sheet http://www.arqule.com/role/DisclosureLoanAgreementTables LOAN AGREEMENT (Tables) Tables http://www.arqule.com/role/DisclosureLoanAgreement 22 false false R23.htm 31003 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS (Tables) Sheet http://www.arqule.com/role/DisclosureRecentAccountingPronouncementsTables RECENT ACCOUNTING PRONOUNCEMENTS (Tables) Tables http://www.arqule.com/role/DisclosureRecentAccountingPronouncements 23 false false R24.htm 40101 - Disclosure - NATURE OF OPERATIONS AND BASIS OF PRESENTATION (Details) Sheet http://www.arqule.com/role/DisclosureNatureOfOperationsAndBasisOfPresentationDetails NATURE OF OPERATIONS AND BASIS OF PRESENTATION (Details) Details http://www.arqule.com/role/DisclosureNatureOfOperationsAndBasisOfPresentation 24 false false R25.htm 40201 - Disclosure - COLLABORATIONS AND ALLIANCES (Details) Sheet http://www.arqule.com/role/DisclosureCollaborationsAndAlliancesDetails COLLABORATIONS AND ALLIANCES (Details) Details http://www.arqule.com/role/DisclosureCollaborationsAndAlliances 25 false false R26.htm 40301 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Summary of fair value of available-for-sale securities (Details) Sheet http://www.arqule.com/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfFairValueOfAvailableForSaleSecuritiesDetails MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Summary of fair value of available-for-sale securities (Details) Details 26 false false R27.htm 40302 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Assets measured at fair value on a recurring basis (Details) Sheet http://www.arqule.com/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsAssetsMeasuredAtFairValueOnRecurringBasisDetails MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Assets measured at fair value on a recurring basis (Details) Details 27 false false R28.htm 40401 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES - Summary of accounts payable and accrued expenses (Details) Sheet http://www.arqule.com/role/DisclosureAccountsPayableAndAccruedExpensesSummaryOfAccountsPayableAndAccruedExpensesDetails ACCOUNTS PAYABLE AND ACCRUED EXPENSES - Summary of accounts payable and accrued expenses (Details) Details 28 false false R29.htm 40501 - Disclosure - NET LOSS PER SHARE (Details) Sheet http://www.arqule.com/role/DisclosureNetLossPerShareDetails NET LOSS PER SHARE (Details) Details http://www.arqule.com/role/DisclosureNetLossPerShare 29 false false R30.htm 40601 - Disclosure - STOCK-BASED COMPENSATION AND STOCK PLANS - Stock-based compensation expense (Details) Sheet http://www.arqule.com/role/DisclosureStockBasedCompensationAndStockPlansStockBasedCompensationExpenseDetails STOCK-BASED COMPENSATION AND STOCK PLANS - Stock-based compensation expense (Details) Details 30 false false R31.htm 40602 - Disclosure - STOCK-BASED COMPENSATION AND STOCK PLANS - Option activity (Details) Sheet http://www.arqule.com/role/DisclosureStockBasedCompensationAndStockPlansOptionActivityDetails STOCK-BASED COMPENSATION AND STOCK PLANS - Option activity (Details) Details 31 false false R32.htm 40603 - Disclosure - STOCK-BASED COMPENSATION AND STOCK PLANS - Shares vested, expected to vest and exercisable (Details) Sheet http://www.arqule.com/role/DisclosureStockBasedCompensationAndStockPlansSharesVestedExpectedToVestAndExercisableDetails STOCK-BASED COMPENSATION AND STOCK PLANS - Shares vested, expected to vest and exercisable (Details) Details 32 false false R33.htm 40604 - Disclosure - STOCK-BASED COMPENSATION AND STOCK PLANS - Additional Information (Details) Sheet http://www.arqule.com/role/DisclosureStockBasedCompensationAndStockPlansAdditionalInformationDetails STOCK-BASED COMPENSATION AND STOCK PLANS - Additional Information (Details) Details 33 false false R34.htm 40701 - Disclosure - COMMON STOCK OFFERINGS (Details) Sheet http://www.arqule.com/role/DisclosureCommonStockOfferingsDetails COMMON STOCK OFFERINGS (Details) Details http://www.arqule.com/role/DisclosureCommonStockOfferings 34 false false R35.htm 40801 - Disclosure - LOAN AGREEMENT - Expected remaining repayment (Details) Sheet http://www.arqule.com/role/DisclosureLoanAgreementExpectedRemainingRepaymentDetails LOAN AGREEMENT - Expected remaining repayment (Details) Details 35 false false R36.htm 40802 - Disclosure - LOAN AGREEMENT (Details) Sheet http://www.arqule.com/role/DisclosureLoanAgreementDetails LOAN AGREEMENT (Details) Details http://www.arqule.com/role/DisclosureLoanAgreementTables 36 false false R37.htm 40901 - Disclosure - PREFERRED STOCK AND WARRANT LIABILITY (Details) Sheet http://www.arqule.com/role/DisclosurePreferredStockAndWarrantLiabilityDetails PREFERRED STOCK AND WARRANT LIABILITY (Details) Details http://www.arqule.com/role/DisclosurePreferredStockAndWarrantLiability 37 false false R38.htm 41001 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS - Total minimum lease payments (Details) Sheet http://www.arqule.com/role/DisclosureRecentAccountingPronouncementsTotalMinimumLeasePaymentsDetails RECENT ACCOUNTING PRONOUNCEMENTS - Total minimum lease payments (Details) Details 38 false false R39.htm 41002 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS - Additional information (Details) Sheet http://www.arqule.com/role/DisclosureRecentAccountingPronouncementsAdditionalInformationDetails RECENT ACCOUNTING PRONOUNCEMENTS - Additional information (Details) Details 39 false false R40.htm 41101 - Disclosure - INCOME TAXES (Details) Sheet http://www.arqule.com/role/DisclosureIncomeTaxesDetails INCOME TAXES (Details) Details http://www.arqule.com/role/DisclosureIncomeTaxes 40 false false All Reports Book All Reports arql-20190930.xml arql-20190930.xsd arql-20190930_cal.xml arql-20190930_def.xml arql-20190930_lab.xml arql-20190930_pre.xml http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/us-gaap/2019-01-31 true true XML 21 R28.htm IDEA: XBRL DOCUMENT

ACCOUNTS PAYABLE AND ACCRUED EXPENSES - Summary of accounts payable and accrued expenses (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
ACCOUNTS PAYABLE AND ACCRUED EXPENSES
Accrued outsourced preclinical and clinical fees	$ 5,748	$ 8,497
Accrued payroll	2,154	1,971
Accrued professional fees	905	666
Accounts payable	801	1,329
Other accrued expenses	325	485
Accounts payable and accrued expenses, Total	$ 9,933	$ 12,948

XML 22 R20.htm IDEA: XBRL DOCUMENT

ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)

9 Months Ended

Sep. 30, 2019

ACCOUNTS PAYABLE AND ACCRUED EXPENSES

Schedule of accounts payable and accrued expenses


	September 30,		December 31,
	2019		2018
Accrued outsourced preclinical and clinical fees	$	5,748	$	8,497
Accrued payroll		2,154		1,971
Accrued professional fees		905		666
Accounts payable		801		1,329
Other accrued expenses		325		485
	$	9,933	$	12,948

XML 23 R24.htm IDEA: XBRL DOCUMENT

NATURE OF OPERATIONS AND BASIS OF PRESENTATION (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended					3 Months Ended		6 Months Ended	9 Months Ended
	Jun. 30, 2019	Jul. 31, 2018	Apr. 30, 2018	Feb. 28, 2018	Nov. 30, 2017	Sep. 30, 2019	Sep. 30, 2018	Jun. 30, 2019	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Organization And Nature Of Operations [Line Items]
Net cash outflows driven by payments for operating expenses									$ 24,225	$ 7,796
Common Stock, Shares, Issued	10,637,500	12,650,000				120,661,081		10,637,500	120,661,081		109,003,637
Share price	$ 9.75	$ 5.50						$ 9.75
Aggregate net proceeds from common stock issued	$ 97,300	$ 64,600						$ 97,300
Proceeds from stock offering									$ 97,327	64,561
Definitive stock purchase agreements \| Series A convertible preferred stock and warrants
Organization And Nature Of Operations [Line Items]
Proceeds from stock offering					$ 9,500
Definitive stock purchase agreements \| Series A convertible preferred stock
Organization And Nature Of Operations [Line Items]
Number of stock issued under agreement					8,370
Number of common stock issued upon conversion					1,000
Definitive stock purchase agreements \| Series A Preferred Warrants
Organization And Nature Of Operations [Line Items]
Number of stock issued under agreement					2,259
Number of common stock issued upon conversion					1,000
Post-conversion price of common stock					$ 1.75
Common stock warrants exercised									114,286
Net proceeds from common stock warrants									$ 200
Roivant Sciences Licensing Agreement \| Roivant Sciences Ltd. (Sinovant)
Organization And Nature Of Operations [Line Items]
Revenue for completing performance obligation						$ 200	$ 2,900		1,600	5,900
Regulatory and sales commercial milestones				$ 70,000
Upfront payment				3,000
Additional development milestone				2,500
Regulatory and sales milestones				$ 12,000
Basilea Licensing Agreement \| Basilea Pharmaceutical International Limited
Organization And Nature Of Operations [Line Items]
Revenue for completing performance obligation						0	$ 2,000		200	$ 15,700
Regulatory and sales commercial milestones			$ 262,500
Upfront payment			10,000
Regulatory and sales milestones			63,000
Basilea Licensing Agreement \| Basilea Pharmaceutica Limited (Basilea)
Organization And Nature Of Operations [Line Items]
Regulatory and sales commercial milestones			$ 262,500
Loan and security agreement \| Oxford Finance, LLC (the "Loan Agreement")
Organization And Nature Of Operations [Line Items]
Loan principal amount						$ 15,000			$ 15,000

XML 24 R40.htm IDEA: XBRL DOCUMENT

INCOME TAXES (Details) - USD ($) $ in Thousands	9 Months Ended
INCOME TAXES (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Operating Loss Carryforwards [Line Items]
Increase in ownership percentage of certain stockholders or public groups	more than 50 percentage points
Ownership change, increase in ownership percentage, term	3 years
Federal income tax
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards		$ 422,045
State income tax
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards		240,916
Research and development credit carryforwards
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards		$ 28,378

XML 25 R21.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION AND STOCK PLANS (Tables)

9 Months Ended

Sep. 30, 2019

Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]

Schedule of stock-based compensation expense


	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2019		2018		2019		2018
Research and development	$	223	$	84	$	741	$	269
General and administrative		785		279		3,308		831
Total stock-based compensation expense	$	1,008	$	363	$	4,049	$	1,100

Schedule of stock option activity


		Weighted
	Number of	Average
Stock Options	Shares	Exercise Price
Outstanding as of December 31, 2018	10,748,157	$	2.90
Granted	2,666,510		4.07
Exercised	(880,868)		2.70
Cancelled	(157,508)		2.44
Outstanding as of September 30, 2019	12,376,291	$	3.17

Exercisable as of September 30, 2019	7,207,088	$	3.26

Schedule of options vested, expected to vest and exercisable


				Weighted-
				Average
		Weighted-		Remaining	Aggregate
		Average		Contractual	Intrinsic
	Shares	Exercise Price		Term (in years)	Value
Vested and unvested expected to vest at September 30, 2019	12,218,754	$	3.17	6.1	$	49,485
Exercisable at September 30, 2019	7,207,088	$	3.26	4.4	$	28,730

XML 26 R25.htm IDEA: XBRL DOCUMENT

COLLABORATIONS AND ALLIANCES (Details) - USD ($) $ in Thousands	1 Months Ended		3 Months Ended		9 Months Ended
	Apr. 30, 2018	Feb. 28, 2018	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Research and development revenue			$ 208	$ 4,979	$ 1,834	$ 22,823
Basilea Pharmaceutical International Limited \| Research and development service
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Research and development revenue	$ 9,800
Revenue for completing performance obligation	10,300
Total transaction price	9,500
Basilea Licensing Agreement \| Basilea Pharmaceutical International Limited
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Regulatory and sales milestones	63,000
Revenue Recognition Commercial Milestone Method Revenue Expected	262,500
Upfront payment	10,000
Revenue for completing performance obligation			0	2,000	200	15,700
Total transaction price	$ 19,800
Roivant Sciences Licensing Agreement \| Roivant Sciences Ltd. (Sinovant)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Regulatory and sales milestones		$ 12,000
Revenue Recognition Commercial Milestone Method Revenue Expected		70,000
Upfront payment		3,000
Additional development milestone		$ 2,500
Revenue for completing performance obligation			200	2,900	1,600	5,900
Other Licensing Agreements [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue for completing performance obligation			$ 0	$ 100	$ 0	$ 1,300

XML 27 R29.htm IDEA: XBRL DOCUMENT

NET LOSS PER SHARE (Details) - shares	3 Months Ended		9 Months Ended
NET LOSS PER SHARE (Details) - shares	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Exercise of outstanding employee and Board of Director stock options
Net Income Loss Per Share [Line Items]
Potential common shares in number of shares used for diluted computation	12,376,291	10,720,022	12,376,291	10,720,022
Exercise of options from February 2018 loan agreement
Net Income Loss Per Share [Line Items]
Potential common shares in number of shares used for diluted computation	93,168	93,168	93,168	93,168
Exercise of warrants from October 2017 common stock offering
Net Income Loss Per Share [Line Items]
Potential common shares in number of shares used for diluted computation	3,123,674	3,123,674	3,123,674	3,123,674
Exercise of warrants from November 2017 preferred stock offering
Net Income Loss Per Share [Line Items]
Potential common shares in number of shares used for diluted computation	2,144,714	2,259,000	2,144,714	2,259,000

XML 28 R38.htm IDEA: XBRL DOCUMENT

RECENT ACCOUNTING PRONOUNCEMENTS - Total minimum lease payments (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
RECENT ACCOUNTING PRONOUNCEMENTS
2019 (three months ending December 31, 2019)	$ 152
2019		$ 523
2020		296
2020	619
2021	642
2022	657
2023	672
Thereafter	963
Total minimum lease payments	$ 3,705	$ 819

XML 29 R34.htm IDEA: XBRL DOCUMENT

COMMON STOCK OFFERINGS (Details) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended		6 Months Ended
	Jun. 30, 2019	Jul. 31, 2018	Jun. 30, 2019	Sep. 30, 2019	Dec. 31, 2018
COMMON STOCK OFFERINGS
Common Stock, Shares, Issued	10,637,500	12,650,000	10,637,500	120,661,081	109,003,637
Share price	$ 9.75	$ 5.50	$ 9.75
Aggregate net proceeds from common stock issued	$ 97.3	$ 64.6	$ 97.3

XML 30 R30.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION AND STOCK PLANS - Stock-based compensation expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 1,008	$ 363	$ 4,049	$ 1,100
Research and development
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	223	84	741	269
General and administrative
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 785	$ 279	$ 3,308	$ 831

XML 31 R8.htm IDEA: XBRL DOCUMENT

COLLABORATIONS AND ALLIANCES	9 Months Ended
COLLABORATIONS AND ALLIANCES	Sep. 30, 2019
COLLABORATIONS AND ALLIANCES
COLLABORATIONS AND ALLIANCES	2. COLLABORATIONS AND ALLIANCES Basilea Agreement In April 2018, we entered into a License Agreement with Basilea (the "Basilea Agreement") pursuant to which we granted Basilea an exclusive license to develop and commercialize derazantinib in the United States, European Union, Japan and the rest of the world, excluding Greater China (the "Basilea Territory"). Under the terms of the Basilea Agreement, we received an upfront payment of $10.0 million . In addition, we are eligible to receive up to $63.0 million in development and regulatory milestone payments across multiple indications in the United States, European Union and Japan, none of which exceed $12.0 million on an individual basis, and up to $262.5 million in commercial milestone payments based upon the attainment of specified calendar year net sales levels for all indications in the Basilea Territory. Upon commercialization, we are entitled to receive tiered royalties on future net sales of derazantinib ranging from the high-single digits to the mid-teens on direct sales in the Basilea Territory and mid-single digits to low-double digits on indirect sales in the Basilea Territory. Basilea is responsible for all costs and expenses of development, manufacture and commercialization in its territory. Under certain circumstances, we may have the opportunity to promote derazantinib in the United States directly. We evaluated the Basilea Agreement in accordance with ASC 606, Revenue from Contracts with Customers . We concluded there were two performance obligations under the Basilea Agreement at contract inception: (1) the grant of the exclusive license (the "Basilea License") to derazantinib in the Basilea Territory and (2) the provision of specified research and development services to Basilea (the "R&D Services"). The total transaction price for the Basilea Agreement at contract inception was determined to be $19.8 million, which was comprised of the $10.0 million upfront payment and an estimated $9.8 million of variable consideration to be received for the R&D Services. As of June 30, 2019, the R&D Services performance obligation was substantially complete. At contract inception, the variable consideration associated with development and regulatory milestone payments was excluded from the transaction price, and as of September 30, 2019 continued to be excluded from the transaction price, as achievement of the milestones is contingent upon future events and is not considered the most-likely outcome. We update our estimates for development and regulatory milestone variable consideration at each reporting date and will recognize revenue associated with a particular milestone when achieving the milestone is considered the most-likely outcome and it is probable that a significant reversal of cumulative revenue under the contract will not occur. The commercial milestone and royalty consideration were excluded from the transaction price because the Basilea License was determined to be the predominant item in the contract. As a result, we will recognize revenue associated with the commercial milestones and royalties at the later of when (i) the related sales occur or (ii) the performance obligation to which some or all of the applicable commercial milestone and/or royalty has been allocated has been satisfied (or partially satisfied). As of September 30, 2019, we have not recognized any commercial milestone or royalty revenue under the Basilea Agreement. The total transaction price was allocated to the two performance obligations based on the relative standalone selling price of each performance obligation at contract inception. The standalone selling price for the Basilea License was determined on a discounted cash flow basis. At contract inception, $10.3 million of the total transaction price was allocated to the Basilea License and was recognized when control of the Basilea License was transferred and the license period began. The standalone selling price for the R&D Services was determined based upon a cost-plus margin approach. At contract inception, $9.5 million of the transaction price was allocated to the R&D Services. Revenue related to the R&D Services is recognized on a “cost-to-cost” percentage of completion basis as the services are performed. For the three and nine months ended September 30, 2019, we recognized revenue of zero and $0.2 million, respectively, under the Basilea Agreement related to R&D Services provided to Basilea. For the three and nine months ended September 30, 2018, we recognized revenue of $2.0 million and $15.7 million, respectively, related to providing R&D Services to Basilea as well as the transfer of the Basilea License. Sinovant Agreement In February 2018, we entered into a License Agreement with Sinovant (the "Sinovant Agreement") pursuant to which we granted Sinovant an exclusive license to develop, manufacture and commercialize derazantinib in Greater China. Under the terms of the Sinovant Agreement, we have received an upfront payment of $3.0 million and recognized a $2.5 million regulatory milestone payment in the third quarter of 2018. We are also eligible to receive up to an additional $12.0 million in regulatory milestone payments across multiple indications in Greater China and $70.0 million in commercial milestone payments based upon the attainment of specified calendar year net sales levels for all indications in Greater China. Upon commercialization, we are entitled to receive double digit royalties in the low teens from Sinovant on net sales of derazantinib in Greater China. Sinovant will be responsible for all costs and expenses of development, manufacture and commercialization in Greater China. We evaluated the Sinovant Agreement in accordance with ASC 606, Revenue from Contracts with Customers. We concluded that the only performance obligation under the Sinovant Agreement at contract inception was the grant of the exclusive license (the “Sinovant License”) to derazantinib in Greater China. The Sinovant Agreement also contemplated that we might provide certain manufacturing services (the “Manufacturing Services”), which we concluded was not a separate performance obligation at contract inception. The total transaction price for the Sinovant Agreement at contract inception was determined to be $3.0 million, which was equal to the upfront payment under the Sinovant Agreement. The $3.0 million was fully allocable to the Sinovant License and was recognized as revenue when control was transferred and the license period began. Our right to receive regulatory milestone payments is considered variable consideration. At contract inception, the variable consideration associated with regulatory milestone payments was excluded from the transaction price as achievement of the milestones was contingent upon future events and achievement of the milestones is not considered the most-likely outcome. We update our estimates for regulatory milestones at each reporting date and will recognize revenue associated with a particular milestone when we determine that achieving the milestone is the most-likely outcome and it is probable that a significant reversal of cumulative revenue under the contract will not occur. Based on the above analysis, we recognized $2.5 million in revenue associated with a regulatory milestone in the third quarter of 2018. The commercial milestones and royalty consideration were excluded from the transaction price because the Sinovant License is the only performance obligation and therefore considered the predominant item under the contract. As a result, we recognize revenue associated with the commercial milestones and royalties at the later of when (i) the related sales occur or (ii) the performance obligation to which some or all of the applicable commercial milestone and/or royalty has been allocated has been satisfied (or partially satisfied). As of September 30, 2019, we have not recognized any commercial milestone or royalty revenue under the Sinovant Agreement. In December 2018, we entered into a Supply Agreement with Sinovant where we agreed to provide the Manufacturing Services to Sinovant beyond the term contemplated for those services under the Sinovant Agreement. The Manufacturing Services are the only performance obligation under the Supply agreement and revenue related to the Supply Agreement is recognized on a “cost-to-cost” percentage of completion basis as the services are performed. For the three and nine months ended September 30, 2019, we recognized revenue of $0.2 million and $1.6 million, respectively, under the Sinovant Agreement related to the Manufacturing Services that we provided. For the three and nine months ended September 30, 2018, we recognized revenue of $2.9 million and $5.9 million, respectively, related primarily to the transfer of the Sinovant License and the achievement of a regulatory milestone discussed above. Other Licensing Agreements In October 2017, we granted a third party a non-exclusive license to certain of our library compounds. The licensed compounds were delivered and were accepted by the third party in 2018. Accordingly, revenue for the three and nine months ended September 30, 2019 was zero. For the three and nine months ended September 30, 2018, we recorded revenue of $0.1 million and $1.3 million, based upon the achievement of the quality and acceptance testing.

XML 32 R4.htm IDEA: XBRL DOCUMENT

CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Revenue:
Research and development revenue	$ 208	$ 4,979	$ 1,834	$ 22,823
Costs and expenses:
Research and development	8,313	7,261	22,091	19,860
General and administrative	3,170	3,429	10,638	8,014
Total costs and expenses	11,483	10,690	32,729	27,874
Loss from operations	(11,275)	(5,711)	(30,895)	(5,051)
Interest income	961	514	2,085	843
Interest expense	(425)	(422)	(1,288)	(1,235)
Other expense				(1,552)
Net loss	(10,739)	(5,619)	(30,098)	(6,995)
Unrealized gain (loss) on marketable securities	47	(10)	222	(16)
Comprehensive loss	$ (10,692)	$ (5,629)	$ (29,876)	$ (7,011)
Basic and diluted net loss per share:
Net loss per share (in dollars per share)	$ (0.09)	$ (0.05)	$ (0.27)	$ (0.07)
Weighted average basic and diluted common shares outstanding (in shares)	120,374	107,445	113,126	95,678

XML 33 R13.htm IDEA: XBRL DOCUMENT

COMMON STOCK OFFERINGS	9 Months Ended
COMMON STOCK OFFERINGS	Sep. 30, 2019
COMMON STOCK OFFERINGS
COMMON STOCK OFFERINGS	7. COMMON STOCK OFFERINGS In June 2019, we sold 10,637,500 shares of common stock at $9.75 per share for aggregate net proceeds of approximately $97.3 million after commissions and other offering expenses. In July 2018, we sold 12,650,000 shares of common stock at $5.50 per share for aggregate net proceeds of approximately $64.6 million after commissions and other offering expenses.

XML 34 R17.htm IDEA: XBRL DOCUMENT

INCOME TAXES	9 Months Ended
INCOME TAXES	Sep. 30, 2019
INCOME TAXES
INCOME TAXES	11. INCOME TAXES As of December 31, 2018, we had federal net operating losses (“NOL”), state NOL, and research and development credit carryforwards of approximately $422,045, $240,916 and $28,378 respectively, which expire at various dates through 2037. As of September 30, 2019, and December 31, 2018 we had no unrecognized tax benefits. We do not expect that the total amount of unrecognized tax benefits will significantly increase in the next twelve months. Our policy is to recognize interest and penalties related to uncertain tax positions in income tax expense. As of September 30, 2019, and December 31, 2018, we had no accrued interest or penalties related to uncertain tax positions. Our U.S. federal tax returns for the tax years 2015 through 2018 and our state tax returns for the tax years 2015 through 2018 remain open to examination. Prior tax years remain open to the extent of NOL and tax credit carryforwards. Utilization of NOL and research and development credit carryforwards may be subject to a substantial annual limitation in the event of an ownership change that has occurred previously or could occur in the future pursuant to Section 382 and 383 of the Internal Revenue Code of 1986, as amended, as well as similar state provisions. An ownership change may limit the amount of NOL and research and development credit carryforwards that can be utilized annually to offset future taxable income, and may, in turn, result in the expiration of a portion of those carryforwards before utilization. In general, an ownership change, as defined by Section 382, results from transactions that increase the ownership of certain stockholders or public groups in the stock of a corporation by more than 50 percentage points over a three-year period. We undertook a detailed study of our NOL and research and development credit carryforwards through January 31, 2019, to determine whether such amounts are likely to be limited by Sections 382 or 383. As a result of this analysis, we currently do not believe any Sections 382 or 383 limitations will significantly impact our ability to offset income with available NOL and research and development credit carryforwards. However, future ownership changes under Section 382 may limit our ability to fully utilize these tax benefits.

XML 35 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} ZIP 36 0001104659-19-057569-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-19-057569-xbrl.zip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end XML 37 R23.htm IDEA: XBRL DOCUMENT v3.19.3 RECENT ACCOUNTING PRONOUNCEMENTS (Tables) 9 Months Ended Sep. 30, 2019 RECENT ACCOUNTING PRONOUNCEMENTS Schedule of future minimum operating leases Year Ending December 31, 2019 (three months ending December 31, 2019) $ 152 2020 619 2021 642 2022 657 2023 672 Thereafter 963 Total minimum lease payments $ 3,705 Year Ending December 31, 2019 $ 523 2020 296 Thereafter — Total minimum lease payments $ 819
X - ReferencesNo definition available. + Details Name: us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Publisher FASB -Name Accounting Standards Codification -Topic 840 -SubTopic 20 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717 + Details Name: us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.19.3 MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Assets measured at fair value on a recurring basis (Details) - Fair Value, Measurements, Recurring - USD ($) $ in Thousands Sep. 30, 2019 Dec. 31, 2018 Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Cash equivalents $ 40,662 $ 14,444 Total 172,576 94,766 Corporate debt securities-short term Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Corporate debt securities 83,014 80,322 Corporate debt securities-long term Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Corporate debt securities 48,900 Quoted Prices in Active Markets (Level 1) Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Cash equivalents 40,662 14,444 Total 40,662 14,444 Quoted Prices in Active Markets (Level 1) | Corporate debt securities-short term Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Corporate debt securities 0 0 Quoted Prices in Active Markets (Level 1) | Corporate debt securities-long term Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Corporate debt securities 0 Significant Other Observable Inputs (Level 2) Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Cash equivalents 0 0 Total 131,914 80,322 Significant Other Observable Inputs (Level 2) | Corporate debt securities-short term Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Corporate debt securities 83,014 80,322 Significant Other Observable Inputs (Level 2) | Corporate debt securities-long term Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Corporate debt securities 48,900 Significant Unobservable Inputs (Level 3) Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Cash equivalents 0 0 Total 0 0 Significant Unobservable Inputs (Level 3) | Corporate debt securities-short term Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Corporate debt securities 0 $ 0 Significant Unobservable Inputs (Level 3) | Corporate debt securities-long term Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Corporate debt securities $ 0 X - DefinitionFair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258 + Details Name: us-gaap_AssetsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in debt and equity securities categorized neither as held-to-maturity nor trading. + ReferencesNo definition available. + Details Name: us-gaap_AvailableForSaleSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesNo definition available. + Details Name: us-gaap_CashAndCashEquivalentsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_ShortTermDebtMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_LongTermDebtMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 39 R19.htm IDEA: XBRL DOCUMENT v3.19.3 MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS (Tables) 9 Months Ended Sep. 30, 2019 MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS Schedule of fair value of available-for-sale marketable securities Gross Gross Amortized Unrealized Unrealized Fair September 30, 2019 Cost Gains Losses Value Security type Corporate debt securities-short term $ 82,929 $ 89 $ (4) $ 83,014 Corporate debt securities-long term 48,857 50 (7) 48,900 Total available-for-sale marketable securities $ 131,786 $ 139 $ (11) $ 131,914 Gross Gross Amortized Unrealized Unrealized Fair December 31, 2018 Cost Gains Losses Value Security type Corporate debt securities-short term $ 80,417 $ 2 $ (97) $ 80,322 Total available-for-sale marketable securities $ 80,417 $ 2 $ (97) $ 80,322 Schedule of assets and liabilities that are measured at fair value on recurring basis Quoted Significant Prices in Other Significant Active Observable Unobservable September 30, Markets Inputs Inputs 2019 (Level 1) (Level 2) (Level 3) Cash equivalents $ 40,662 $ 40,662 $ — $ — Corporate debt securities-short term 83,014 — 83,014 — Corporate debt securities-long term 48,900 — 48,900 — Total $ 172,576 $ 40,662 $ 131,914 $ — Quoted Significant Prices in Other Significant Active Observable Unobservable December 31, Markets Inputs Inputs 2018 (Level 1) (Level 2) (Level 3) Cash equivalents $ 14,444 $ 14,444 $ — $ — Corporate debt securities-short term 80,322 — 80,322 — Total $ 94,766 $ 14,444 $ 80,322 $ — X - DefinitionMARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS + ReferencesNo definition available. + Details Name: arql_MarketableSecuritiesAndFairValueMeasurementsAbstract Namespace Prefix: arql_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -URI http://asc.fasb.org/topic&trid=2196928 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258 + Details Name: us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration XML 40 R6.htm IDEA: XBRL DOCUMENT v3.19.3 CONDENSED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands 9 Months Ended Sep. 30, 2019 Sep. 30, 2018 Cash flows from operating activities: Net income/loss $ (30,098) $ (6,995) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization 82 35 Amortization of premium on marketable securities 533 387 Amortization of debt discount 239 242 Change in fair value of warrant liability 1,552 Non-cash stock compensation 4,050 1,100 Changes in operating assets and liabilities: Contract receivables 5,065 (6,401) Prepaid expenses and others, net (1,081) (229) Accounts payable and accrued expenses (3,015) 2,513 Net cash used in operating activities (24,225) (7,796) Cash flows from investing activities: Purchases of marketable securities (125,645) (100,285) Proceeds from sale or maturity of marketable securities 73,742 38,779 Purchases of property and equipment (476) Net cash used in investing activities (52,379) (61,506) Cash flows from financing activities: Costs from notes payable and warrants, net (48) Proceeds from stock offering, net of offering costs 97,327 64,561 Proceeds from stock option exercises and employee stock plan purchases 2,458 738 Proceeds from warrant exercises 199 Principal payments on long-term debt (417) Net cash provided by financing activities 99,567 65,251 Net increase (decrease) in cash and cash equivalents 22,963 (4,051) Cash and cash equivalents, beginning of period 19,236 20,229 Cash and cash equivalents, end of period $ 42,199 $ 16,178 X - DefinitionThe sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585 + Details Name: us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 1A -URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.8) -URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227 + Details Name: us-gaap_AmortizationOfDebtDiscountPremium Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.1) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 830 -SubTopic 230 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 24 -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585 + Details Name: us-gaap_DepreciationDepletionAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of expense (income) related to adjustment to fair value of warrant liability. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 480 -SubTopic 10 -Section 25 -Paragraph 13 -URI http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875 + Details Name: us-gaap_FairValueAdjustmentOfWarrants Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585 + Details Name: us-gaap_IncreaseDecreaseInContractWithCustomerAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585 + Details Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 24 -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 24 -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 24 -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 1A -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 1B -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227 Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585 Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow for cost incurred directly with the issuance of an equity security. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585 + Details Name: us-gaap_PaymentsOfStockIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow for purchase of marketable security. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 45 -Paragraph 11 -URI http://asc.fasb.org/extlink&oid=118954083&loc=d3e26853-111562 + Details Name: us-gaap_PaymentsToAcquireMarketableSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585 + Details Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from entity's first offering of stock to the public. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585 + Details Name: us-gaap_ProceedsFromIssuanceInitialPublicOffering Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period. + ReferencesNo definition available. + Details Name: us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from exercise of option under share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2A -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=116856206&loc=SL79508275-113901 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585 + Details Name: us-gaap_ProceedsFromStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from holders exercising their stock warrants. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585 + Details Name: us-gaap_ProceedsFromWarrantExercises Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585 + Details Name: us-gaap_RepaymentsOfLongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 41 R11.htm IDEA: XBRL DOCUMENT v3.19.3 NET LOSS PER SHARE 9 Months Ended Sep. 30, 2019 NET LOSS PER SHARE NET LOSS PER SHARE 5. NET LOSS PER SHARE Net loss per share is computed using the weighted average number of common shares outstanding. Basic and diluted net loss per share amounts are equivalent for the periods presented as the inclusion of potential common shares in the number of shares used for the diluted computation would be anti-dilutive to loss per share. Potential common shares, for the three and nine months ended September 30, 2019, include 12,376,291 shares that would be issued upon the exercise of outstanding employee and Board of Director stock options, 93,168 shares that would be issued upon the exercise of the warrants from our February 2018 amendment to our loan agreement, 3,123,674 shares that would be issued upon the exercise of the warrants from our October 2017 common stock offering and 2,144,714 common shares that would be issued upon the exercise of the warrants from our November 2017 preferred stock offering. Potential common shares, for the three and nine months ended September 30, 2018, include 10,720,022 shares that would be issued upon the exercise of outstanding employee and Board of Director stock options, 93,168 shares that would be issued upon the exercise of the warrants from our February 2018 amendment to our loan agreement, 3,123,674 shares that would be issued upon the exercise of the warrants from our October 2017 common stock offering and 2,259,000 common shares that would be issued upon the exercise of the warrants from our November 2017 preferred stock offering. The preferred shares and warrants from our November 2017 preferred stock offering were converted to common stock and common stock warrants in May 2018. X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for earnings per share. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -URI http://asc.fasb.org/topic&trid=2144383 + Details Name: us-gaap_EarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration XML 42 R15.htm IDEA: XBRL DOCUMENT v3.19.3 PREFERRED STOCK AND WARRANT LIABILITY 9 Months Ended Sep. 30, 2019 PREFERRED STOCK AND WARRANT LIABILITY PREFERRED STOCK AND WARRANT LIABILITY 9. PREFERRED STOCK AND WARRANT LIABILITY Our Restated Certificate of Incorporation , as amended, authorizes the issuance of up to 1 million shares of $0.01 par value preferred stock. In November 2017, we entered into definitive securities purchase agreements with certain institutional investors. In conjunction with this stock offering we raised net proceeds of $9.5 million through the sale of 8,370 shares of series A convertible preferred stock (Series A Preferred) and warrants covering 2,259 shares of Series A Preferred (Warrants). Each share of Series A Preferred converted into 1,000 shares of common stock and each associated Warrant converted into 1,000 common stock warrants in May 2018. The terms of the Series A Preferred for which the warrants were exercisable required that the fair value allocated to the warrants at the date of issuance be recorded as a liability on our balance sheet. The warrant liability was marked to market value through the statement of operations and comprehensive loss as a non-cash gain or loss at each reporting period until the conversion of the Series A Preferred to common stock in May 2018. Upon conversion, the warrant liability of $3.1 million was extinguished with an offsetting amount included as additional paid-in capital in stockholders’ equity. Accordingly, at each of December 31, 2018 and September 30, 2019, the warrant liability was zero. In the three and nine months ended September 30, 2018, we recognized a non-cash expense of zero and $1.5 million , respectively, recorded in other expense on the statement of operations and comprehensive loss related to the change in the fair value of the warrant liability. X - ReferencesNo definition available. + Details Name: arql_PreferredStockAndWarrantLiabilityAbstract Namespace Prefix: arql_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for preferred stock and warrant liability + ReferencesNo definition available. + Details Name: arql_PreferredStockAndWarrantLiabilityTextBlock Namespace Prefix: arql_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration XML 43 R2.htm IDEA: XBRL DOCUMENT v3.19.3 CONDENSED BALANCE SHEETS - USD ($) $ in Thousands Sep. 30, 2019 Dec. 31, 2018 Current assets: Cash and cash equivalents $ 42,199 $ 19,236 Marketable securities - short term 83,014 80,322 Contract receivables 874 5,984 Prepaid expenses 1,952 861 Total current assets 128,039 106,403 Marketable securities - long term 48,900 Property and equipment, net 463 69 Operating lease assets 2,691 Other assets 249 204 Total assets 180,342 106,676 Current liabilities: Accounts payable and accrued expenses 9,933 12,948 Notes payable - current portion 5,000 1,667 Operating lease liability - current portion 546 Total current liabilities 15,479 14,615 Long-term liabilities: Notes payable - long term 9,582 13,093 Operating lease liability - long term 2,155 Total liabilities 27,216 27,708 Commitments and contingencies Stockholders' equity: Preferred stock, $0.01 par value; 1,000,000 shares authorized; no shares issued and outstanding Common stock, $0.01 par value; 200,000,000 shares authorized; 120,661,081 and 109,003,637 shares issued and outstanding at September 30, 2019 and December 31, 2018, respectively 1,207 1,090 Additional paid-in capital 729,910 625,993 Accumulated other comprehensive income (loss) 127 (95) Accumulated deficit (578,118) (548,020) Total stockholders' equity 153,126 78,968 Total liabilities and stockholders' equity $ 180,342 $ 106,676 X - DefinitionPresent value of operating leases assets. + ReferencesNo definition available. + Details Name: arql_OperatingLeaseAssets Namespace Prefix: arql_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19,20) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAccumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 11 -URI http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -URI http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580 + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionValue received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details Name: us-gaap_AdditionalPaidInCapitalCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionSum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.9) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.1) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.25) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03.(a),19) -URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.17) -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349 + Details Name: us-gaap_CommitmentsAndContingencies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionSum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19-26) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.21) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesNoncurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionCarrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details Name: us-gaap_LongTermNotesPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of investment in marketable security, classified as current. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.2) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details Name: us-gaap_MarketableSecuritiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in marketable security, classified as noncurrent. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.12) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details Name: us-gaap_MarketableSecuritiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19,20) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details Name: us-gaap_NotesPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 45 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 45 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of noncurrent assets classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.17) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details Name: us-gaap_OtherAssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details Name: us-gaap_PreferredStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6787-107765 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -Subparagraph (g) -URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 340 -SubTopic 10 -Section 05 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316 + Details Name: us-gaap_PrepaidExpenseCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(14)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(13)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount to be collected within one year of the balance sheet date (or one operating cycle, if longer) from customers in accordance with the contractual provisions of long-term contracts or programs including amounts billed and unbilled as of the balance sheet date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.3(c)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details Name: us-gaap_ReceivablesLongTermContractsOrPrograms Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe cumulative amount of the reporting entity's undistributed earnings or deficit. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 44 R36.htm IDEA: XBRL DOCUMENT v3.19.3 LOAN AGREEMENT (Details) - Oxford Finance, LLC (the "Loan Agreement") - Loan and security agreement - USD ($) $ / shares in Units, $ in Millions 1 Months Ended 9 Months Ended Feb. 28, 2018 Jan. 31, 2017 Sep. 30, 2019 Debt Instrument [Line Items] Loan principal amount $ 15 Interest rate description (a) the greater of (i) the 30 day U.S. LIBOR rate reported in the Wall Street Journal on the date occurring on the last business day of the month that immediately precedes the month in which the interest will accrue or (ii) 0.65% (b) plus 6.85%. Interest rate 0.65% Basis spread interest rate 0.85% Applicable interest rate 8.94% Amortization period 36 months Maturity date Aug. 01, 2022 Aug. 01, 2021 Percentage of final principal payment 6.00% Term of payment of interest and principal after amendment September 2019 to August 2022 Additional interest rate after default 5.00% Percentage of prepayment fee if payment made before maturity 1.00% Term of payment of interest after amendment Monthly basis through August 2019 Common Stock Debt Instrument [Line Items] Number of warrants issued to purchase common stock 93,168 Pre-share exercise price of warrants or rights $ 1.61 Exercise term of warrants or rights 10 years X - DefinitionExercise term of warrants or rights outstanding. + ReferencesNo definition available. + Details Name: arql_ClassOfWarrantOrRightExerciseTermOfWarrantsOrRights Namespace Prefix: arql_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionRepresents the description of interest payment period under terms of the debt agreement amendment. + ReferencesNo definition available. + Details Name: arql_DebtInstrumentAmendmentTermPaymentOfInterest Namespace Prefix: arql_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionRepresents the description of interest and principal payment period under terms of the debt agreement amendment. + ReferencesNo definition available. + Details Name: arql_DebtInstrumentAmendmentTermPaymentOfInterestAndPrincipal Namespace Prefix: arql_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionRepresents the additional interest rate charged on the debt in the case of default. + ReferencesNo definition available. + Details Name: arql_DebtInstrumentDebtDefaultAdditionalInterestRatePercentage Namespace Prefix: arql_ Data Type: num:percentItemType Balance Type: na Period Type: duration X - DefinitionRepresents the percentage of final payment of principal amount of the loan. + ReferencesNo definition available. + Details Name: arql_DebtInstrumentFinalPaymentPrincipalPercentage Namespace Prefix: arql_ Data Type: num:percentItemType Balance Type: na Period Type: duration X - DefinitionRepresents the percentage of interest rate for debt instrument. + ReferencesNo definition available. + Details Name: arql_DebtInstrumentInterestRatePercentage Namespace Prefix: arql_ Data Type: num:percentItemType Balance Type: na Period Type: duration X - DefinitionRepresents the installment percentage if prepayment occurs thereafter. + ReferencesNo definition available. + Details Name: arql_DebtInstrumentPercentageOfPrepaymentFeeIfPaymentMadeThereafter24Months Namespace Prefix: arql_ Data Type: num:percentItemType Balance Type: na Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(i)(4)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: num:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(i)(2)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionPercentage points added to the reference rate to compute the variable rate on the debt instrument. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentBasisSpreadOnVariableRate1 Namespace Prefix: us-gaap_ Data Type: num:percentItemType Balance Type: na Period Type: duration X - DefinitionRemaining amortization period for discount on the liability component of convertible debt which may be settled in cash upon conversion, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 20 -Section 50 -Paragraph 5 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109500613&loc=SL6031898-161870 + Details Name: us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionFace (par) amount of debt instrument at time of issuance. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 55 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400 + Details Name: us-gaap_DebtInstrumentFaceAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe average effective interest rate during the reporting period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(1)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details Name: us-gaap_DebtInstrumentInterestRateDuringPeriod Namespace Prefix: us-gaap_ Data Type: num:percentItemType Balance Type: na Period Type: duration X - DefinitionDescription of the interest rate as being fixed or variable, and, if variable, identification of the index or rate on which the interest rate is based and the number of points or percentage added to that index or rate to set the rate, and other pertinent information, such as frequency of rate resets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(1)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details Name: us-gaap_DebtInstrumentInterestRateTerms Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDate when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(2)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258 + Details Name: us-gaap_DebtInstrumentMaturityDate Namespace Prefix: us-gaap_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - Details Name: dei_LegalEntityAxis=arql_OxfordFinanceLlcMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: arql_AgreementAxis=arql_LoanAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 45 R32.htm IDEA: XBRL DOCUMENT v3.19.3 STOCK-BASED COMPENSATION AND STOCK PLANS - Shares vested, expected to vest and exercisable (Details) - Stock Options $ / shares in Units, $ in Thousands 9 Months Ended Sep. 30, 2019 USD ($) $ / shares shares Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Vested and unvested expected to vest, Options | shares 12,218,754 Vested and unvested expected to vest, weighted-average exercise price | $ / shares $ 3.17 Vested and unvested expected to vest, weighted-average remaining contractual term (in years) 6 years 1 month 6 days Vested and unvested expected to vest, aggregate intrinsic value | $ $ 49,485 Exercisable, Options | shares 7,207,088 Exercisable, weighted-average exercise price | $ / shares $ 3.26 Exercisable, weighted-average remaining contractual term (in years) 4 years 4 months 24 days Exercisable, aggregate intrinsic value | $ $ 28,730 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (e)(2) -URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (e)(2) -URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (e)(2) -URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: num:perShareItemType Balance Type: na Period Type: instant X - DefinitionAmount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (e)(1) -URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (e)(1) -URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: num:perShareItemType Balance Type: na Period Type: instant X - DefinitionWeighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (e)(2) -URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (e)(1) -URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 46 R7.htm IDEA: XBRL DOCUMENT v3.19.3 NATURE OF OPERATIONS AND BASIS OF PRESENTATION 9 Months Ended Sep. 30, 2019 NATURE OF OPERATIONS AND BASIS OF PRESENTATION NATURE OF OPERATIONS AND BASIS OF PRESENTATION 1. NATURE OF OPERATIONS AND BASIS OF PRESENTATION We are a biopharmaceutical company engaged in the research and development of innovative therapeutics to treat cancers and rare diseases. Our mission is to discover, develop and commercialize novel small molecule drugs in areas of high unmet need that will dramatically extend and improve the lives of our patients. These product candidates target biological pathways implicated in a wide range of cancers and certain non-oncology indications. Our discovery and development efforts are guided, when possible, by an understanding of the role of biomarkers, which are indicators of a particular biological condition or process and may predict the clinical benefit of our compounds in defined patient populations. Our clinical-stage pipeline consists of four product candidates, all of which are in targeted patient populations, making ArQule a leader among companies our size in precision medicine. ArQule has a long history of kinase drug discovery and development, having discovered and introduced ten kinase inhibitors into clinical trials. Our drug discovery efforts have been informed by our historical expertise in chemistry, our work in rational drug design and by our insight into kinase binding and regulation. We have applied this knowledge to produce significant chemical matter for a number of kinase targets and to build an extensive library of proprietary compounds with the potential to target multiple kinases in oncology and other therapeutic areas, such as rare diseases. We may bring further preclinical programs forward and interrogate our library against new targets beyond kinases either directly or with collaborators. Our proprietary pipeline of orally bioavailable product candidates is directed toward molecular targets and biological processes with demonstrated roles in the development of both human cancers and rare, non-oncology diseases. All of these programs are being developed in targeted, biomarker-defined patient populations. By seeking out subgroups of patients that are most likely to respond to our product candidates, we seek to identify small, often orphan, indications that allow for focused and efficient development. At the same time, in addition to pursuing these potentially fast-to-market strategies, we also pursue development in other indications that could allow us to expand the utility of the product candidates if approved. Our clinical pipeline includes the following product candidates: · ARQ 531 is a potent and reversible dual inhibitor of both wild type and C481S-mutant Bruton’s tyrosine kinase (BTK) that is in Phase 1/2 clinical development for B-cell malignancies refractory to other therapeutic options; · Miransertib (ARQ 092) is a potent and selective inhibitor of protein kinase B (AKT), a serine/threonine kinase that is in a registrational clinical trial for the treatment of Proteus syndrome and PIK3CA-Related Overgrowth Syndromes (PROS); · ARQ 751 is a next-generation, highly potent and selective inhibitor of AKT that is in Phase 1 clinical development for solid tumors harboring AKT, phosphoinositide 3‑kinase (PI3K) or phosphatase and tensin homolog (PTEN) loss mutations or that are PTEN null; and · Derazantinib (ARQ 087) is a multi-kinase inhibitor designed to preferentially inhibit the fibroblast growth factor receptor (FGFR) family of kinases that is in a registrational clinical trial in intrahepatic cholangiocarcinoma (iCCA) in patients with FGFR2 fusions. Derazantinib was exclusively licensed to Basilea Pharmaceutica Limited (Basilea) in April 2018 in the United States, European Union, Japan and the rest of the world, excluding the People’s Republic of China, Hong Kong, Macau, and Taiwan (collectively, Greater China) where derazantinib was exclusively licensed to Sinovant Sciences Ltd., a subsidiary of Roivant Sciences Ltd. (Sinovant) in February 2018. Our uses of cash for operating activities have primarily consisted of salaries and wages for our employees, facility and facility-related costs for our offices and laboratories, fees paid in connection with preclinical and clinical studies, laboratory supplies and materials, and professional fees. The sources of our cash flow from operating activities have historically consisted primarily of upfront and other payments received from our collaborators in connection with license agreements. In the nine months ended September 30, 2019 and 2018, our net use of cash was primarily driven by payments for operating expenses which resulted in net cash outflows of $24.2 million and $7.8 million, respectively. Our cash requirements may vary materially from those now planned depending on the results of our drug discovery and development strategies, our ability to enter into additional corporate collaborations and the terms of such collaborations, results of research and development, unanticipated required capital expenditures, competitive and technological advances, acquisitions and other factors. We cannot guarantee that we will be able to develop any of our product candidates into a commercial product. In January 2017, we entered into a loan and security agreement with Oxford Finance, LLC (the “Loan Agreement”) with an initial principal balance of $15 million (see Note 8). The terms of the Loan Agreement, which was amended in February 2018, required only payments of interest on a monthly basis through August 2019 . As of September 2019, we are required to make payments of principal and interest on a monthly basis through the maturity date of the loan on August 1, 2022. In November 2017, we entered into definitive securities purchase agreements with certain institutional investors. In conjunction with this stock offering we raised net proceeds of $9.5 million through the sale of 8,370 shares of series A convertible preferred stock (Series A Preferred) and warrants to purchase 2,259 shares of Series A Preferred (Warrants). Each share of Series A Preferred converted into 1,000 shares of common stock and each associated Warrant converted into 1,000 common stock warrants in May 2018. In September 2019, holders of the common stock warrants exercised warrants covering 114,286 shares of common stock, resulting in net proceeds of $0.2 million. The remaining common stock warrants have a post-conversion exercise price of $1.75 per share, are exercisable immediately and expire in May 2022. In February 2018, we entered into a License Agreement with Sinovant pursuant to which we granted Sinovant an exclusive license to develop and commercialize derazantinib in Greater China. The agreement provided for an upfront payment to ArQule of $3 million and a $2.5 million development milestone that was paid in the first quarter of 2019. We are also eligible for up to an additional $12.0 million in regulatory milestone payments and $70.0 million in commercial milestone payments. Upon commercialization, we are entitled to receive double digit royalties in the low teens from Sinovant on net sales of derazantinib in Greater China. Sinovant will be responsible for all costs and expenses of development, manufacture and commercialization in Greater China. In the three and nine months ended September 30, 2019 , we recognized revenue of $0.2 million and $1.6 million, respectively, for providing certain Manufacturing Services (as defined in Note 2) to Sinovant. During the three and nine months ended September 30, 2018, we recognized revenue of $2.9 million and $5.9 million, respectively, related primarily to the transfer of the license to Sinovant and the expected achievement of a development milestone that was ultimately paid in the first quarter of 2019. In April 2018, we entered into a License Agreement with Basilea pursuant to which we granted Basilea an exclusive license to develop and commercialize derazantinib in the United States, European Union, Japan and the rest of the world, excluding Greater China. Under the terms of the agreement, we received an upfront payment of $10 million and are eligible for up to $63.0 million in development and regulatory milestone payments and up to $262.5 million in commercial milestone payments. Upon commercialization, we are entitled to receive tiered royalties on future net sales of derazantinib ranging from the high-single digits to the mid-teens on direct sales and mid-single digits to low-double digits on indirect sales. Basilea will be responsible for all costs and expenses of development, manufacture and commercialization in its territory. Under certain circumstances, we may have the opportunity to promote derazantinib in the United States directly. In the three and nine months ended September 30, 2019, we recognized revenue of zero and $0.2 million, respectively, for providing R&D Services (as defined in Note 2) to Basilea, recognized as revenue on a “cost-to-cost method". In the three and nine months ended September 30, 2018 we recognized revenue of $2.0 million and $15.7 million, respectively, related to providing R&D Services to Basilea as well as the transfer of the Basilea License. In July 2018, we sold 12,650,000 shares of common stock at $5.50 per share for aggregate net proceeds of approximately $64.6 million after commissions and other offering expenses. In June 2019, we sold 10,637,500 shares of common stock at $9.75 per share for aggregate net proceeds of approximately $97.3 million after commissions and other offering expenses. We anticipate that our cash, cash equivalents and marketable securities on hand at September 30, 2019 will be sufficient to finance our operations for at least 12 months from the issuance date of these financial statements. We expect that we will need to raise additional capital or incur indebtedness to continue to fund our operations in the future. Our ability to raise additional funds will depend on financial, economic and market conditions, and due to global capital and credit market conditions or for other reasons, we may be unable to raise capital when needed, or on terms favorable to us. If necessary funds are not available, we may have to delay, reduce the scope of, or eliminate some of our development programs, potentially delaying the time to market for any of our product candidates. X - ReferencesNo definition available. + Details Name: arql_OrganizationAndNatureOfOperationsAbstract Namespace Prefix: arql_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -URI http://asc.fasb.org/topic&trid=2122369 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -URI http://asc.fasb.org/topic&trid=2122149 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -URI http://asc.fasb.org/topic&trid=2134479 + Details Name: us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration XML 47 R10.htm IDEA: XBRL DOCUMENT v3.19.3 ACCOUNTS PAYABLE AND ACCRUED EXPENSES 9 Months Ended Sep. 30, 2019 ACCOUNTS PAYABLE AND ACCRUED EXPENSES ACCOUNTS PAYABLE AND ACCRUED EXPENSES 4. ACCOUNTS PAYABLE AND ACCRUED EXPENSES Accounts payable and accrued expenses include the following at September 30, 2019 and December 31, 2018 (in thousands): September 30, December 31, 2019 2018 Accrued outsourced preclinical and clinical fees $ 5,748 $ 8,497 Accrued payroll 2,154 1,971 Accrued professional fees 905 666 Accounts payable 801 1,329 Other accrued expenses 325 485 $ 9,933 $ 12,948 X - DefinitionThe entire disclosure for accounts payable and accrued liabilities at the end of the reporting period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19(a),20,24) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details Name: us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 48 R14.htm IDEA: XBRL DOCUMENT v3.19.3 LOAN AGREEMENT 9 Months Ended Sep. 30, 2019 LOAN AGREEMENT LOAN AGREEMENT 8. LOAN AGREEMENT In January 2017, we entered into a loan and security agreement (the “Loan Agreement”) with Oxford Finance LLC, as collateral agent and a lender (the “Lender”), and any additional lenders that may become parties thereto. Pursuant to the terms of the Loan Agreement, the Lender issued us a loan with an initial principal amount of $15.0 million. The loan bears interest at the rate equal to (a) the greater of (i) the 30 day U.S. LIBOR rate reported in the Wall Street Journal on the date occurring on the last business day of the month that immediately precedes the month in which the interest will accrue or (ii) 0.65% (b) plus 6.85%. The applicable interest rate on the loan at September 30, 2019 was 8.94%. The Loan Agreement required interest-only payments through August 2019, followed by an amortization period of monthly principal and interest payments of 36 months. The original maturity date of the loan was August 1, 2021 and in February 2018 we signed an amendment with the Lender which extended the maturity date by one year to August 1, 2022. The expected remaining repayment of the $14.583 million loan principal at September 30, 2019 is as follows (in thousands): 2019 $ 1,250 2020 5,000 2021 5,000 2022 3,333 $ 14,583 Upon prepayment of the loan or on the maturity date, we will pay to the Lender a final payment of 6% of the full principal amount of the loan. We may elect to prepay all amounts owed prior to the maturity date, provided that a prepayment fee also is paid equal to 1% of the outstanding principal balance. Pursuant to the terms of the Loan Agreement, we are bound by certain affirmative covenants setting forth actions that are required during the term of the Loan Agreement, including, without limitation, certain information delivery requirements, obligations to maintain certain insurance, and certain notice requirements. Additionally, we are bound by certain negative covenants setting forth actions that are not permitted to be taken during the term of the Loan Agreement without consent, including, without limitation, incurring certain additional indebtedness, entering into certain mergers, acquisitions or other business combination transactions, or incurring any non-permitted lien or other encumbrance on our assets. We were in compliance with the loan covenants at September 30, 2019. Upon the occurrence of an event of default under the Loan Agreement (subject to cure periods for certain events of default), all amounts owed by us thereunder will begin to bear interest at a rate that is 5% higher than the rate that is otherwise applicable and may be declared immediately due and payable by the Lender. Events of default under the Loan Agreement include, among other things, the following: the occurrence of certain bankruptcy events; the failure to make payments under the Loan Agreement when due; the occurrence of a material adverse change in our business, operations or financial condition; the rendering of certain types of fines or judgments against us; any breach by us of any covenant (subject to cure for certain covenants only) made in the Loan Agreement; and the failure of any representation or warranty made by us in connection with the Loan Agreement to be correct in all material respects when made. We have granted the Lender, a security interest in substantially all of our personal property, rights and assets, other than intellectual property, to secure the payment of all amounts owed to the Lender under the Loan Agreement. We have also agreed not to encumber any of our intellectual property without the Lender’s prior written consent. In February 2018, the Loan Agreement was amended to extend the maturity date and to require payments of interest on a monthly basis through August 2019 and payments of interest and principal from September 2019 to August 2022. In connection with entering into the amendment we issued to the Lender warrants to purchase an aggregate of 93,168 shares of our common stock. The warrants are exercisable immediately, have a per-share exercise price of $1.61 and have a term of ten years. The amendment was determined to be a modification of debt in accordance with ASC 470 Debt. We have recorded the relative fair value of the additional warrants as a discount to the carrying value of the notes payable with a corresponding increase to additional paid in capital. X - ReferencesNo definition available. + Details Name: us-gaap_LongTermDebtAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for long-term debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -URI http://asc.fasb.org/topic&trid=2208564 + Details Name: us-gaap_LongTermDebtTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration XML 49 R3.htm IDEA: XBRL DOCUMENT v3.19.3 CONDENSED BALANCE SHEETS (Parentheticals) - $ / shares Sep. 30, 2019 Dec. 31, 2018 CONDENSED BALANCE SHEETS Preferred Stock, par value (in dollars per share) $ 0.01 $ 0.01 Preferred Stock, Shares Authorized 1,000,000 1,000,000 Preferred Stock, Shares Issued 0 0 Preferred Stock, Shares Outstanding 0 0 Common stock, par value (in dollars per share) $ 0.01 $ 0.01 Common stock, shares authorized 200,000,000 200,000,000 Common stock, shares issued 120,661,081 109,003,637 Common stock, shares outstanding 120,661,081 109,003,637 X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: num:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: num:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details Name: us-gaap_PreferredStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details Name: us-gaap_PreferredStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfFinancialPositionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 50 R18.htm IDEA: XBRL DOCUMENT v3.19.3 RECENT ACCOUNTING PRONOUNCEMENTS (Policies) 9 Months Ended Sep. 30, 2019 Accounting Policies [Abstract] RECENT ACCOUNTING PRONOUNCEMENTS Recently Adopted Accounting Pronouncements In February 2016 the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) No. 2016‑02, Leases (Topic 842). This standard established a right-of-use model that requires all lessees to recognize right-of-use assets and liabilities on their balance sheet that arise from leases with terms longer than 12 months as well as provide disclosures with respect to certain qualitative and quantitative information related to their leasing arrangements. This standard became effective for us on January 1, 2019 (“the Effective Date”). The FASB has subsequently issued the following amendments to ASU 2016‑02, which also became effective on January 1, 2019, and which we collectively refer to as the new leasing standards: ASU No. 2018‑01, Leases (Topic 842): Land Easement Practical Expedient for Transition to Topic 842, which permits an entity to elect an optional transition practical expedient to not evaluate under Topic 842 land easements that exist or expired prior to adoption of Topic 842 and that were not previously accounted for as leases under the prior standard, ASC 840, Leases. ASU No. 2018‑10, Codification Improvements to Topic 842, Leases, which amends certain narrow aspects of the guidance issued in ASU 2016‑02. ASU No. 2018‑11, Leases (Topic 842): Targeted Improvements, which allows for a transition approach to initially apply ASU 2016‑02 at the adoption date and recognize a cumulative-effect adjustment to the opening balance of accumulated deficit in the period of adoption as well as an additional practical expedient for lessors to not separate non-lease components from the associated lease component. ASU No. 2018‑20, Narrow-Scope Improvements for Lessors, which contains certain narrow scope improvements to the guidance issued in ASU 2016‑02. We adopted the new lease accounting standard on January 1, 2019, using a modified retrospective transition approach of applying the new standard to all leases existing as of, or entered into after, the Effective Date and with remaining terms of 12 months or more. Our assessment included the lease of our headquarters in Burlington, MA which commenced in May 2015 and , prior to our October 2019 amendment discussed below, was scheduled to expire in July 2020 and our laboratory space in Woburn, MA which commenced in March 2019 and expires in April 2024. The adoption of the new standard on January 1, 2019 resulted in the recording of a right-of-use asset and lease liability of $0.7 million related to the lease of our headquarters in Burlington, MA that existed on the Effective Date. The lease liability is based on the present value of the remaining minimum lease payments, discounted using our secured incremental borrowing rate at the Effective Date. As permitted under ASC 842, we elected several practical expedients and therefore did not reassess at the Effective Date (1) whether any existing contract is or contains a lease, (2) the classification of existing leases, and (3) whether previously capitalized costs continue to qualify as initial indirect costs. We also elected the practical expedient to not separate lease and non-lease components. The application of the practical expedients did not have a significant impact on the measurement of the operating lease liability. In addition, we implemented internal controls to enable the preparation of financial information on adoption. The adoption did not have a material impact on our condensed financial statements related to the existing lease of our headquarters in Burlington, MA for the three and nine months ended September 30, 2019. As a result, there was no cumulative-effect adjustment. For contracts entered into on or after the Effective Date, at the inception of a contract we assess whether the contract is, or contains, a lease. Our assessment is based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether we obtain the right to substantially all the economic benefit from the use of the asset throughout the period, and (3) whether we have the right to direct the use of the asset. At inception of a lease, we allocate the consideration in the contract to each lease component based on its relative stand-alone price to determine the lease payments. Leases are classified as either finance leases or operating leases. A lease is classified as a finance lease if any one of the following criteria are met: (1) the lease transfers ownership of the asset by the end of the lease term, (2) the lease contains an option to purchase the asset that is reasonably certain to be exercised, (3) the lease term is for a major part of the remaining useful life of the asset or (4) the present value of the lease payments equals or exceeds substantially all of the fair value of the asset. A lease is classified as an operating lease if it does not meet any one of these criteria. Our leases are comprised of operating leases related to our headquarters in Burlington, MA and laboratory space in Woburn, MA. For all leases at the lease commencement date, a right-of-use asset and a lease liability are recognized. The right-of-use asset represents the right to use the leased asset for the lease term. The lease liability represents the present value of the lease payments under the lease. The right-of-use asset is initially measured at cost, which primarily comprises the initial amount of the lease liability, plus any initial direct costs incurred, consisting mainly of brokerage commissions, less any lease incentives received. All right-of-use assets are reviewed for impairment. The lease liability is initially measured at the present value of the lease payments, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the secured incremental borrowing rate. For our operating leases, we use our secured incremental borrowing rate if the implicit lease rate cannot be determined. Lease payments included in the measurement of the lease liability comprise the following: the fixed noncancelable lease payments, payments for optional renewal periods where it is reasonably certain the renewal period will be exercised, and payments for early termination options unless it is reasonably certain the lease will not be terminated early. Lease expense for operating leases consists of the lease payments plus any initial direct costs and is recognized on a straight-line basis over the lease term. Certain leases contain rent escalation clauses and variable lease payments that require additional rental payments in later years of the term, including payments based on an index or inflation rate. Payments based on the change in an index or inflation rate, or payments based on a change in our portion of the operating expenses, including real estate taxes and insurance, are not included in the initial lease liability and are recorded as a period expense when incurred. Our operating leases may include an option to renew the lease term for various renewal periods and/or to terminate the leases early. As an option to exercise the renewal or early termination of our operating leases were either non-existent or not reasonably certain as of the ASC 842 Effective Date for our headquarters in Burlington, MA and the lease commencement date of our laboratory space in Woburn, MA, we did not include such options in our initial lease liability. Subsequent to the Effective Date and during the quarter ending September 30, 2019, the option to renew the lease term of our headquarters in Burlington, MA became reasonably certain. This resulted in a $1.98 million increase of our right-of-use asset and lease liability of as of September 30, 2019. As of September 30, 2019, we recognized right-of-use assets related to our headquarters in Burlington, MA and laboratory space in Woburn, MA of $2.7 million and the related net lease liabilities of $2.7 million, which represents the net present value of the remaining lease payments of approximately $3.7 million, discounted using the Company’s incremental borrowing rate of 8.87%. We have included the right-of-use assets and lease liabilities in the condensed balance sheet as of September 30, 2019. The following table summarizes future minimum lease payments for our operating leases as of September 30, 2019 (in thousands): Year Ending December 31, 2019 (three months ending December 31, 2019) $ 152 2020 619 2021 642 2022 657 2023 672 Thereafter 963 Total minimum lease payments $ 3,705 In October 2019, we entered into an amendment to the lease of our headquarters in Burlington, MA that increased the amount of space subject to the lease and extended the term of the lease until July 2025. As previously disclosed in our 2018 Annual Report on Form 10‑K and under the previous lease accounting standard, ASC 840, Leases, the total commitment for our non-cancelable operating lease was $0.8 million as of December 31, 2018 (in thousands): Year Ending December 31, 2019 $ 523 2020 296 Thereafter — Total minimum lease payments $ 819 Recently Issued Accounting Pronouncements In August 2018, the FASB issued ASU 2018‑13, Fair Value Measurement (Topic 820): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement, (“ASU 2018‑13”). The new standard removes certain disclosures, modifies certain disclosures and adds additional disclosures related to fair value measurement. The new standard will be effective beginning January 1, 2020. We are currently evaluating the impact that the adoption of ASU 2018‑13 will have on our consolidated financial statements. In August 2018, the FASB issued ASU 2018‑15, Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350‑40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract, (“ASU 2018‑15”). The amendments in this update align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). The accounting for the service element of a hosting arrangement that is a service contract is not affected by the amendments in this update. The new standard will be effective beginning January 1, 2020. The amendments in this update should be applied either retrospectively or prospectively to all implementation costs incurred after the date of adoption. We are currently evaluating the impact that the adoption of ASU 2018‑15 will have on our consolidated financial statements. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + ReferencesNo definition available. + Details Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration XML 51 R37.htm IDEA: XBRL DOCUMENT v3.19.3 PREFERRED STOCK AND WARRANT LIABILITY (Details) - USD ($) $ / shares in Units, $ in Thousands 1 Months Ended 3 Months Ended 9 Months Ended Nov. 30, 2017 Sep. 30, 2018 Sep. 30, 2019 Sep. 30, 2018 Dec. 31, 2018 Preferred Stock And Warrant Liability [Line Items] Series A Preferred stock, shares authorized 1,000,000 Series A Preferred stock, par value (in dollars per share) $ 0.01 Proceeds from stock offering $ 97,327 $ 64,561 Change in fair value of warrant liability 1,552 Warrant liability extinguished 3,100 Warrant Liability $ 0 $ 0 Warrant non cash expense $ 0 $ 1,500 Definitive stock purchase agreements | Series A convertible preferred stock and warrants Preferred Stock And Warrant Liability [Line Items] Proceeds from stock offering $ 9,500 Definitive stock purchase agreements | Series A convertible preferred stock Preferred Stock And Warrant Liability [Line Items] Number of stock issued under agreement 8,370 Number of common stock issued upon conversion 1,000 Definitive stock purchase agreements | Series A Preferred Warrants Preferred Stock And Warrant Liability [Line Items] Number of stock issued under agreement 2,259 Number of common stock issued upon conversion 1,000 Post-conversion price of common stock $ 1.75 X - DefinitionCommon stock conversion price. + ReferencesNo definition available. + Details Name: arql_CommonStockConversionPrice Namespace Prefix: arql_ Data Type: num:perShareItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: arql_PreferredStockAndWarrantLiabilityLineItems Namespace Prefix: arql_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionRepresents the amount of warrant liability. + ReferencesNo definition available. + Details Name: arql_WarrantLiability Namespace Prefix: arql_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the amount of warrant liability extinguished. + ReferencesNo definition available. + Details Name: arql_WarrantLiabilityExtinguished Namespace Prefix: arql_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents amount related to warrant non cash expense. + ReferencesNo definition available. + Details Name: arql_WarrantNonCashExpense Namespace Prefix: arql_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of shares issued for each share of convertible preferred stock that is converted. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 6 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644 + Details Name: us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAmount of expense (income) related to adjustment to fair value of warrant liability. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 480 -SubTopic 10 -Section 25 -Paragraph 13 -URI http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875 + Details Name: us-gaap_FairValueAdjustmentOfWarrants Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from entity's first offering of stock to the public. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585 + Details Name: us-gaap_ProceedsFromIssuanceInitialPublicOffering Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionPer share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 480 -SubTopic 10 -Section S99 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (27) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details Name: us-gaap_TemporaryEquityParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: num:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details Name: us-gaap_TemporaryEquitySharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_TypeOfArrangementAxis=arql_DefinitiveStockPurchaseAgreementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=arql_SeriesAConvertiblePreferredStockAndWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=arql_SeriesAPreferredWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 52 R33.htm IDEA: XBRL DOCUMENT v3.19.3 STOCK-BASED COMPENSATION AND STOCK PLANS - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2019 Sep. 30, 2018 Sep. 30, 2019 Sep. 30, 2018 Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation $ 4,050 $ 1,100 Share-based compensation expense $ 1,008 $ 363 4,049 $ 1,100 Stock Options Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Aggregate intrinsic value of options outstanding 50,100 50,100 Intrinsic value of options exercisable 28,700 $ 28,700 Weighted average grant date fair value of options granted (in dollars per share) $ 2.54 $ 1.70 Intrinsic value of options exercised $ 3,900 Compensation cost not yet recognized related to non-vested option awards $ 7,200 $ 7,200 Weighted-average recognition period related to non-vested option awards 2 years 7 months 6 days Number of shares expired during the period 28,350 Number of shares forfeited during the period 129,158 Weighted average remaining contractual life for options exercisable 4 years 4 months 13 days Share-Based Compensation $ 1,000 X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionWeighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (i) -URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount of cost to be recognized for option under share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (i) -URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (d)(2) -URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(4) -URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (d)(1) -URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: num:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionWeighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionNumber of non-vested options forfeited. + ReferencesNo definition available. + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: EXCEL 53 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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htm IDEA: XBRL DOCUMENT v3.19.3 LOAN AGREEMENT (Tables) 9 Months Ended Sep. 30, 2019 LOAN AGREEMENT Schedule of expected remaining repayment 2019 $ 1,250 2020 5,000 2021 5,000 2022 3,333 $ 14,583 X - ReferencesNo definition available. + Details Name: us-gaap_LongTermDebtAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 1A -URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(e),(f)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399 Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 7 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644 Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644 Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 470 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823 Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 55 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400 Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644 + Details Name: us-gaap_ScheduleOfDebtInstrumentsTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration XML 57 R26.htm IDEA: XBRL DOCUMENT v3.19.3 MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Summary of fair value of available-for-sale securities (Details) - USD ($) $ in Thousands Sep. 30, 2019 Dec. 31, 2018 Schedule of Available-for-sale Securities [Line Items] Amortized Cost $ 131,786 $ 80,417 Gross Unrealized Gains 139 2 Gross Unrealized Losses (11) (97) Fair Value 131,914 80,322 Corporate debt securities-short term Schedule of Available-for-sale Securities [Line Items] Amortized Cost 82,929 80,417 Gross Unrealized Gains 89 2 Gross Unrealized Losses (4) (97) Fair Value 83,014 $ 80,322 Corporate debt securities-long term Schedule of Available-for-sale Securities [Line Items] Amortized Cost 48,857 Gross Unrealized Gains 50 Gross Unrealized Losses (7) Fair Value $ 48,900 X - DefinitionAmount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 326 -SubTopic 30 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=118942338&loc=SL82898722-210454 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 326 -SubTopic 30 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=118942338&loc=SL82898722-210454 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 45 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=118954083&loc=d3e26610-111562 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (aa) -URI http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563 + Details Name: us-gaap_AvailableForSaleSecuritiesDebtSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_ShortTermDebtMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_LongTermDebtMember Namespace Prefix: Data Type: na Balance Type: Period Type:

MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Assets measured at fair value on a recurring basis (Details) - Fair Value, Measurements, Recurring - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	$ 40,662	$ 14,444
Total	172,576	94,766
Corporate debt securities-short term
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Corporate debt securities	83,014	80,322
Corporate debt securities-long term
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Corporate debt securities	48,900
Quoted Prices in Active Markets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	40,662	14,444
Total	40,662	14,444
Quoted Prices in Active Markets (Level 1) \| Corporate debt securities-short term
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Corporate debt securities	0	0
Quoted Prices in Active Markets (Level 1) \| Corporate debt securities-long term
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Corporate debt securities	0
Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0	0
Total	131,914	80,322
Significant Other Observable Inputs (Level 2) \| Corporate debt securities-short term
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Corporate debt securities	83,014	80,322
Significant Other Observable Inputs (Level 2) \| Corporate debt securities-long term
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Corporate debt securities	48,900
Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0	0
Total	0	0
Significant Unobservable Inputs (Level 3) \| Corporate debt securities-short term
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Corporate debt securities	0	$ 0
Significant Unobservable Inputs (Level 3) \| Corporate debt securities-long term
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Corporate debt securities	$ 0

CONDENSED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Cash flows from operating activities:
Net income/loss	$ (30,098)	$ (6,995)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	82	35
Amortization of premium on marketable securities	533	387
Amortization of debt discount	239	242
Change in fair value of warrant liability		1,552
Non-cash stock compensation	4,050	1,100
Changes in operating assets and liabilities:
Contract receivables	5,065	(6,401)
Prepaid expenses and others, net	(1,081)	(229)
Accounts payable and accrued expenses	(3,015)	2,513
Net cash used in operating activities	(24,225)	(7,796)
Cash flows from investing activities:
Purchases of marketable securities	(125,645)	(100,285)
Proceeds from sale or maturity of marketable securities	73,742	38,779
Purchases of property and equipment	(476)
Net cash used in investing activities	(52,379)	(61,506)
Cash flows from financing activities:
Costs from notes payable and warrants, net		(48)
Proceeds from stock offering, net of offering costs	97,327	64,561
Proceeds from stock option exercises and employee stock plan purchases	2,458	738
Proceeds from warrant exercises	199
Principal payments on long-term debt	(417)
Net cash provided by financing activities	99,567	65,251
Net increase (decrease) in cash and cash equivalents	22,963	(4,051)
Cash and cash equivalents, beginning of period	19,236	20,229
Cash and cash equivalents, end of period	$ 42,199	$ 16,178

NET LOSS PER SHARE	9 Months Ended
NET LOSS PER SHARE	Sep. 30, 2019
NET LOSS PER SHARE
NET LOSS PER SHARE	5. NET LOSS PER SHARE Net loss per share is computed using the weighted average number of common shares outstanding. Basic and diluted net loss per share amounts are equivalent for the periods presented as the inclusion of potential common shares in the number of shares used for the diluted computation would be anti-dilutive to loss per share. Potential common shares, for the three and nine months ended September 30, 2019, include 12,376,291 shares that would be issued upon the exercise of outstanding employee and Board of Director stock options, 93,168 shares that would be issued upon the exercise of the warrants from our February 2018 amendment to our loan agreement, 3,123,674 shares that would be issued upon the exercise of the warrants from our October 2017 common stock offering and 2,144,714 common shares that would be issued upon the exercise of the warrants from our November 2017 preferred stock offering. Potential common shares, for the three and nine months ended September 30, 2018, include 10,720,022 shares that would be issued upon the exercise of outstanding employee and Board of Director stock options, 93,168 shares that would be issued upon the exercise of the warrants from our February 2018 amendment to our loan agreement, 3,123,674 shares that would be issued upon the exercise of the warrants from our October 2017 common stock offering and 2,259,000 common shares that would be issued upon the exercise of the warrants from our November 2017 preferred stock offering. The preferred shares and warrants from our November 2017 preferred stock offering were converted to common stock and common stock warrants in May 2018.

PREFERRED STOCK AND WARRANT LIABILITY	9 Months Ended
PREFERRED STOCK AND WARRANT LIABILITY	Sep. 30, 2019
PREFERRED STOCK AND WARRANT LIABILITY
PREFERRED STOCK AND WARRANT LIABILITY	9. PREFERRED STOCK AND WARRANT LIABILITY Our Restated Certificate of Incorporation , as amended, authorizes the issuance of up to 1 million shares of $0.01 par value preferred stock. In November 2017, we entered into definitive securities purchase agreements with certain institutional investors. In conjunction with this stock offering we raised net proceeds of $9.5 million through the sale of 8,370 shares of series A convertible preferred stock (Series A Preferred) and warrants covering 2,259 shares of Series A Preferred (Warrants). Each share of Series A Preferred converted into 1,000 shares of common stock and each associated Warrant converted into 1,000 common stock warrants in May 2018. The terms of the Series A Preferred for which the warrants were exercisable required that the fair value allocated to the warrants at the date of issuance be recorded as a liability on our balance sheet. The warrant liability was marked to market value through the statement of operations and comprehensive loss as a non-cash gain or loss at each reporting period until the conversion of the Series A Preferred to common stock in May 2018. Upon conversion, the warrant liability of $3.1 million was extinguished with an offsetting amount included as additional paid-in capital in stockholders’ equity. Accordingly, at each of December 31, 2018 and September 30, 2019, the warrant liability was zero. In the three and nine months ended September 30, 2018, we recognized a non-cash expense of zero and $1.5 million , respectively, recorded in other expense on the statement of operations and comprehensive loss related to the change in the fair value of the warrant liability.

CONDENSED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 42,199	$ 19,236
Marketable securities - short term	83,014	80,322
Contract receivables	874	5,984
Prepaid expenses	1,952	861
Total current assets	128,039	106,403
Marketable securities - long term	48,900
Property and equipment, net	463	69
Operating lease assets	2,691
Other assets	249	204
Total assets	180,342	106,676
Current liabilities:
Accounts payable and accrued expenses	9,933	12,948
Notes payable - current portion	5,000	1,667
Operating lease liability - current portion	546
Total current liabilities	15,479	14,615
Long-term liabilities:
Notes payable - long term	9,582	13,093
Operating lease liability - long term	2,155
Total liabilities	27,216	27,708
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.01 par value; 1,000,000 shares authorized; no shares issued and outstanding
Common stock, $0.01 par value; 200,000,000 shares authorized; 120,661,081 and 109,003,637 shares issued and outstanding at September 30, 2019 and December 31, 2018, respectively	1,207	1,090
Additional paid-in capital	729,910	625,993
Accumulated other comprehensive income (loss)	127	(95)
Accumulated deficit	(578,118)	(548,020)
Total stockholders' equity	153,126	78,968
Total liabilities and stockholders' equity	$ 180,342	$ 106,676

LOAN AGREEMENT (Details) - Oxford Finance, LLC (the "Loan Agreement") - Loan and security agreement - USD ($) $ / shares in Units, $ in Millions	1 Months Ended		9 Months Ended
	Feb. 28, 2018	Jan. 31, 2017	Sep. 30, 2019
Debt Instrument [Line Items]
Loan principal amount			$ 15
Interest rate description		(a) the greater of (i) the 30 day U.S. LIBOR rate reported in the Wall Street Journal on the date occurring on the last business day of the month that immediately precedes the month in which the interest will accrue or (ii) 0.65% (b) plus 6.85%.
Interest rate		0.65%
Basis spread interest rate		0.85%
Applicable interest rate			8.94%
Amortization period		36 months
Maturity date	Aug. 01, 2022	Aug. 01, 2021
Percentage of final principal payment		6.00%
Term of payment of interest and principal after amendment		September 2019 to August 2022
Additional interest rate after default		5.00%
Percentage of prepayment fee if payment made before maturity		1.00%
Term of payment of interest after amendment	Monthly basis through August 2019
Common Stock
Debt Instrument [Line Items]
Number of warrants issued to purchase common stock	93,168
Pre-share exercise price of warrants or rights	$ 1.61
Exercise term of warrants or rights	10 years

STOCK-BASED COMPENSATION AND STOCK PLANS - Shares vested, expected to vest and exercisable (Details) - Stock Options $ / shares in Units, $ in Thousands	9 Months Ended
	Sep. 30, 2019 USD ($) $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vested and unvested expected to vest, Options \| shares	12,218,754
Vested and unvested expected to vest, weighted-average exercise price \| $ / shares	$ 3.17
Vested and unvested expected to vest, weighted-average remaining contractual term (in years)	6 years 1 month 6 days
Vested and unvested expected to vest, aggregate intrinsic value \| $	$ 49,485
Exercisable, Options \| shares	7,207,088
Exercisable, weighted-average exercise price \| $ / shares	$ 3.26
Exercisable, weighted-average remaining contractual term (in years)	4 years 4 months 24 days
Exercisable, aggregate intrinsic value \| $	$ 28,730

CONDENSED BALANCE SHEETS (Parentheticals) - $ / shares	Sep. 30, 2019	Dec. 31, 2018
CONDENSED BALANCE SHEETS
Preferred Stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred Stock, Shares Authorized	1,000,000	1,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	120,661,081	109,003,637
Common stock, shares outstanding	120,661,081	109,003,637

MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Summary of fair value of available-for-sale securities (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	$ 131,786	$ 80,417
Gross Unrealized Gains	139	2
Gross Unrealized Losses	(11)	(97)
Fair Value	131,914	80,322
Corporate debt securities-short term
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	82,929	80,417
Gross Unrealized Gains	89	2
Gross Unrealized Losses	(4)	(97)
Fair Value	83,014	$ 80,322
Corporate debt securities-long term
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	48,857
Gross Unrealized Gains	50
Gross Unrealized Losses	(7)
Fair Value	$ 48,900